var title_f24_36_25152="Chronic pancreatitis MRCP";
var content_f24_36_25152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance cholangiopancreatography showing a tortuous and markedly dilated pancreatic duct (arrow). There appears to be relative narrowing of the pancreatic duct just before its confluence with the common bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mohamed Miqdady, MD and Seiji Kitagawa, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25152=[""].join("\n");
var outline_f24_36_25152=null;
var title_f24_36_25153="Biceps tendinitis or tendinopathy";
var content_f24_36_25153=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Biceps tendinitis or tendinopathy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/36/25153/contributors\">",
"       Authors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25153/contributors\" id=\"au1781\">",
"       Stephen M Simons, MD, FACSM",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25153/contributors\" id=\"au1795\">",
"       J Bryan Dixon, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/36/25153/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25153/contributors\" id=\"se7143\">",
"       Karl B Fields, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/36/25153/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25153/contributors\" id=\"de97\">",
"       Jonathan Grayzel, MD, FAAEM",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?24/36/25153?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Tendons are tough bands of tissue that connect muscles to bones. Repetitive activities and overuse can injure tendons, leading to pain and impaired function. This is called tendinopathy. Some people call this condition biceps tendinitis, although the more correct term is tendinopathy because most people do not have inflammation (-pathy means pain, -itis means inflammation).",
"    </p>",
"    <p>",
"     Although the most common cause of tendinopathy is wear and tear over time, overuse can cause sudden swelling and tendinitis. It can also be caused by other conditions, including rheumatic diseases.",
"    </p>",
"    <p>",
"     Tendinopathy is a common problem. The risk of developing tendinopathy increases with age and is higher in people who routinely perform activities that require repetitive overhead activities in work or sport. Treatment focuses on resting the injured tendon to allow healing, using techniques to decrease pain, and exercising to improve muscle strength and tendon stability. In most patients, biceps tendinopathy resolves with treatment.",
"    </p>",
"    <p>",
"     Tendinitis can affect many different tendons in the body. Other forms of tendinitis are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=see_link\">",
"      \"Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/18/44321?source=see_link\">",
"      \"Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS BICEPS TENDINOPATHY?",
"     </span>",
"    </p>",
"    <p>",
"     The biceps muscle is located in the front of the upper arm, and is used when lifting, bending the elbow, and reaching up over the head. The upper portion of the biceps muscle attaches to the front of the shoulder in two places, and the lower portion attaches to a bone in the forearm (",
"     <a class=\"graphic graphic_figure graphicRef74486 \" href=\"UTD.htm?15/19/15670\">",
"      figure 1",
"     </a>",
"     ). Lifting, pulling, reaching, or throwing repeatedly can lead to biceps tendinopathy or even tears of the upper biceps tendon.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      BICEPS TENDINOPATHY SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Patients with biceps tendinopathy typically have pain in the front of the shoulder that worsens at night. Pain may increase with lifting, pulling, or repetitive overhead reaching. Symptoms usually develop slowly over time with tendinopathy, although they may begin all of a sudden in people with tendinitis or biceps rupture.",
"    </p>",
"    <p>",
"     If the biceps tendon ruptures, the person will feel sudden pain, a pop, bruising, and swelling. It may be possible to feel or see a lump in the lower biceps muscle. Shoulder pain is sometimes completely relieved after the rupture occurs. Surprisingly, a rupture only causes only about a 25 percent decrease in muscle strength.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      BICEPS TENDINOPATHY DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Biceps tendinopathy is usually diagnosed based upon a person's history and a physical examination.",
"    </p>",
"    <p>",
"     During the physical examination, the clinician assesses the person's pain while moving the affected arm through a series of movements. X-rays are not usually helpful in confirming biceps tendinopathy or rupture, but may be recommended to help evaluate factors that led to the condition or rule out other problems.",
"    </p>",
"    <p>",
"     An ultrasound can help to confirm the diagnosis of biceps tendon injury. MRI (magnetic resonance imaging) can provide detailed images of the biceps tendon, although it is expensive and not usually necessary.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      BICEPS TENDINOPATHY TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of biceps tendinitis focuses on reducing inflammation and swelling, strengthening, and preventing tendon rupture. Surgery is not usually necessary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Initial treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Initial treatment of biceps tendinitis includes:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A nonsteroidal antiinflammatory drug (NSAID), such as ibuprofen (eg, Advil&reg;, Motrin&reg;) or naproxen (eg, Aleve&reg;) is often recommended for 5 to 7 days. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"        \"Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Limit lifting and reaching until symptoms improve. It is safest to use the following strategies:",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"hyphen-block\">",
"      <li>",
"       Keep the arm down in front of and close to the body",
"      </li>",
"      <li>",
"       Lift objects close to the body",
"      </li>",
"      <li>",
"       Only lift light weights below shoulder level",
"      </li>",
"      <li>",
"       Do sidestroke or breaststroke when swimming",
"      </li>",
"      <li>",
"       Throw balls underhand or sidearm",
"      </li>",
"      <li>",
"       Do not overhand serve in tennis",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       An NSAID gel or patch may be recommended for pain. These are applied to the skin.",
"      </li>",
"      <li>",
"       Apply ice for 15 to 20 minutes each hour as needed to reduce pain and swelling.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Physical therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;If symptoms do not improve, a course of physical therapy may be recommended. This usually includes stretching and strengthening exercises, and may include massage or ultrasound treatments. These exercises are intended to help keep the muscles, joints, and tendons mobile and flexible.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h3\">",
"      Pendulum stretch",
"     </span>",
"     &nbsp;&mdash;&nbsp;The pendulum stretch may be performed for five to ten minutes a day during the first few weeks of recovery.",
"    </p>",
"    <p>",
"     Range of",
"     <span class=\"nowrap\">",
"      motion/flexibility",
"     </span>",
"     exercises should not cause more than a mild level of pain; patients who feel sharp or tearing pain while stretching should stop exercising immediately and consult with their healthcare provider.",
"    </p>",
"    <p>",
"     This exercise should be performed after heating the shoulder with a warm pack or in the shower for five minutes, once or twice per day.",
"    </p>",
"    <p>",
"     The exercise is performed as follows (",
"     <a class=\"graphic graphic_picture graphicRef75504 \" href=\"UTD.htm?1/21/1366\">",
"      figure 2",
"     </a>",
"     ):",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Relax your shoulder muscles",
"      </li>",
"      <li>",
"       While standing or sitting, keep your arm vertical and close to your body (bending over too far may pinch the rotator cuff tendons)",
"      </li>",
"      <li>",
"       Allow your arm to swing forward to back, then side to side, then in small circles in each direction (no greater than one foot in any direction). Only minimal pain should be felt.",
"      </li>",
"      <li>",
"       Stretch the arm only initially. Gradually increasing the diameter of the movements until you feel discomfort (not to exceed 18 to 24 inches or 45 to 60 cm)",
"      </li>",
"      <li>",
"       After a few weeks this exercise should be supplemented or replaced by other exercises to target specific areas of",
"       <span class=\"nowrap\">",
"        tightness/restriction.",
"       </span>",
"       The pendulum stretch may be recommended as a warm up for more localized flexibility exercises",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       strengthening exercises.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     When performed correctly, the pendulum exercise should not cause more than mild discomfort. If more pain is felt, consult a healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Wall walks",
"     </span>",
"     &nbsp;&mdash;&nbsp;Face a wall, standing close enough that you can touch the wall with your fingertips. Starting with the arms outstretched, parallel to the floor, walk the fingers up and down the wall. Keep your shoulders level (do not shrug the shoulders). You should walk your fingers high enough that you begin to feel mild discomfort or aching, but not sharp or severe pain. Continue for up to five minutes. Perform several times per day.",
"    </p>",
"    <p>",
"     To increase the difficulty, try to walk the fingers higher. Again, you may feel mild discomfort but you should not feel sharp or severe pain.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Injection",
"     </span>",
"     &nbsp;&mdash;&nbsp;If symptoms are severe or persist despite using the above treatments, the clinician may recommend an injection of a steroid into the affected area to reduce inflammation and pain. Following injection, patients are generally prescribed a regimen of rest, ice, acetaminophen (Tylenol&reg;) for soreness, and",
"     <span class=\"nowrap\">",
"      stretching/strengthening",
"     </span>",
"     exercises.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Biceps tendinopathy or rupture rarely requires surgery, although it may be considered if a person is young and very active, has severe pain after trying the above treatments, or if there is a cosmetic concern (eg, due to the appearance of a lump in the biceps).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      RETURN TO ACTIVITY",
"     </span>",
"    </p>",
"    <p>",
"     When it is possible to move the arm in all directions without pain, it is safe to begin slowly returning to normal activities or sports. If symptoms recur, reduce activities that require repetitive lifting and overhead activity.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2413302880\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14512457\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/32/2563?source=see_link\">",
"      Patient information: Biceps tendinopathy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/53/29522?source=see_link\">",
"      Patient information: Rotator cuff injury (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/47/38642?source=see_link\">",
"      Patient information: Elbow tendinopathy (tennis and golf elbow) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14512474\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/49/24341?source=see_link\">",
"      Patient information: Rotator cuff tendinitis and tear (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/18/44321?source=see_link\">",
"      Patient information: Elbow tendinopathy (tennis and golf elbow) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25991?source=see_link\">",
"      Biceps tendinopathy and tendon rupture",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/7/35961?source=see_link\">",
"      Evaluation of the patient with shoulder complaints",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4392?source=see_link\">",
"      Musculoskeletal ultrasonography: Clinical applications",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Academy of Orthopaedic Surgeons",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://orthoinfo.aaos.org/\">",
"      file://orthoinfo.aaos.org/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"      www.niams.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American College of Rheumatology",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"      www.rheumatology.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Arthritis Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.arthritis.org/\">",
"      www.arthritis.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?24/36/25153/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 24, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?24/36/25153?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25153/abstract/1\">",
"      Patton WC, McCluskey GM 3rd. Biceps tendinitis and subluxation. Clin Sports Med 2001; 20:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25153/abstract/2\">",
"      Eakin CL, Faber KJ, Hawkins RJ, Hovis WD. Biceps tendon disorders in athletes. J Am Acad Orthop Surg 1999; 7:300.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f24_36_25153=[""].join("\n");
var outline_f24_36_25153=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS BICEPS TENDINOPATHY?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           BICEPS TENDINOPATHY SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           BICEPS TENDINOPATHY DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           BICEPS TENDINOPATHY TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           RETURN TO ACTIVITY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/19/15670\" title=\"figure 1\">",
"           Anterior view of shoulder anatomy",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/21/1366\" title=\"figure 2\">",
"           Weighted pendulum PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f24_36_25154="Patient information: Microscopic colitis (The Basics)";
var content_f24_36_25154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86919\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?13/6/13410\">",
"         Patient information: Celiac disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/11/18611\">",
"         Patient information: Colonoscopy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/5/9299\">",
"         Patient information: Diarrhea in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/31/36339\">",
"         Patient information: Celiac disease in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/14/7395\">",
"         Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/30/9698\">",
"         Patient information: Colonoscopy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Microscopic colitis (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H867922255\">",
"      <span class=\"h1\">",
"       What is microscopic colitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Microscopic colitis is a condition that causes watery diarrhea. It involves the colon, which is another name for the large intestine (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). There are 2 types of microscopic colitis. Both types cause the same symptoms and are treated the same way.",
"     </p>",
"     <p>",
"      Microscopic colitis happens when the colon gets inflamed. But doctors don&rsquo;t always know what makes the colon inflamed. In some cases, the condition seems to be caused by an infection in the digestive system. In other cases, it seems to be caused by medicines. For example, a group of medicines called nonsteroidal antiinflammatory drugs, or &ldquo;NSAIDs&rdquo; for short, sometimes causes microscopic colitis.",
"     </p>",
"     <p>",
"      Microscopic colitis happens most often in adults age 45 and older. Although the symptoms are bothersome, the condition is not life-threatening. It does not lead to serious problems, like cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H867922287\">",
"      <span class=\"h1\">",
"       What are the symptoms of microscopic colitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Microscopic colitis causes episodes of diarrhea that is watery and not bloody. Most people have 4 to 9 watery bowel movements a day, but some people have more. An episode of diarrhea can last weeks to months.",
"     </p>",
"     <p>",
"      People sometimes have other symptoms, too. These commonly include weight loss, belly pain, or feeling very tired.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H867922302\">",
"      <span class=\"h1\">",
"       Is there a test for microscopic colitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Your doctor or nurse will do an exam and order different tests. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Lab tests on a sample of your bowel movement",
"       </li>",
"       <li>",
"        Colonoscopy &ndash; This is a procedure that lets the doctor look at the inside of your colon. The doctor will put a thin tube with a camera and light on the end into your anus and up into your rectum and colon (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"         figure 2",
"        </a>",
"        ). During a colonoscopy, the doctor will do a test called a biopsy. For a biopsy, he or she will take small samples of tissue from your colon. Then another doctor will look at the samples under a microscope to check for microscopic colitis. A biopsy is the only test that can tell for sure whether you have microscopic colitis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H867922340\">",
"      <span class=\"h1\">",
"       How is microscopic colitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on your individual situation. It usually involves 1 or more of the following:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Medicine changes &ndash; If your doctor thinks that your symptoms are caused by a medicine you take, he or she will recommend that you stop taking that medicine.",
"       </li>",
"       <li>",
"        Diet changes &ndash; Some people with microscopic colitis also have another condition called celiac disease. Celiac disease can cause diarrhea and other digestive symptoms. The treatment for celiac disease involves being on a special diet, called a &ldquo;gluten-free diet.&rdquo; If you also have celiac disease, you will work with a dietitian (food expert) or other professional to learn how to eat a gluten-free diet.",
"       </li>",
"       <li>",
"        Anti-diarrhea medicines, such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?40/33/41492?source=see_link\">",
"         loperamide",
"        </a>",
"        (brand name: Imodium) &ndash; These medicines reduce the number of bowel movements you have.",
"       </li>",
"       <li>",
"        A steroid medicine called",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?38/37/39504?source=see_link\">",
"         budesonide",
"        </a>",
"        (brand name: Entocort) &ndash; This is different from the steroids athletes take to build muscle. This medicine helps reduce inflammation in the colon.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If these treatments don&rsquo;t help enough to ease your symptoms, let your doctor or nurse know. There are other medicines or treatments that might help.",
"     </p>",
"     <p>",
"      Some people need to be on treatment long term. That&rsquo;s because symptoms sometimes come back after treatment is stopped.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H867922355\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=see_link\">",
"       Patient information: Diarrhea in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       Patient information: Colonoscopy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?13/6/13410?source=see_link\">",
"       Patient information: Celiac disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=see_link\">",
"       Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"       Patient information: Colonoscopy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=see_link\">",
"       Patient information: Celiac disease in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/36/25154?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86919 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-79.122.249.114-555B9DE994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25154=[""].join("\n");
var outline_f24_36_25154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H867922255\">",
"      What is microscopic colitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H867922287\">",
"      What are the symptoms of microscopic colitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H867922302\">",
"      Is there a test for microscopic colitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H867922340\">",
"      How is microscopic colitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H867922355\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86919\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?13/6/13410?source=related_link\">",
"      Patient information: Celiac disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/31/36339?source=related_link\">",
"      Patient information: Celiac disease in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/14/7395?source=related_link\">",
"      Patient information: Chronic diarrhea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/5/9299?source=related_link\">",
"      Patient information: Diarrhea in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_36_25155="Erythema multiforme face";
var content_f24_36_25155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65570&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema multiforme",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDancLuBOeM061RXQknk8e9ItvvBkfDdsEVYt41QlQMqo5x3ri3PXRNGm0jYxPHU1OVPkKFAzzk02MBtvHBqSfaI9o9egosNbkSMDIgHLDk8VOSZXYjC7faiGLY6nr6jFPCvlt2B9OpprQq45Ih5YDflmlAbdyowpxnNDjy48OSZByFIxUtqXk+YqSepAFW+xPmQFTjOBgHPHFPlU7Fdc7fbmrF6GSUIFXJGSCcVFl9rq21BngjnNS1d2C7IxlfmwSwOMVOjqn3m2kLxmmoGiAGzIHOR6VHNMgkEbZR+vIyaVrOwb7kRYhyVUvn16VN5jld2FAzgKKZNII48uxAPQetLCTs3sNzHkKDjFO72B6FeQSozHg+lSozFRvjTHY+lVru/hjZvMynf5hgfnVG1vPtTuS4WHGBk5P4VmnaRW6NSQ7VAOQobjFJIQH3tg+inq1V4Y2d1VR+57c5Iq3JGUVQ2eOhIou0KxXk3vIHYYz+QpY8xkkEH696ga5xJgKXbGDxgClkMpXCbQT1I7UKSYOLW4+SUu2xUI4yT/ShycYRgMDnJpYEMC5YHJ7+tIWDZz83pmm9USmRRPgku+FJ5yP5Vdj3SbTGxdBxVKON1DAhQMnHfFPC4XMEpEnfFEbrcLluVkyMgoynG4d6SISLLwu/cOtMaWUqBMA69PSnKgtzHJFIMfeKNnrT5b6juibYikEORj+AjpQAQ7OiruH+sQ9DSG4WfjADg8Z6VDLKrSFVUiTdjr1qm1HULXJFkEiBkVRg/Onc/SiVpLIiW2dlViM89/cU2BNyyI4UMD8pHUUkkjtCYZRmMfNlTyaSd9ybEly63AEqrh8fOhPfvVUTbJl3AvAflJx09qeZEgmRyrMCAMgfzp1xJC0jMfkD9R2P0qrX1JuU7qJ1ysWfL+8jmollaRRuH79OPrU1wTbv5Tneg5Ug9vaopgqqrwyBty5PtS16Ejt6pL5kY3K3DrnpRcKIDGm7aCflf/Paq0cqyXJUZ3AbT6fWnOw8to7g5iOdpPYik20tAsSzybp9jpuEgIfjv60ibFsYpDIDGGKE9x9RSSzedp245W5iGQ+OGA9feqdpMs7S28v8Q3qSPvUXXXqDu0EVsIJwwbeoO7Cn+HPUUup7RI4EuVHzKM/eFLbuYWHn/dTIyOwpsoxco0jHyZARHu7Z70lLQTVjJuIi6wmQ7j0POcf/AF6vRIPIErnB67cehxmnCEoro67iB1HPA71UGoeRcRCQboAWXb65pqy1E3fQ0LiZbqFEbh1J3A9MfwkVUEnleUrZ2P2HY04FZoJXVRnzMrzjjHAzUcGx8RMP3ucjB4qpIks+Uj264BV95Ax39KrXsayW0QCASYO7B9DUtkxRp4zgkfvMnp9BUPmKgLHKh/m65x7U011Ja1MzU9IhvYYtgDYG8Y6qfSsPUNE22wfazADO5Cdy4711+nSsySRgqflbnHJqtNEYbVgHKP2Dd/aqaVjK7PJ7pJFfyw+6MybxxyM9RxUN478xy7W8lc7hyGGetdLr2nu2oPKg8p5QcK3ADAZ/WubvpllYsU2uAqttPX/69YNtaF2uY/kRSzCNm8uQDKP0BPpVYvJbySRXKYGc8Dge9bhtI7iKVJsB84U55Bxwazbj73kXedwG1ZPrVxehEopELQR3HzxnaW4YxnFU76zligRmYNEOjU+AG3ueCUZTgrngn1rRs5FuY5Y2IK8ttNbJmEkz6XfIQLk7D1zVoKFgIOM461DIybVUHgnFE0u10UkBuh/xrG2lz1b3si/H/qd2BlQOnehmUyOTyoA9qqXVw0FlLPCCSi8ADOeartqO2IbzncSeRz9KV0mPY2IAMZztYc59RSyKwkDYL7jwB1rJjvd8+XbEYUIc8bc1twyK8H7lSzdjVJpgCWubpZJnLOR2PSpy22RzHuI4A44FRTXsawFHmRZTjgkA/rUaXEckkp+0hg4wrZ/oKduw+buWJwVneSdW3sAT3yPWkd4ijM5QkcAY7Vm3U1wg3IVmOMAtlf1rA1jUlhuI9qRSTsvKI5JH1JOKTvHUOZM6WWZpWKwuyp1PAFMDrbF5AIweh3tkk1zljcxW9rK15MtueWJLdPb/APVUVpr9mhke1t5Z2JwZGHA98mpvpdiujpFiNyrPM5LdlUYAH1qC41eGxiK7134x8ozz6fWsSS/nuRJOZJEj+6YyT/P+gqexs4gBeTlC5JEcWOg9cUrrYZQkW41a/MVwXjhXDNu5+gI6Z9q6OGzW3hGEKooBCkAFvU1SF/p6yfOTI46RxDOPrjvVG/uruaVY7GCRI3OfLf5mHvjtUxdtQ62OnvJreGPYzLvxzjjH41mi8+0uFkcvEvA+bk/l1rHtdQ1G3mYXFvJNztwACD6/jWrHs1E4hg2soxjChhRfmKtbUkeERhdm4oOhRycfWhbxba1Z/KLx9iGySfYdaq6ja6ioCwb3ONvBAx9TUNjZyRqG1MyFwc+YzAqv+FO1mF2yzaz3t443p5cR/vgg49KsvPHayMipvfrhSCaYLzS1t2kl1KI7eDHGxY4+tZ8eqW8rldCtHkJ+/My/L+Z61XL5iv5GrBNLMjN5SpnjLmnLGSN7kYX+7WXb3siSE3ciR5HRj71c+3FstHG8ingFBhaFZkehbLtHDgncB90elIfMnhG4/u+oHaqZmnRtzRKkZPBLZxVhUMcTZGFJzntmhPoJoTyy5KMWwe4NKltPBE4VhIoPAPJX/CoUmIY7B8/cA8GtW1uxcD51QSjjA6mkoqa1Kcmth1qvnQLKWIm6Fj1P1qlMZba4PyZQjDKefxFTzKyTq2TGkmQcU4yhZ4y5PHGT6e9U1pZCT6lWRHMbKgyG6A9qzFdSssU2fMU9McD6V0V9ChPyAjIyOvFZGoRPGvmRnnGC3p61Li/uLg09DMN6fs5QOjCLkZPINZsF9c5coAy53EYzxSX1sba7R4ysscnKse4qGa4kDLcW4VMZjfGai7e51KCsX7Ntl1C0TrhmKnP+e9aBLpKUnQLHv49Qc/yrCSeH7MJVyTuw6g9G7Gr32xbkN5jcnAPP4VcZJqxzTjqadrM8jvbSDBUkDoMj0qrGqwzxXH8GTG2T930NQWkvlah5cp3YBVifQdCKtzyHBSMK5l64Ax7Ubr0MXo7ETFJlmgDYJU5OOwOc1JEVuECyHgJsTPX2IqpBckTy3ewEE+W8PYZGKnaIwxRqf7okRwMEj/GiOuoSWgomUQAjidRjOep6H8xVDUERYpYsHKtvUdPzrRuYUDbhliw35x1FVL1fPk+Yb3K5yvfinbSxD30K8U/kxsnG0hSSBxn3oWP5tytiVD81NS3CmeIMD0bdjgiljkKorkcH5WJ7mhX2E7FiBW8xWAyNpOQeMe9QMqK0ZyXjHJx1NWUxBauS+MMPxBqtukeXZGFDIMg44oEyGSaCGdmG5Rg7RSzA32yV8AAjaM9/U1Xe32Hex3St39KfbSsTvIG0Njk4A96u5DjcPFFtDJpIu0AeaAAgE/fPOV9687lskWFyzBRPMXEYHOPUH2r0cSiVDckFoIQQqnucH5v6VyOo2xhSG16Par5iHqSGGcfkTUS11FFWdjkGixI6MdkrL8rdmI5xUNxtlsTKoBVl5DD0rSv7cx/aupMDK6MvcVDa+VJFLa5BdiJFx0Kkcj8/51MAmjm512urN8w9fUUgykTkMCUGQQMHHer2oWxijULhiinj1H/6qz5EKYlUZToyn0Pf6VouzM3G6PpeyljnnAkkVZMZ4NN8QXDxvbqOCUbB9emBWdqFubG7jZVDx7guV4Zc9jWhrY8/TbaZZNwD8rIOcelS72sdyldply2nF3pk+3JUjkjr061W079/eQPckGG2iOAecn1P5VS8Mu1jPdWXLW4JaM9SB6H2qaOUNdS+X8sfkKQR35ORQlZITd2WtDtRPunlQtHuaQsxzk9AB9Oag8Q689irCDy4n6K2fmx7Cr8zx2Ph0+XICZASq9CWOcc/56VwlpB9ov5Z71jKtty27neQOB+dOWmiGmaFhdXlyVvNRnWWPJ2rKck+4X61Nfa7/ZSGKJJWuJOY4shTnvlRzirVxGNO0qG4UK17MhbcVB8sD09OtYNtbtDprXtwVbUr9/JTzfmZV9R74qWmh7kOoajq+q/6Rd3CxQ4wNvA464Aq3ZaW1tpz3d9K0ELj5Sx/eSn0A6gVr6RpcU827b+6tscsuenbHueayPGOoAXbw2yssr88jJAPfHr+g96EtLsmT1sjMLS6tcorbVt1ztjyVU/7x7mu48PaXZNDt8pZmVQQGBVFPqexrjNEt5bmYEMtvbRDa0sh5JzyR79q2NW18QQR2GnSl58YKg7Qq9ycf1qla1xb6G7qesWmnhoY7JHcHdv4x+FZ9vJc6rI0syuFJwsa5/Kue0R2KtNeJJOCc/7o7Hn9K7nR50SIvONsmMpAEPA7fWp+PcpuxY0/TUgfdcIzHqYoiCR9T2/CrPnJJI0Vm6RTt959uAg9iepqtHcPPPm5liiiJB8lJACP94D+VS397BuSLzkGwYC71VePpRotCrF22sbO1Q+VKrMeWPJ9+pqG9SJUE9tb7puhaMspP6c1kf6yVTHG8oHJ8vKKf+BHr+FaMdrc3EZM6fZ0z8oLuc+9CY9irHqk8YMUEZklXJcOcMBTk1a3kRwlkJZTxge3fPSpZNPjR98kMwYZy5JGfp3rJu4xZo1xZrsOPmEoA/rS1QKXc0RbTXkLJcGOGE/8s4lC59iR1qGSxitEXyYnQDqq9TVS38US/ZVVtMDnoZFHyn07c0F1uyJpkWNmHCRE5ofcLksl1p6ESXdvOzntKu4H6EdKSLWIxcKtnDMUByYxjH5H/wCtSxWbyFRDZ+WB/G7Y59cVZ/sUl/3s3mNg5WNRgVd31FYq3OrW8hcSS7OOBtxis970PGy/aJUHZccVqz2VraWqxta2gk67idzD8PSqh0p72QfZleVRwDuKj/69SzWEO+xlw6mkQKRoHcHO7nOK2bPV4WCHeyMeeDyDWFe6elvciEyFD0kDrjGPekMFlFE5+0pvHKgHBqYl1IJK52ceqC5jEcjliBwcVoLj5ARujA4P90/4V55a3MEACh52XBHA6VtWWo3GzBlcxY5UjnFUpW0Zi4rodhI7yIUlk3hcbGH8I9DVaU7V8qWQJIxyhPINQ2iu0Ylh3lTgjI6+1STwR3FmPmAeNiCrHnPt7Vav0ITtucdrUc0cyBVJKnIGevqBWbqbmSHzoydr4/dr2Pof8a6ycC7+0C5VhKi/Iyd/TiuVvQ62zqyEEDlcevWsXHc7ottK5lWs7QTN9oTdCx/egnGPp7+9b9zbozpLEqmIAMuOrg84PvWTZRi6sxGygSQH+Pq6mrVg5tLgBPnj4ySTwDUwQqm+m5ZuH2XSS4ZTz1/u9K3IkMIwqKqlfNGe47Csi52SXMjTYeNM52ng+mKkhdv7MYOw3ld0Y9cnGPwrWPU5KiukX7QI8RiIDtL84J9epFSwyM1m25TiIkDjoPSljg8qKzIYCN8MM9c//rq2kfmPdwxuoVv3mw8AEjmrUXsYp9zInl2JFLtbbzjnoKRC7XkABxk8Ht7is+8mIR4lDGRDk4HAHrUttObu7icBgRggDgE96zU9TZ0rK5a1gCK5bGARxgelV5trM0UR3IWDA/Wr+uBZYCQclj8vt7VRWFvsfmKR12nPbFU9JGHQgueVkGS3I4J4FTJMrJDHuwyggkjtUdxJugCxEFnwSD/eHXmpIRmB342sct6j2FHW5PQrx5nlALDDDr6VSukYMLWJtpJy7ei5/rU1zKltEFChmBwoH8RPQVPHCFeIOCZNwaU+ueMfhT3RN7C3UfkWCwqQNzKn0yR1rD1cErLcxqA5bev+6OP5Vq63Ni4CBSDlmx26YH86qupNwF2cAcAjjgUm+gJdTlYUie7cS5aN1ETEdeQSv9a5iS3kt9RRN20oGQH2B4NdPdRNDPdQLwAPMj4+Ygc/pWfeqt5qDqOH2Iw+XruIU1JL2KOqQyDYJUBdVHKjkEev4GsBiY9kgO5Fxwe3PP1Fdrcr9neJnUNlTG/f6H9K5CSLynYhRhWOQfTNNaBE+kr+CO80+Q25QnbuGOpI9RVbTdt9p0kMw2lgBnurdj9Kiso+d0ZV1/u9GH40+2V9P1De43IwyMHqpp83c2sRWZkTVEyCG8vYwxk7hx1+nNQ2zeb9sSPAaMZC45I6kVuanb4mt7qAAqT8wHr6/XFZ0lv5GoC4Qny2Yq/06j+tXawXGRPvbT1mIKLbO4HuOB/OqscMccCxkEyOhBcf3s8fzNWLhArRrISDAWTI/iU8ipbqL7PqljIH3IVyemD2zSeo2tCjOj3SWsMvGPnuG7Kg6KPrjNZmn3QvfEcjzkC3tDmNPQAdfr0rojbmPT5bd1InkkKliM8dR+GK5y2tDFql2fLJV7bsO4Lc1Mi0dLJcyWmlqLFgJrvkseSCe59gOawtG0hp73zpcSFIyRv6tk8ua0Y0XyLiCOMmZo1RCP4QeDXRQ2q+W4VQrMBGWU9B6Vpy3M3LU5G9SO7uF062jjjsVDb5yMYUDlh6mk0vwzHMFlkU29qSHeRvvbR3P1HNdHFpYTzYnj/dBQiL6DrW1bWi71WRv3J5xjq3v9KXLzasq9tDlprUS4MSO8bn92u3B2dN7emewrReKcMpsYWkbbsIkk3Ln+lbS26xxS8AsxG7H90dvwqwoX5VjIHGBjvUtJMqxx1z4avr6Qte3CRfxYt+w78mtDRPDNikfmGF9xYhQ/J+prdeQCVWxiU8YPcVZt3KuQuNpPAI6UuVXGriwWCxQJJG2ZAcKDjA/Co5/tIYK8P2l2+6wPyr9BU6SGJ2HZuOOwqSFw6qVO0dAuetD7IpR0uY01vBKvlzFi2fnEuQo/qarJots0wbMdwq9FRQpA/HrXRpGnn7Y+cfeGeKlW2tZZJZJ0jUemM59MUBY56f7HAo/wBH5VsAtgEfSoblrYBjOsJjx8ucZP5V0LadAXZnSDaD9BTYbW0UmVYkDluAw5H0os2Oxz0FwswC2Fh54/vBNir9c9adcyXKnaI40k7RRgkD6nvW5doyEo77WYDCRnCt9T1pnltaKJC0UQ6FFIBIpGkYPc5+PSxuM9zOktxjAUnAXnoBUty14HUCGGGBlIAjbJB75ropZLW9VP7PjMspOd5HGfcnis26tp5jsupVjjYYEUCgE/8AAqHG2pop20ZzWpwxrIBMGcleBK2ce/FV49IjlDHyofm4V2OP0rsbDS7O3QgxrtI6nJIqDVLK0u4S0z42/NuSPaAP50cvVkSndnKHSY4l/f3McJIydvHH4mrFiILcFTcB4gfvN1qeTTbWe6EtnBPwAM7NxJ/Gop7OeUHy4zGnPykglvbI6fSlsRLYv2uom3n/AHTb0x8xb07Yq1LPFOoa3lVyRljnke1YA0+SCNTLb7iAcAyYFSWwlChFCxxPw7KucD0yf51SlbczcbiX+WbzeQwGMA5P1NY0UMty5EZYgnA+XgDHr3rrfspktAUT9yDyc8nFSNCjbfJCqCBwoocS41rKxxlrZzxX3mABSwAIxxirgQjzBGuN/HHQZFdJcQKINrgliTz7dqyRCgSQDcOpz6H/ACank5dCvbc2pk2zF4/KG1dmTg/zq1AqGzMez50cYJ9z+lMx5cyyqgKlthwOOnNTTy+VfrH96OV1B2nvmqVkZTfMSxNsLWzt+7bDJn+HntWlaXAh8t2ZWHIc+oPWsqVHXXI/MGUOQF9M9BU0MhjieFhkAsOeo9c1cW0zBpWuNubNCyJHx5h7Hjk1WgsnXUhbPlSuVUr69q1YpWnNvG6jdj5eOuBVS/kZL2Paf3rkc+hqZJbmkZt6FbUo5LeZUkyXbqCaddKWG3OfMUNgHg1Jdn7RdQqw3MoO4Z71CY0e6AyEb7pHrSd73M27oit4UVj93O/AA7jHNV4lZp5Ao6ggBj7GrUsREW4nGCVOOMc1m6k7I6ww8PLyDnlV7n8avoiHqV2zcyGYj93Ef3Z65PQmr0rjKgKVBxinFUjmEcZwqrtwR0FR3KhXaJdxbjYe1GgijqchkvJWHzMiKTz/ALQqVXVJI2cfNzk1BpzxytdGQHDOV/ACmIUS4hguThRn5j0PtWdrO4J30MTWkcTedCcyRjfgd1zyPyrD1VxbXmn3EefKmARwPZgc/wAq6+aNVvgxPDxkID3wa4XU3+zXS2cmcROSjezEEUSFvsdJqaiWOEx42uhb6gd64rVA8c8iOArLjI/CusUbb3yFIEeAhDdAc5I/EisTxUFeMvtxIkjc/wB5aErhex77JZW7jzraQoxPNOEe9PJdB5o+ZWz1qcRiRlZAEkHDehoiV0kIMZZlO4AHkf41a1R0rQbDtRDbndGrchvT1qEA+cYZ4w6SDaQPUdCKt3fk3Kk7yJRyreh9xTYVbGyVQu8fdYYz/umhvoTy9SnJaCKRWJ3BW2lscOnofcUtxZlY41jQERMcZP8ACe1aZVXVldTuAxgd6hkCrCyIS2Qcg8EGp8h6kVqysrNuy2drZ7H/AOuMVR+wkam1xHjDIVIHrn/9dXlUBAwHzY5b1qONjDIw2Eq3PHHNVzLqTZiRWZhnJBUllwSfrkVatT+7Cn7x7nvVKe6CMoXcX6AdzSxyMq4B6cc9jS5rFcrNXf5m1QThO9S+dgfKffGOVNZHmlsEkoegJHBoaeQKA7EDtjvUyqOxSgbDTF42YjgjnbUDXRATerBh3qrFM+AGI2sPxqV2dEKOAY854I4qeZyNCy9x8+4DLDvVhWJyUAI25IPrWY8iRMVlGR64xxUpmTbuVwBnA5607jLnmABCSAW6jtinqw2qA3yhvWqSs+dg+77UrFSCh3Kw7mjcaNSIlvM2MeTjpUsc+xthTJIAxWMlyykLnAPUHtV63lRJ/nVRkY49KtNMLWL0r7EMaYZc4bPp2NRS5VUJ+Y5xkHGR7VHc7UQm3O4H1b9KbH5tzlSwj2c7R2p210EmTCXFwwkYr/cJPI7gfmKlQC5+efYZR86lsZ57dP8AOaqzqAi8DzdwJdjz/n2qWS4dzt8k+qtngYqbcrOmDuiRpIodv8IXJ8uM/rUrLm3h+Ukuu/gjA57AVUt1Se6ckhggPzY4NS3MvmhVgUKMkcdT60hysTWsgMwhuF6kgyD+H2ourO3aYHa8jAEj0NCZtnZSwZlPQ/T+dMln/fRkNtUjA4zn1xVtq2pjJa6EIheSAeSEWMH5iW5PtWZLEYX2m6WKMnIVBuY/iavziJ2Y+VlOR1+8afBHsRYwiBz0OO2KhtXsiDnG04XAcxrKQrEmR2JLf/WqxFZk26JIvy4wcH07mtuZNyiMEAHk/hWfPJK064+6OSc03puS7bEFvN9mTyjwrcnjjFK0ieWHjBKKcZ69BUU9vJcuNxIxzhVwP/1U8yMLLCqd4YsP7o+tVF9DOSIrybciALtQHGM8moJIAYvu4VQRtqUxHarufMYnOegqViuF3chjj2oWqIehitATbSKcfuznPTIxWbeIVmtnAHMi5B4rekAW4IZ8KDtZfasi+iIljfPylgDj1Hep6WGri6rMjX3mJtKkg7gO/So0lIncSAksOf8Ae7VIYzNaToQS0bfIcfnTbZDL5qAYcYJP0qrXZEuyL+Q00vIEiqGQe/fFVdUj+cTbs5A/SlWRkdSdxKrtH+0as6myfZ0B5389OhPWm46akKTIFQLLayHhWG7jqar3e1cMCuSVIxROhjkfyS3kZG0nrwecVDdqFk4YbQDyTx61Duyiw+3zCHYDcnzHsO+ayLZBNE9zIMl2G2M9l7UuoFrny4Imw8rAnb1Cjk0lxMJC7KAMjooxjHSm2JICoZwq5Xd8wyeSOeDUNyzpKjBtwYVbhOJIWjG7+6R0JrI1OaRYJixIIyD2FPZXFbUbpKo1iztjO8seeetLesspdeCMUy2V7eziVhtDrkcdeKfC+JXRh780S1REdyW9tvs9nG8wMkTYxJ3UEYwQP515z4q2f2qDGxdtiYyR68D+Vd/fT7bRlBOOCDnhQDXD6giahrtzcAeXGImVNo7qoIOP1qZNGiVkbukx7oitwqsXUbyeu4D/AOvWXr0C/YJIZVy4L7JB/Fz3960dKmkXRY3ki5YZ3rzznnNRX6xXGmzFWzHubBXsaI66GctNWe4FTKNynDdM4/mKULJuCsMOOhFWJI4mXcG2uTnb2NK0btGCGDbeMZ6UHWVSVORKrCQHg461Lu3IFyCPQdP/AK1LKjblWQmMkfxdPwqIxlSMOGA6kUrlWRYOxYwCHUn0P9KicZyV2+me5pEKEHYxJ9xzUNx5hI8vHTkGpk7DSGPxnuB1yKrSOzdAQc/nVmOKR85BZvQ9KZIoUEZeIr1HUGlzAyrNF+98xFQuBggHpURdQ4WVQHByccEVNcq+V8xY2z914qh2P8pwX9zUOeoJBKrGENG+9QeQO1ELpJ8kshRv4SOoNTIEYKYUCEjB54aoJVeJgJkUjqCf5VWjC5YRnijDKBKh44ByKd9pTHVg3QqR1qLc8SIwKvGxyUHFTs6SMpjClh1RuKaigba1ZVj1Cfa0NwApz0PcVOuyUEI5DYzgdvwq0tpBcW+6ZT1wAO1U7m0EDAjcsmOuapRtpuUmumhHHqMlvIqyZ+XmrE9+0jBoypY8HPSoXt3VxsjE6NwVIxioTbPC+3BjDfMmOQBQ00aqz33Na3nSaNfMXbIpwDVhpPKmDSxlIwoB2rWLbzbDucEjOGOOtaFvdmbywSzRhuVPU4oU0/Ulxs79DURgGWaIq0IbC9M59xTjdYdXU4cnucDFZ21XZihMfqh7DNRvdod8buPZtvatOflCNPnZ0JuYbhlwG8wHJUdDTB9+RHYxYGOlZVpIhVQs4RkPAPUn1FWVm8+QmY4J/ipqSa8y3TcC0GWEEAnd1wTwaBMMK8LfPn16UwurbW3hlUcHHSqf72WUiKSNMc/MDSM+a+5rGTzW+YZOct6mla3UzKWDKCpx7VmrLLkETKGHXatOWRmbdLKzHuCcVLsJJs0jtaIRlwSvO3PSokLeUQ3Mo7jt6VRLFJ1w3yk4NXnO9VIZRtGenJpavcHpuK8iCIcEscZz61FKh8ps4ZyevpUb/u5l5cxSdfY0SNjaxBzjFUS9SJlLMwiJ34wcUSYWTylxswfzp8RKTgDjeOp7fSoZkwSfmwpzu96SJZWkJicoVzgd/WludkQCyKcYBp0zhw2fvduKg1P99bAu3zk4GOuB6U72JSM4XkRklyN4HBAphjWW1uUjwPl3oTzxVeO3ZJwJAFRzjJ5JxWgR5UccahdwBHTrUQd9WOcUtirZszJKpXmVNy9sHvVWLK7QowzNwe/HY1YcG3n3biEDZ/3lPUVJMga8SWJS6EhgO2K1Wxm1qQsMrI7Ha+QUHf6U66IMkYB/dHAJ780kqyzXZZACsbBh+NRkMJG3DA3h+Dxik5GbiRzEq4QH7soJPrnrVK7YC5kBxsD456Y9a0HjV3kCBizYZM98daydSb/R5ZFPz5CgY7mhpsERWzeZeTuXGwLsQ+w6/rTtrbFKjdsPzEdcGrcFtDEfJVcqEyC3Ucd/xzUdu4/fMByFwfb3oUejC99RjlobeQIdsasCAPWsXXASZAg3Bivb1rSuXLxnbn3/AAqjqMn+oZDtjMqjPXoaTd9Bbajp0Vlj8skiPgk1EyPtEhBO7IJxTmDIHwCGZj9MVYbyzHCFHLL831pyJjoY2rStFZMI13O58pfqa5+BDAAow7IZEz65GP6V0IgFzcy5G2O2PHqzHr+QzXPIu2ZTyBLKXx68kVi9zU29IVWimgUfLDM6fh2rKuoFjjvMko6Mc4PbHpWxYP5NxeAgHzZXGMd+KztZQt9pXIyEBJ98VtAyme/x25YBA8cikdD2pJrGVDkZYAeoNTJbGIfMHIPRkbJpHT7oMr/Q8Gs9jrsU5QQpLb8DoCvSoZclSRDnPUir0kLBgEDSEns2TVe6ifb5m0rxzgEc0m7jTRT/AHgb7y7PSpGukAUOie+BVZ2P8YITsRUbYTDMVIPQmptJDckW5Zdzrv2vGBgFfSkkQOp2tuU/wt1AqOeddikKpwMZVePxpiSLIg2q244A9jRLQm5TRhFK8WSY2PIHY1etwxK7lC4yATyDTUtFkmYhmAOBg9jTjvjXkA7ehNTCk27sU6iSsMniVsMMZ78VWnSNoyvDEdOc4qld6gY5WCsA3SqkVxJNuLYGOeKt26DimWiWVtinJ/lWhFIMIJsbieGPSqkLRxkDjLdSasq6SMFkOIl4pWS6mt79CaFmB+WTchPHtVtbgyrtkQNjOc96yHYRNjhRnhs5qRJCciTCtkBSDjip5mnoXGKZozSok/GYojyT6cUoYTR8v8pGApBqGRXuXcrIrJjLHOM/hTvKuEVBFIHjUfKpGMGq53ctRQ6Jo9zpJFwW+8eAvtRJYkAy24+RDyhOfxpTNHEUSWIqc5ck8E1ajkAj8yCRShOMD+Kq51sxuLZREnmSBWjERxgHJw1RX8bRtmUFCRgsOhq8+drO0eB6LyKeluJw2HIz0U8jFD1VhJcjuYCSkTqvzFVOVIrRiaR5C0mS5PDE8UTac8akhkIWoreYxnbJ+BxUR912ZtKrzK6NJZjkq2Q395eh9jSyuyYO3APJPUVT89JODlCDkmnSSAIGGdjcHnNaXvsc9kTyS4Kj5gfp1qNZiGCFsr/CfSoUkbbjcSpGVz1xUMJyCGPyH9KiRVtGbAkwhB5zzkdqsRuWOAQ4AyTnFZ0LpnJIGO56Uy4zsxGfl9M9a01itBRSb1LQuTcOEiyyrjJ9Klik3kfMSUPI9ay7SJopi7NgsMEA8Vow4jQ7FBI45PapTb3JqJJ6FmUJuLkdeAKilbbGcnGfWkmmwCMZbpn0qESEyAMucjAGK10sc7FtwGudknK9+aQnNwwA+XOBin2wIeVk5Kjbn61Gw/0hR/EDxii2hLepn6mm4IhGGHPpVKczzmSSBGRBg7ieh9K05GjS8A4+ZtoJpHceUYo+Y5G3ZHbFS43YlKxmmNbiMxyKzKzZz33UK8sCPE37xx8qr0IH8jU9vGVu0UPlPv8APY9qbkm+EjA5wQcjqT2q9kK6ZBDcJu2SAxOxJw3GT6Zp6t5kMhxznBPXIqTa0chYlGbAYA8+1Q3trEIlELMjE8sh/pUJMTFgcp5RRuVbrjt3rGu/3uoeXyVV/OyOg7CtGdZrO4jVSJIwA3IxnNV7J0kluJZMxknCgj+FeOv51Su9CHoWJkDi5GOVGQfesu2VVjuNxAlPQ+1bNozy/aS2eeASPasu5ZUmdl5AAIPrVNKyZCfQz06yBjlMY49ar3KD7Vp6bcAyElQfTuauPsWfaMlThvx9KoyyhtUi3DgBuPrUJWQ27ll1VpMEAEZz9aoXreTDI6EkrwPrV4oJLwnawQNioLiHdZv0KowZvUHNEgjsVLTEenNIQQTGzt3zXPRx4S1lPRiRg/UGul1PEekyLFuAZAgx/ETisJirLbEnCpE0p+gOKzaLuXLNNguJScj7TkkeneqOtsTevGpH72Jh9MetadugWyk65JaQ9xjINZd5zqUMkoK792c9lxwK0ijKTufR0Wx8BJXDg9070+Vf3hDSIwA67earIk8YzJjJPpyKVvOXBKEL67azU77o9BxJVjtVkXMkuO7AY59qqXG0M4jZvxNSMJHj5Py9OnNReTKQqi3clj1xyau/NsZtWMy44dwgBIHIYfyrGuJirsoYlT1XGMGtvVYXiUMwdWHO0jBArnNT5/eZIHU4NTO6dgjZllJWMDAHBJxjsRVq0BjMbKAiZ3Ag85rGt2aQgquTW3p37yAoU5XOM1Ci5McjSAVpPlx83JNZGq3BigIBy2SM1duMwlSD271y2qXRffng/wBa2btGyMIK7uzMCtJOWJbIOMetaljsHyv8pHFZcV1tOOp7nNXLeDzXQliADn8ayWhu22bZtHfIR15wc1KQn2Y/ITIB81OsnxGiqA205yRj8DVyJlUuQOScnP8ASmoa3Gp30M9kV0USIdvTkVJ5X+jOyKvygnitQOjKAqAOeSPT/Cl8iKbeSmCenvS5OxpGdjH0yKTdvUYiYAtxgg1elvUB2xyOZc/KCvFaAgkjjCRNu/ujrniq7QxGVDOPLlHO4EfyqeTlVkaqfMNaCWe2fO1mOTxwf1qjaaYjMIy7Rucjrj8a3THLNtKAMijLEd6f5AlRAnykdc9zTdPmdxqq1oVrO2vEhYKv2iMDDKUPApu+OEB1V4iCSVYkipvtVxBJsdWwpwCGxUv2gTbUlXdg55oS6Jkyn3RAX3R7gUeNvvN121GEh3EgDjoWHWnXP2V5sR/uwBzuOBn0qujIJCAvAHO0/qKtqSYk42ITbxyE5RVYDHBx+JFI7SomBtlx6dhSyrbxsztNuY8gHIp82BCXgUMPVeuaEnYbZQkmkndSq7GHChT/ADp6nYB5qMeeMcZNTBnfBjj8piMNxxmkkWXzAWGFXsCT+XoKGkVciLFJgcYRjnaW6VKsyFiSSccZ4prCUq3KPGTnJ71KfLMa+YkYA5BUdRQJkgBkkQABh6A4qwFZmIGFHsOlVI9rsdoRADwOlWoi7fJCCwPJwaF3MZaB8sZKnOT0NIANpcH7xwKgvGcKAqNwc7iaeIy8QKErGOpHSmn0E43Vy6s/+jiOEH5jyRVWcMu5sDGeWqzaxrGGCusUeOGPJJpCF3/OFIUdM9TVKWhk4lJoBITleSAeeMf4Uy4xsCoFAHGBVuSYjPAJPUCmGIKoLgNk5yD/AEprUTjoV5lCW+FX5sdT1NRy2zSsv+yQRg9KlTMkkrBfuHp2xToRIq7OnPygdTT3M3EpSlXlCkHdz0HSkZcxNG+Cx5GOKuPEFYiNgeeTWfcGQSb0HKnn0NNKwirq8wSMTDkeX93dznoBVaINHbGPBj2xrkHnnHOalvR5lzCpGP3gZVxkYHJqe5j829IY7T3PrUveyDQzmYxqSjbNx+aPqpqK5IJ2SDaMY9j0xg1rSxD95IVXBxxxwfWsrUEL3E0E0rLE6hl2cZ+p9aVrE6MqtGXeNV+VgDznpx3qlE6NrfDY2Q5BPr61a+yEKXjkn2gHnd0FYz2zm5mkE8vygDJAJP6U1oria1NNn2TBSPmHLHsaJ2UW03nYQPhhk44zUIsZFU755W3oGPOPoOlNaBBFgqHYrjJ5I9uaJMUVdFXWrtP7JRIldn3rgjpjFZSealqVWJQzQpBhm/vHcat3zB4rENyNrsFB6kDA/U1XFw7Q3coXdiYxxL7gAfoBU7j2LkEV00W1YUaFRtd1Jxls4XOOvtWP4vcxpbgw3MVzjbKJUAKtzkD2xjrXoOlwW914atLA3qWs1uzSSLLkLKW535A69q4/x3NFe3FpHFcG5a0i8mS4ZSPNfJPfnABxn2q5KyM3ufR/71sBWVt5Jye31pcO6ETSgkdCiH8qcJFUKz8Y78GoGePlllcYORikegRSjY25S6Y6A/0pTvkwyCVTj7zPg1JCZW3GBBIAMbiORVZopWIDspBPAJzTjoS1co6ojKjAXCu5XBXnkfWuD1KbDFehHBr0K/UyHy5pFDYwqxjbiuE1eOSSVlkA3J3xyRU1d7hBWIdNdd5BYg9z6V0FhIM5BB7cVz9lGsalgwPqM1tIRHD8pOCNwPvSh3IqEOv3JiHJHToa4m+mluSducelb3iS5jOfmy+MDmuUSV1coByOpJ5qJjhZI1dNSOJMnlupzW/ZSoTyvvnFc3Yy5HlohcnnOMVoNN5SdNpIwMtUpNalPXQ6QTBVVcKR6+tJFfr5w7kdT1Oa5yGa9c/dAB4+XsfWtDa/mKZVJIA+YDvRKcktBxidIMt935nPLVat2+QFgVYdARWJa3h+VX+UY+8eK2EkQoEDbz3Ipqdymmiy6b0AZmGD8hFV5oZWCrFtj3DaXYdRn3q1EQgGxdwHGTyKmW8imA84nI4xngCr92S1HFtFVUET/OcRnhRuwTj0q4se4B4Gbrwmefzqo+nW8s/2mB/3yNyvYirkYiYFV3RDnj0/GnB9CpdyOSdTKwedjIRyJFzj2qFoZFmZY2RwRnj/AAq7LazkecY0lhJ25yCQfwqr5LWxJVijNggHP86T52wvYrXFpvQGSIZJBK//AFqrSqGidRF5ZJ3Ej+grVkmlcgXDEEcK4xUU0cUrZ6uq/K2eBVOK6BzMyJoFePz3O1h0ZuckdsVKnkgKWTAJyCOBj6U65SSNPMX52Yc45ApV8mVEEyv65z0PbpUNFqZLAxkjcpNlR/EB19qjLShW2JIwI53elXrZ1WNFj25PVh1z70SwyMW2yrkHbg89aqMHYLq5nsInZNscgYAfOB0oe2f7qozg/wAJGKlVvIwpycjBHWnqWibdnIHP3vu1LSvqO73Ky2zsULsqjP3SKmcKCFMgUE/dC9KldSpDRbmVuW707BmUkqgbGcml0sZy11IykQGSVc/7eeBUaGaaXaDuiBxgcAmrMwhgH7zLMB2PFSIzKgwcE/dQd/Sny3ZN9COdGES+ccFeiDtTHkiiiZurHpkdfepowCTNcDbjoCefxply3nuXUPsABLle/pVWKiZZklgXeU69Rj+dQ3FwQ+F5ROcd6s6niMuZXcBwDHyMsPWsSSbZkAYwDn39M+9K9jb2XObMV0GX7u1WGCf6VbhjwFklcowTG0DpXP6fck3BMo4Uhsep7fjW9HcySyEuQZAcBe1VGS6nHVpuLG7ikZYAAHkZqi37uVWLg8cr1q5cIry7XZco33s4waqvGrNJKcu7ZH0pyuZcpkribVZAPkjjjGc9PmP/ANarczDywM/MTg4/SkXalxctIoOdqj14HT9aYQFJeQrnjAB7VKkkPlHKR+9WVcIB3HWo5I0lglV9pB5BPYj3qa4AdBliEOGwepqnLG6wDGdh6n0NPqQ4mdA4iJS4bkg4I6OPb3rJ2FXu3Uu0e8Ag9Rx/KtyWMSwiNiV+behHZh3rDW42tNuOHdzkDoe2RQ3oK2pfSXfHt+8MDd24qC+C5UoBgDp6UkUX2ZSxAZGPI7g+tTeWuxHzuDH5SOc0PYS0ZzepXCw3MhLfLENyAe4J5/Sl0y3zp8bTA7ljZgPdjjP1OTWZq+LnUpU6ok+XXOOAOn+fSuqsWxaQysiOHmXAYfKwB6cduP1pRd2FjrtLN7FotsdMltYWLP5gd0DOc8HntiuG8VrfXEwbUJYZpQ+VaJkYBBnjK8Z610d/rcCRlv7G004GB8rdfzrl9ZvY2UOlnBaRhhHsgBAPB5OferTuRNW1R9DEJE/Mhcjpt5BqXzB5bK6RJJ2HU1S86MyAuixZ4xyaUSW5f7wHodvJrNSR3tFiS5jVVy3GcEKMGqN1JhwwbA6DPWpYzE7Ayj5W7sf8Kr3c0CIyxRhwO561rG9rkMq3BdwxUpwfTk1zmthmDPJ8jjoQAARXQQ3O+Td1Yc5UZwPpVO/KXKv5iMxPYjb+QqZLmWgr8rOUtTGSZCu0Hg49a0JZojZEk5dDjFYt+zW8zG2/1R6qeao212w3qpL7s+9ZwlbRhUhfVEGu3IJXbtxzgEd6zbaF3lXexwfmY+/pSzSNNLKxUhU6j3qW0dhFEdp3M2OafqR6G1psXzhMDgda1J9Njlj3MASKrablYTuxmteO5Ea7W6jr6GuqEE46mb5rjbO2VMDbgdDWkLeJsAr0/I1TiuU25PcHBqzp9wssQ3IxJOKTprY2Sa1JhpwkIKJlMZ25zT4rQox58vqSBwTVuHKnG7aSCAKnkl4AmGcdjwazdBdh87M2CKaFmSKRsuehHH/660ozdyTGI2RklAIKIMMB64NRyXDCMLjcjHccgZyOmDSRIss7XEd40UjgIyySN09Qe1Q6dnZGl7mlZx2Cxyrqa3VpOeUYoVUj0z61L/ZLy7pLG6WQgcxq+TjHNUPtF2peI37CM9Um/eKV+pFWZLYh7mNJY7cAq8ckPKZIppX3RNuzG3EEkOEnjkgLcfPkA+4qrKkkDEApMmPvE5IzRf3mqWUzR3EoulQBgc+YD7ZqlJqUDRAyp5XmDO48DPeleIR5lsTSzy2wzJarIjfKW3cClR7dsb1KAD7rEkE1VkuoYyBFNFMCOMH/ABqm1+6XMuWlO/BYbOlRzqL1ZV29EbNyYWtiyM5JGNgbOT/SszznWPCbSCPu55H9akkdGiDCY88FQOlUlhWKRjvIHUle9VKSb0KjoWbOILNmOQr7AdKvzzFWMZVgzegwKy4pQ8g8kncOTzjIrUjE44kRFVhkEjgimpK2g5XHCFRGpYY77s8Gmuz4DIiBCeuOfyqS6Ro0WRwGXrtyDmqayTNKXA7AciiTWwjQLrGit1LDotVRIJItp+VlPBI5oSNnw1wrbQPlKigwgfMUIduPwpaiTXciKxlwN7MwPJIyKnjjbdkO3qG28ih7gQkbYlI7ZpqzybTv37CchR60LQTVx+C+cS5IPpms67kIL+ZM3y9NvQ/l1q882IiGXO79KyL+SMfdDqeuAcVV1Y0p76mbeTFtuzbvHIIJzmqMRcCfc+Vc5HPX2pb6Ka5O1I2Kt6Dk/jVyxsWO3zV2leg6DNc925HfJxjG9yXSrR0fzpV+QA7R2JrUVlEe/GT6L/jTLaGQbQwIRewqZo3SNxGnO75c960XunnVHzSuyFv3g3XB2gg8fT1oXzJlVITiM4/D8aha2kmYFnYuenHH0qW3gRCpQuAucKT39amM2yJJWGrbLLLP5rEv5hxjoOBUbQxwkhEGScc9vWljLhpXHygSZ246nApZQZG3D745CnoK2suxgyC4nWA5GNv3fm9KguH4KsQ/8QUU8Rq1w4uF3DGTjsf8KpX8rS4Fj/CMGQ9B6/WkxEFwWDg42/QViXD27bUaZB8zHIIzmtc2yzsz3TtIQOMnC/lWbp8UaRj92mCSOnTmouD0K66hErMrSrweff6e1TNdJbRNPFMrRclgGB2n1HtU1/aKEAQqXz94dPoayfEBgNvHbpbr57uEcEDj8qV9R9DEMW1bQjmW8lZ5Gx0Ln+gFdSjrDHBCR/qmO3twBxXLta+VrCpAZfLhjDfK3KEDNajRSzX6PFcl0KcOVBBNEXa4tzUuoZJfKKxu5kkCAKpOTnp9ayvELQxQxWptbqG+DkuJWxluf4cZA6d66+xu9umWzCe5NxZLMywxQ5VnYHEhYdMAnrXK+JzCNU0+3SWaY20IjaacEM7ZLZ55xggCtF0IfY96k5GfvY6VH5CnEg9elKsigBTnaD2606KTlvLfI6HApKKe51u6CONXlU4HThc8VVuHVUb5fY5x/Op7kfumfJ2ZweayGlG/DkYzwMda1iklZEN3EPmF4/JOyTOBmq15qHlK/mkPLgqzEZ59BVic/u5WUsSQfes9dP3lRdblxx0zk1hUbXwlws1qctqLyynEQKlj2qk9sbVUZW2u3XFdJeadIUlCjy5I13KCPvDNZF4rkKJDhgRkHoPes43e4qkuxzMh2zSkL99ueetXEUSGMH5QOcntUdymy7bqRnIyMZFXRtZiEGcLurZK+5gnqaMU6LGpP93GexqNb3JUKSSORUMcFw9oYiMEjr6U+HTZgQFOCBW93ayOqioXuzSs5GePLZJxyfStqCdbFUWH55l5IByCc1kwRvDaSKocOMDJHHvWlZ2cskRCROJQgkG0HgDn+XNEW7mjt0NW3nNxv+0NsJ64GdvtU8N+Gd0kIlgzhGxk/lWYxljtpYhIGdmBB3Z3ZGTgjjgVfhsHjsmmG+InCpk8ZNdCbeqOedkWLe+Uu0UTL5h4IbjA9KkdrV3CSEIVHUc81hPp0wLPK+64LYUAZz7g1s2unXxjCyIJWAycjkVneU3qiJSS1uOimCKxS4jlA4KOOcexqa0u7MoilzCyt1C4P509NPhEL/bQIVXu/BP0AqtPawCP/Qw0iKfmdlwFpOD3J511HC8No7G1m3xkFgCBgms25+yXvnLNGkbschVTG33HapNS0+BArW9wHkGCdrbR9KzboQM5/eszEkqA2SDiuecJLdFwnHoyodPXcr2bysBkbTyM/SrsUV3BH5kkIkhGDKqthuTTbaV7SBnKOcjap/hbAqtdX8k8kSIMzAZwgOBWHJGOrNudy0LqXtgcxsvkuW43H7tTs/mNuikXb6E8VhyWV3qkRuVtmdF4LZGR9aigsL6A5jt5CqLuznIHoaluS6FKKfU354izxY2ISeoNX7ZbtAQ0q7sfLubqPYVgImpPGA2yQDHyqQD+NTw3DiAzXDsNjbSokFVzjcGbxYou4x+YcdGPAqCWSVpFl8tix4GDjH41mxasrOi2sW9wuWAbOPzpbifU5gT5ConQEEYFVz3WhPLbcttqM8aMGA2n+/1qu+pySBiXUYGME1Ta1wu67WaR88KpyPzqWK5ht+JLZNh5AY4P50ry6srlja6JIZIgFL7i/U7Rn8asrdzbMQxEe5zUKata4bdHsU+jZxViDUlfKpMFQ9C2Oae+zFZ/ykggnlXMsrAfWniyiQL5o3/7XWiK4d+u2QDuD0FWGnBBGUVcY5HNUkiHKSKYCIdsKnHvSMrsm0IqYOCTVoMA42yKCemKS4kAkCkcDqRxzQNyGMimENvJYHBFMkdXUCMMWPBPpTpHRiojBYjgACo2Yxvgocnp70EPzCJDGmCq/Lz7VWaRI2DcMrcAelWG3DA5C9CDUF4i5+b5lJABx0NFtNCdzOErxtc8AjzSOmccCkJZQSAS+QwHqKdahTcXYfDnzOSD04HNRXM373bHxtOOnb1p3FbSxnX980zNBADvbBbnkD09s1PbQSR2bR71Cvk/KKzi8cdw8sn3nJ5Xv7iriFiinOEzwD1FJSvuJx00G+Ru3AMT0GPas6KMrhjtJDH5eneujs1WN85zu6cVhOuC42cq5x2J5okjNN3Kwc7pi67cHPqAPWsS8jWeeG45aQB5XX2Awtbs2GQw/cc/ePfaOtZd0wk07VLhgAIkCRsBjGBzn8TUjKOjoZtRlnjZSs29ic9FyAP5GrNnE8cU7RAqY5AoU/dYD/8AXVPQ7X7KwhkbG62Q49ySSP61dtkVbeQM0m9wXxnGP84pBtqddo1ykmkwWou4LdhFcLPFLKF3sw+Rueo7e1cV4/u45JrRIp0ubmC28uWeM5DMM4574GBmujsfNOl2r2Ol2t/I3mCaVrcSuhB4U9+Rzk/SofFttBLol60+m2dpLb2kcpMKBDFMzY8skddw5welaJuUSH7rPWkkVgMgA96QyqowoBNVYXJIIG73I61M5XqRgnoRSTOtohmlOCSCB/dNZMzDzgAD7nHStK5BYH5j+FZkzmNupOepxVpu2pDsWSFVQQA27HzZ60O80pEduEZV5PPGfrVC3VpHKCQKh5wec+1aoVoz5hwsZPIXgZrCom1oXFqJXmgWYk3G9jkL6H3rlfEkTgT7MeWvAbvn0FdneywpExYqARnIrzzxBdvtka381tuThuBRBWRM2cPrGqXsUhzEilDtLbs5AqhpniuVbvbjzGHLEDhR3/Cs7xHd3KxvudC7sdqqcsPesOCUW8eXwrkZbH8z7+1dcIpann1Zu57XpfinT5LYmSRfl4bJxitiy8RaY4Gx1Unrkivm+e6ll3Audhbdj+VNNxNtUeY4A6YNa3ZCk+p9HHXLK4aXEyFORjcMketWbbxFDHKIoZt5HT5+nY181pd3EUm5ZGViuB9Ku29/eWO2YNIrKQMMScnk5/WocXe5uq9lY+kRqlvEqM0mAzdAe59KUeKLYuYTcI4XJPz8CvnTT73UXvEmSeTzNzSYJ4wR1AqCWC90/UZbR96zlijK3XAwc/1oTktgdS+59EWvjfTLmdoY7lFKAtnPpUb/ABItbUTQLfBIWGWO7l+fWvnVJNl4xjYqQTnPQqP/ANVKfNvmULGVThd3bjrR7y6i5k9LHuL/ABAtZovNiucSK3AY5z6mmX/xMSO3LQStIobG0/dc15JaaXO88VssdzK7H/VQKC+w8k57GtG38KalI0dmbeZbx3+UbQVVMf55qORvW5rzK9rHdT/ESHzYlJfy5eSwXBBqxbeL02EwHBDbdxHU07w58LZruxeO4VpJD95iDuyOm09hWrp3wuuY7tIIZ3ZWIcuy8KSMYOaJ0pWNYTjexWXVdRuIWAjcwHBZsfoK0rey1BXSe4tZI4Y8fMBwO4HpXWx+FtTsLODTr+9jZGwysUB3Y7ewp2oWuo6kqQSXA+yACKNCu1M/5HX3rKVNrc3jNPY586u7TTSTeYhm5VVISMcY6Y6fSrFtfOEeSOZn86LDrjC7x0xVyfw4sQhE9ybkpkKOgABqJtEggCrM7bMkgK351KjU6lN0+hmqyIxV53IbMkixlVb8/rT4II5bVnP2RSxChnc5PH3gTWy+n2Cy5ggG7ZtBGSpwOtZ13pcbQ7dqCbPSMYI/3jnis5Ra3LjNMiZlULFHdIEC5PlR4yR6nvTGubrGY5CfMOV3FfwpX05LZAk6+YGYDeJB19vapLixG3NruAx0IOM1muZ+RskmKlrfT4WS4QE8gecq81Rl02cuftMxCt02OH/rVdxekO7BCq8YZR0psV2Yx5csIAPzDAq9OpapSWqsOufD8yQrIjicMN37vLYHvVQaTMuShbj7w3EVv2k1uJRJFctFIeCNmOD2461dhtGlclp1Y8kMCOee47Uezi9ivauKszC0u3vx8qTMM9DuORWrIuoRBcuXxyMkc1pWsMqOjkDC8A9j9astjDs6qW7MO3tVezVtzlnNylojni2os5KtG2OSGFSJcXwAaQRk9AN2K05T5ZbzYRszjKHrSNFvwUH3RyO9Qoa7g3psVI766iU74CydyhzimPqr+YN8UqqP4ihzT7q4EDArnGcEMKWOaC4woJDj19aq3mZuLSvYYmqRSlk8wBjzljg0ouGOdmCRzuzxUjwgDKgPnkkjOKBZQvEWjiXceoHANUova5k2uiMsO8Wo3KD78iq+f0pjwtI7eZuVT/dOTn3pl3axrqURLOAwK43n61LJBlW2XEqgc/f5IpBfsRR2cLxIxOWTDc/WrW2F1ZmQA4zwO+ayxG6yFDNKNpI4wfcfzqUecWQ/aWAP3jtBqkZu5YaRlJO4Ybpjgg1m25MryqzjO49ec5qw9s5lCrdE8DllAFVprHYJy0zHLhNvTOe/H40O7J2KE6tOzmFm2E7C2egFUdZz/wAI/MkYwJpViI9fmA/pW/crFaRokQG3Z90DFcvf3HyaZbN0ll84/QDP86C7cyJbn95d3ON37tVVGHqBgVIJFfyTtJAGG/liqcNwdquQCZmLE+wNDXCiWWMHqN+B7/8A16Xwg4tnVeF7SyhgtDJDcSXV8kzB45mjVfLJwgx1JxWF44W3mjsGtImt4LwLKEdyxJBIYtn6cH0q/pMttZaRZ3F1c3+ZZpZES2KhI2Q9Tn+L+lc74x1aO8vLe9je7lBjKqLnbuz7BeAOa0W2hjJNvU94tkIRQcnAxUxUL94cDmot4G1kK+XjGB1FKWJB64PTBpJ2Otq5BMGJJUgrjpVJ9hJEgYDGCQav3QIGMrgjtzis2dG2FQwPv1quYhxuQW6pBcSLuyzkMCRyBWjsO0GU75CScDt71RttkM3mOSz46kda07V1ZCVTe79z/CKTeliXuZ90yRwlpMED7zMK8u8WahLO8sUf3m5yyliB24r02/itxGyz/NEMkjOM1yevWZCERJ5anlflwQPpSVgs5M8gubR4Q7uSC/WSQZY/QDoKwbyGaaQRQxSNjvt5b3r1GLQ0nugJkJ+bG1eWNTaVYQWct08cIVjkbj1A6f41cZ2MZ0bnk0WlXBmVSgYY3NzwB7mpLKyfzzIY1dAfkyPlJ+nevUbPw6mos0C5DOdzhfQdq0H0RIM+VFufATPoPQVTqOwvYq9jzfT9KEMbXdyfOnc4GRnH/wBc/wAqqW2l3F9eGeTiIEse4A9/evVjoayMA4kjUdAmOKtWWgpGi7IgI16Jnhj6n1oVTQp0TgtO09Leznv7hCrzOFjRh92MHgfiabBokjxKgtTNOxeV5QMMxbgDPoBmvTf7Jju5ovtgxHAMoqDG5h61dFlH5ASGMKz/AC+496ftE9gdI8n0PwIbqNrhy0sSLmXnnk44H4V0mneG1GoIIpEaKC3XaNvRyeg9eAOa762so4bMQQgBSdq/59K0YrZExhlbAxuK/mafOCp22IdA0u3s3eS2srdZpVw8jZXnHY9fw6V0WnWWnxxgtM0c+7DM6jp2IqtBPb+UxZNuRjIbAB9eagl1aOO4jkYxSgdSR1HpR7flHGhdmtLa3BbzLG5/cs2zLPtJx7dqI2uUZorq4mRG+Y7fm6dMgVjHXA24w229GbkAdKVri6eRQtnEnmHgA1Lra3TN1h2lsask7o8RlmLqmcA8EZ7c1UuLt52jFrC0ix8cZwv/ANeqsGnzrMHeaTeCeNuSo9avRxtGAPPuSCeTs6mo55Naj5VHYDLJcFjeXDQrtAG1ODjoKhEkBRVhjaUngsynj35qwI4GwJJJHbphhjn6UkqQocrw4P3R3/woT0C12V/PljhYIzRo/wB7YnT0FNg8u1Rsxb22/wAWTz9O9SKY0yXbBxkIDj86iSRFPmDJmGTtPf8ACovc3hC5FLZiWXzJVwTgg7P0p8jCECTbwP4dxXNJJcsXUsHyeVAbn/61UvLllO4kbAcnnLYNLTob8vKtdhbhbJpG86QoWztfP3T6VkKv2mQliskQO0My4I/H0qabzFcg5YDuBxjpzVvTYE+zr50uIST82zp7VO7N4JRjcoWcckUjI4VkJ+XjlT71t2cKABmUhuhyf5Gs+BHa7cYxEx2kdnxyOa3AjQkKSexIYZ69qcUYV5XsJMZo7cmORWH901nNdlm2uFZuoxwT9a05Y/nAAEh9M9qja0jykh2+WeQuOVIpTT6Cp2SuxkTxNEUXIzwwI7/0qURmNWXq3XJNCRIz8DODkEdDVmNZHBZyqDpg8n8a0SM5yWxjXECTq7SZRwMDnlqzp4o7I/uplw2Rk4JHvXRXsEcuzLB16ZJ6e9Y15aeXKI9qOpHCgZz71DVtjSLurMjtrsJFGjXG4Du3JP1q7bXan5Qy7Car2kLxoxK9/lBFR3MJRhK0SlTxjHSqXNuck1G9kSasi3SoIcCQHeh6cjtUAeMkbE3NjlSOnqDTJkdN727NFjkgHP8AOs28muEHmL949SvQ/UUN3d2Qo9iK9nUTHCgcZDe4J/pRaMWhcscHtiq85S4CSMwWRSAyHvnipIDsUq4wBnrUq7eo3ZIsTtsKZA6bDxUYkzqexTlVXcSfU8fypXhYyDeC27B69M9KqRkLO0m3942efUDpVO6Zm1oWb545t46BA2M/pXFajIx1aFUXcYbU4Hu3Arqb64LW03JJxziuRkZj4ln7qqDcO+FHA/OnJocW07GglqIrlLUc+XGR9aqtCRdLL0Vsx4HB6ZqeznElxPJIzGTaFQdT1NU728VZYmZBN5UgYwdmAPIJHQVF09x3aOss7q4j0G3/ALN1LT7CIXDicTugaQnofmB7cVzvjWa7a+s2vrm2vJmj+U25VlRMnjgDn1NSnW4LmYtL4e0+O2jYFUZnPTAz97tVbVbmG+vppbS2itHjjWNVjJO9iSdxz3xWl9Dnbdz3JPkGcBlH+easq8cqbt4VlIzGwwxHqKqx8NkMHUjJPTH1FTqqO4Z8flUJPod0gnc5UFAc+vFZ10FKljkc4Az0rULusO0qHVvXkD6VUuLdHAwQG/u9qpmZmKDh8IAegLc/lV+KQ24Xc4YtglVqu0bI7Kg8tsdcZBFSIoCg7uV7kVDTWoWTK+qr56yySgmQkEADgViaxC06xCJwzqCcHrgd66SXdcEFjhRnnOMmueuonWYv1CjGCetPmFYw7S0aSdiSUWJCSfVvQVlrKyXojjXcZONoHUmuilCQq0YUkmMse3JrEnhEdxbzrnBw3BwcUdEbUkm/eL2lrJbsXQAOrHdk8+2asxnD84JJzUe9FvJVKjdIQ/B46ZxTppfLYbMAHrxjHrSn6idN3NJo4wqMhBBUFh6H0qaMJvLD5UHvzVBJSsgaFcgAZ71oS2wmhLqxRjglc0r9iXGxato4sfKd2Txk/wCeatNbxIwCHdnsx6VhRCW2ztwMHqTVyPUHLbZEynTJ7GhVLCcGnoXzGcgmLIBz0zUytFKCJFhTnB4IqC3vUQZVW3duOKt29yJmYzojZ5Ge9NTvoDQeRBJsULkr0AOSaUW2mowLQA9imeT+NTNbwSAHa0RI4KGq6WAwwjuJgQe9Np9ENeoyfRrSdwYnaBs52jmnw6Y0eRDcZbOcMM063t7qJzg7x6gVdEcyoCdoB4wODmp0fQ055bNlZYJo5P3cp3jGSpJpZ4btAvmTMOflz1/KrG2cqcOOPSoUupY5SJw4z/EeSaltXtqioxcuw0vdDaSQQOOmDTVdop1JhD8+vUVamnEpQIzsD1Ix+tAYsSA4BHAq4tPRMF5orSSKyNuABz3PQVTv3QDc0g3r93a2Mj1xWlcQJIw8z5vbdWRPFFHIAc7WzuyM7fpRJSOig09EUnuBBlid8pOdwI/lTzdKzh4gwJHzegNNc74plFuXIwVIUAAURLvQB02oOcAYJqFdG8op7ocAkhbyH+U8EKc5rRtLG4WNprZC4XhkdfzGPpWSXC/MkTbF6hV5+tallNKgEkDyKh5KE/eGPWri11IqXUdCaOztwzMqlQxwRu6e4q0qyW2EJ8yHqSRkipW2/LgEZGT3B9qjLOCASMHjHr7VT0OFtsmjVUXKIWDAgjocetRfZmi3E8jIOCfXpSLNiPO4LyQARg1IZu5PGOeKLolSY0xmIttXnP3T296jkkcFzglDwTirEE6uwA2jtzUhTzCQMbWHSn6Et66lJZQ+QUUjGB7VU2BNwVPmP4GtCS1VTuHDnsRVKZWLkgdsjdxRr1HzDQdwIaM/j2qLzlMjI5+YDoelTlw5Y7gp9M1SuAVnBGc9GyO1JuyIepFdAI5KKrKeoNZ7ZxhSFJ6AjirUtyjscFVJ4GTgVnvKBIAX+VTg0ISWhXu7eO63qUIbGOBgZrJmjuY3CwMrJjhZOo+hrVuXVEXy3wwO7IOc1WmxvBGcY5BFD1FexTl1KdbZ98EiHH1GenWi5uCkcRhRiFxnGORVh9vnRRKN4J3MvUcD/HFZep2mySQI5hTrwcZ/xpva4k7sk1Gd0iciFR5i8AnpXOaZteXUbmdm2vKUAXqQPart5czx2LuCrDacM4wxrP0edItOaRo5POldiDjIx3qbrYTvcsIsjeawBijB2hR16dz2FMkKwwgzwgQjDeWpwZPqfektJtylndSoYsEJzn8KWSQXDlsbkiyQMdW7D8KmKCTZ1ui6fb6lpEk1v4cLxLyZGviuSOSAT9eax9bslstTlU2YsmaMTNH5/mnHODnt24qxo+rRWvh7TxdQXL/Z3ltJSoyrLKD0P94Z6elVvFUsTXgtIEuA9tEls8ksfls+CTnb6YOBWl0YNM9kgwB8+CT1qzna6EYPHAzxVFQCxCnk1dRVYqFJXjkEdTUpnfJWZZl2OVJxnGDtFQNCjSNtcFQP93NWt5jUBkVwe44NU54nfJhKuM/cPBq2yUuhC6IHJcSMvQUwpIyHamfQdeKuIXEI3ZVB146H0qIs3YlT6rU7isQsocKmxVBGS3rVHUIlSMoiDr941qmMiPINQzRmSNVVfmHJJNNqwjktRtodhKHe7cY6YrHngJkwVZiFyRjpiuovrPbPuYZx1xWLqELhwYcrx24+tQ3pqaU9GZepxkTwyAk7kD4HHFNVnaGQl2yB0NWJ4SyjqrxgA+wocIUXPLY2nA4PoaTXU74yTiiOxe4BaSNgwzzWtayyT/KAN38XaqFuDalQ5GOu0dcGr9q6Iw8s/vPz4rON0FWKlqkW3t3kORuUDt1qWOQbivlKpPGMcfWrEFxhs55xVpEjcLtwe+/+6arlvqmcT00aK0lxAIxs+U/3R0xVm0dHBAKEdTg5p5t4WySF3dmHeo4rWFZN4j2nuQcUm5JisrGjHGMq24Y9c8Ui3LLvZlPynjvmovJKYPUEdjjNNfy/JIjmbcRyDxz6VTbWqEop7llbyNmKlQueSV7VYXf5bGNlIYfxdT+NYSljIVOV5xVoyPGqqjnJPHoKE21eRXIk9DVtZZVXHBPcNTvMiUFnh3Z7dazVuCeHBY9ye1R3Vwynygz7e7Z+Wq5h8l2XJ0i2kQv5WRwAelUbeeW2kkXAdM5zHVG/ud4DxswZOhPNZQllLkqcnruAxn6VnJ63R1U6PMtTrku4pijLwe/Oc0TKk0/lKd2VzngCuVguMv8AMzqwzjJ4NWBfKHVmYkDoxGatVb6Mf1Vwd0bZtF8qQBV2ZIDZwSfSoUsZTGHAAORtxUMV9wFCKdw5AHU1NHqNwnIj2lDnFNSi2PkkkMv9PljYbXEjqckKen+NQwMyRRpG4DjJKFdvetqHVrR7h5tQgBcpjaV4P5UiWccquYgjg/dVuePY1TinsTOTStJC6ff7nZJCCSMNnp9RU0sS4ZlBZPUVl3FmU+Qjy3HrVjTLmRf3cjhXU4yecjtRe2jOWUb6oDE6ZYYdR69R9KUMJCGXggc59K1zafabfzRt4PzAHBI9qxpraSzumLE7G+6xHGKJJrUiOu49UyMxNuJGDTGl3HDfKc4xT2bds2/KevHeoruAufMZ8On3BjqfX+lJrsNb6lxLktuXIOB0Y9aS7VN+ySPAxkY5GD0qpLEUOcdcH6H2qxZzo8ciEAMoJJP86qOujIa7FC4ToFHQZFUbrdIoG8liOaffyvFJ8rDBHGO1Zs12zhlDe+c8H8aTavYfs3uRPCMMAG468cA1Tljw+JDyep9M1clkO8KdwJHOOh6VBJzLgkYI7jvRZMm7RXW1CxnBxjvj+VQOdoZX3K5459KdqNzFC4ErAKgHfP6VUmke4ZyytFAynBY8v6fSjROyM3cqrf4u8W/7xlXaSegz1zTbyaPzFcuZJCOF9Pw9KoMpiklwdyZCbQcD8qWGPBKxHBxkH1qU5bMfKtzN1SZ/JmjICgKWbPPHbFTaev2bTVbHJB6dz71W1Vt0E7dQSE96fExzHEBk4Jx2FCWtyZCCAPEUXDEscv8A3R/jUIiKQnymYH/VqPUnvVuL/RdPeQ5YjcSfU5pbcvAbR0YiZGDgg8gjniqtoRc0YoUvNLttPlvUtXtfMch4mKSbj97K5+YdMGqmuX8c09rbxSTTJa24jNxIpDSnJ5APOBnAz6V0VldPaaVbXlxr2oWguZpCIoYQ4xnBbr0zn8aqa3pqT2f22PWZ9Sn+yeehni274d+ODnqCTkGhRvqTc9RVCUVgwKN0Iq3HI6BQSAM/exnFVIYx/CcDuOxqyu0HOM+xHSpitDvmy2NrRs/CuOPl6NQNqyMocAlflVhn8jTIZFQJn7revNPu0VUDo8Tg/dwCCDRJ6CitSTy2kjG1hKVONvcfWo2gmdxgAMeOBxUZz95QqN3ZT1qzARy7k7R19/eqjZ7kz02K8yzRybHUKV4bHNJkH5+iDAqa6c7CYTkdMkf0qlPJtDeVnYOzfzpydmJRuV7qMMrEjJPYVh39q/lkg55rpUy6dMHHWs+9XKEAD3rOaGlqcpcRsoDANuXIPvVWFNrcg7T/ACrcnRkIyOPWqrr/ABFgADioUup0JtGTfEKreXguOv09ans58KPKUKAAOeee9FysaBvM+UfwkdansIwhXy1EiEZJJ5pJ3kdHOuXUuQFpDnGCOp7VdhaSPJ3L09KhG5s7RjA6UiSEYHXnNU0jCUrvQvx3EjKuWyV6HFWVu5AMZ+bBB9xVHzwhAxS+YzN8o/8A1UmrEWLr3KRxMTkkjIHpUcYkkCseB1IzmoQysmyQYHTNWICgj4OPqea0tqJrQG8xgoU/U45xT1jAVhJ0HQiohPuVdpwe/uKc8gJAJIU1DXYcUyKa48leDlfrzWVeX7H5RnJ4xnpT9TZ4BnIZTnFUbG2e4fCHcT0BHWs3Loelh6Ca5mRoZjIAJCN3UA5x9attHKjgE52jI5pUtLi3dXBUITjGzr+PetHyVkLeaUUEccd6II2lpsZBhaQFmyxHG4UtuwjcI65X0PQ1oraybyIVzgYIxkEd6kQOuwPAkiE84GCBTUBuWhasbXzmLp8p67T2/Gr5iZRukQZHpSRxx5AQFRjqe9O+0SRs0bFWjxj6itkuVHmSbcrlJYAxk34OTkbhj8M1etLqO3lKMMAjC4PGfepwsJhQpIBnsetULmEuCRtGB2FNxa1QufmfvG0Q1yC2UwBisXULd8gLke/+FV7BpopWG59ufu7s5rcEiyxndhmUADjFK6no0ZSjyO6Kmn38lvtQEgDuD0rXikW4jIDZLZHl1z91avDMzQrwDnPY1PYztG2clGIJx2IohNp8rRMkmrotFFizlSwHUEdKcoSQFs54wpAxxUkE8bQlZchy2cHkEYprKkMiMCpTOdp7+1X6Gd+jKd2THK29zsIwPbNQxSqG2nGQvD4xmrUgQkLIfkJ/Ksq6uIrYyJnec5UfrSbsO+liHVt0uwxqF2ggt1rCit5LZtzsPLY8lu1bckssu0grFGTkHgmq09ujPuHzle7HJo0k7lKq4rlM68kWRAsILrn7/RR+JqrIuWIDF34yqDaB9TU11ITlYQDggl+oWqVzMsa/uhyT9487vqaL2MXqV51SJiX2bxyPQVXm8yePepwuMHAp/lFmDSZIY5Ppipxg8JgenvQLoZkkQ2NIACd+TntTgoS28xgAOSMetW7a3zvVmHzKSPrmobiP9zDFwTnewHoKpLUiUkkczqiFYljIBfOfxqxZhRsJ5JXJJ/lVbV2bz8gfMevtk1LBuYlEdQDxz0FTbUGk0V725MdmqYAJkJb2+aorG5Am3u2SF+Tb3NPERk8zeekgAB/E1DawMrZJG5iSPQCom3uKPLax2+iyx/8ACNY1lrEWrvItsLmN3fJPzFdnIXP61DrNzf28MkUwsmiuLdFjlt1wnkZyFT+6M9c88VSXUbH7FBaarayyxwFhFLDKEYBuSpBBBGap+Jr2UpbZhFrazWyx2iCTeVTJGWPqTuNbRehi+57fExUkNkNnkdqGcFC4fGKqW0zy5JOW7DPNTSsjxKWJBwQeKy6HpW1JWkHRZFLkdxxTbWRnkkXezIvdehNRbfM8ll2oqnLAD71X0ZGP+rCseTjpWej1Za0RPFCGHYeh3cflU0kbEguQQvHHSoDydjBV54JOAKsE708sOR/sg8N7ito7GMk7lWWTL7WIZQf4aq3HzTFu7D7ueOKvTRbExkYA4AqAgOQGYLjjOOlEgjoRneEPPGOlVZwFXkgsTyKkldFmKhiyKc5/vUNGr5ZetZv39EXa2pk3sbDpycdDWPKSzNkfL2b1rpZ4fNdlyQf1NVrqzTaQq8KeOKxlF30KUlY52W1F1AFZep4NSWtq1vGg3KWUYO2tTy1IOFwCBSxsFkJIUgjAFENHctyurEMcixru+8cdKhkkjaQsM556dqdLBhzggZPrVa4VlXcuFwO/StJS0BQ10JoJJJM4X5OgHpU7ymL58bQQM1mW7u3zYbAODjvTrksBgt83UA9qUWrFqld2L4uw+7c+F7c1S+2tvZUOQB1PWqsjbo1LAhs9qTPlMhCbiexNS5nbSw0UWTdS7ic8AYIzVuHUPMjG7JA96zCzRlo5YCoI5yO1WxAhiDMpEZHBU80uZnS6ELWaHyt9qiI3HnkZ/pUNvbyqwXc8YU53D0q7odsZkZZY28tRn1Psa3bbTgwBThByVahRb1IlVjS9xGZbsWj3DzJIx1IJLGtXTYbaaPdFtZe6vwfyq1BYPAM2bLGwzuIGcikkQxuA0SMuOHhIytbRTRySqp6IrmA27AxAkMSGXHr3FWYYvOG2IOxUbTwOOO1LHdKG8sOSwHG7giiPzIpVljZlbOeOlW3YlTl1EuraW2hDKrYI6YqoLiNyAw+ZlyoIGK3YZlnDfO6IMZDc7R3NZ8ukwh3lLM6tkAY4Pr+dVa+xFNqWkjB1CUxRl9mxRxuXtVaDWZXIDqrqg5cdT6HFb8+nIsJSWFjz3wAFx0PvWHdWcdtJuVGjHJQKMEKR/Kk1JanVCMGrNG9AEmXzY9uzqBjpT1DBumY/fpWHod8bORY5HACno2c4NdHMocqyNlegINP4kcFWm6crPYsBTMuGA2qOhP3RVF4VjDcjbnv2/wDrVKCYMoTvjIyTnBX3qlfTuFV1UBGO0Fhhc+lJyXUxUH0J/PKqwbHycFuufehbiOcBUUuwOQe351TZsspY+ZxkDsKkgniEmNwLZ+76E1Kdgkhl9uX965by+4HQf1NVnaNoMIEAHy49al1i4ZbUhCSoP3TwPxrHNyUiw52jAwQMke1Emk9B8l43JWcRkM5RSpJw33cVV8ySaM+SjCDJyT8u7/Cia3ababhBtHKgnOf971p7xyLCDnC98mlG5lJozfJXnOSnXGeB+FV54wx3DJU9MVoyYi5+U8Z57VWwPn3HjPQd6u19CGykXQZjOScHG0cZpIykbmLd1AyQKluYVRx1281A5R2Zk/h6k9qHdEg52yIwVV5wc9gagjCz+cW+UOML64H/ANemai7bdjFcPjJH93qao3cpULjKqBgD2qk7bmbTZi6mrGY88FtvHfA5p1uSJUx25+pqM/NeQ9/kZ8c96uWqCOf1JUsQf4SaS11E3pYoTTeUZlRQCJcH8RxVq3EaXVusm7ygR5pX7wXvjPGazZ0K3ckbNu/eqST/ADretLOW5ljiVN0srAKOnU4qLX0FayLN+fDawpltZA3A8iLNc74n1K0u720isPP+x2FqE/f7dxbc3p7NW54g0/SoGeO61plkThhFbM6gg885Gfwrj7uwazvElM0dxazp58UyAgSrkjoeRgggg1dgaR9Axh0Pyj5lOc5wavIxn2M4/eL1H98e9NaIZDHO7HekZ41QhgW4xwcVimnoekk3qWchNxRcqR930qWKQcgKXyMehrNNyqRhQzFc8ZHP0qQSEFCgJB756UnuHK9zQMgY4diQOg64q7a3CQuNwVwV+6w+7WYJFDZUuM9iM5qzHIpU7kAYDqc81UHbUmSuWX2ykuSwXP503Ykq75SFVBxzVI3Ijwyk+h3dBTJZGZRwf6Gn7SLJUGIsQlfg989aeoKYXgqalVBw2V4XqD0quzHODjHalotS7dCTyxv34pJU3qx6YpUdQR3NLJL5RLYyD6UKyTZLWpnSxl0JVTkfyqvJBnawBx06cVpkGSNyowcYB9KryIywlWHOOo9az2ZpFnNakzQkrtJyeOarF3l2oEKj+JmPGK0r21d1G5h7VSeFo4iWcHt9Khps9SnGDiPtIsOoVz0ztFaUcIljdGCq+M8nvWbbRvsLICQMVt2AKKJCg3dNuP1rSETGquV3RnC1C7Mk5HIqC4hUy5KiQjjHoa2tSAQApzu5/wDrVSMQmiURgjdwecEGiUUtDajN7srJbSmQeYoKEEBWOSakmWN5PKhbYIxjkdquRHy2hRgElQlgScgt2qzpaHyz5iBZWJB7/IfelGPQ1c7K5c0yze3mh84GPcAFJ6PW4YkQDdGSzgZOeBVRrN2gjbzSUh7jp7VZW5kiVEKhoH43+jVutNDzKrc9UPdREoRGZkI+Y/3cmqk7RkAoVMSjIyMEmrjmJ8MhO4AYY81hancbZGhtoG83HyejepFNtJajo03IryCaa1Mpmj2bsEN/Dk8fStHTY0eEREZfOCY2xzSWUamxhBVXRl/eB0wu/uD71ctLSNRK2NrH7u0f56UKKvc2q25dRbqx3sDE7B84ZR1FU5HuS5iWaVg7cccKRx+BrcZJkhQM4HoVFMuLZpVMiplnXO7pn1IquS2qOOE7PUxLk3KSJH5zyMC2HVATjvkd+Kybi08t8XFyNrKZFBXnaew9PpWrcJPlIgjtGW3bwOh+tFvoscyMZpDIe2DjHPHWna7sjtVSMVeRzMVqb25Z7jkEhU28Dit2CN0CDfkkdCBz9fSrb2v2cMiKFlf5lOOnvUTYilCg7kb7zHr9aztbqc9apz6LYlYTMApbceSwUAYqhNaHyCjzO43bgwOPwp1tK8ZyT93vnrzVuSTerblyrdfrUr3kYu8WVWsxbsk0XXGduapw7lnZ8LkE7cVpRALhSQF9WPSqVzLumdIhk5wX7L/iacorcz5+lht0ylPKdd8snRc/qazZbfygGlbdKDgccJ34q6mERyN7NuCgnk9KhAE7NuDZx+dCRLb2Fin82Mqo7jLCo55NilFyoDZyRU+1Ym+U+Xkbto5xVHUpSIt20u3UN/SqSsZvV6FO4GYSf7o5zUVu/mRgMRu5H4UyWUtAc/xYyDTbOOTluFGDxTW5MlbQS5wJAADnJPrWeQUUs3APerU0g56+nBrMvJGMQQH/AFnBHoKT3JRWnY3H7yUYD4Cn/ZqveOJImIHGMZ74qS7mAiHlj5h8ige3esw3aqCrZEnT24pNktXQ2AH7VNKQAsYVRn3q9Zx7iSwO4H06iqNgTMpmLIFkbOD6VrSBoYYzGyswBPHpTREtDJv4o/7TmQAMWh3ADjJBxWpp88qGOeMsLhNrR7ecnqOKxJ5A9w9yr5WFvm4wSvQ1espj5AEcmySNsiTOCvcEGnFq9yZLQXxpqEMxX7R4a33MpDFkeVFLHnO0f0rD1CWe5ljV7ZbaOG32RQqhVUQHoM8nkk5NdRqlx4v16/F/bR6nBDFAI1KOyiZv74XjHGOlcxrdxfvcgam1y1xGm1vPJ3KOuOfrVA27H0TfERchhzyAf50xbV3GVAwRn6/Sp7oSXUgiQAJB3AByauaOY5LRYbgYudxEZHBx6VioJyse3dKNzHa2KhVK8dcGkEPzkJkN+mK66TRorgK0L72xgjuD6+lUptHuIJW3QhdoILdRj1pTpOOpj7RPS5k26yghUUh+uQM/pT1mJyMBXPOSP0qdY3ifHmMducbeDn1FOxCV+VSWI+YSnBP0oitCepRkdw6M4C7DklQCPqaSCSS4IIwAM4zUlzabhuiiwh7lsfpUAlRZtgUOq8gr1z71nbllqbRSaLNxGykx4BbqSD3qo0TyFTkjB6CpQzJjIwx696JP3UR8skkDgd6t9xdbDuRjAAH50rx+YCDx2A9arJI+QN3Q5IqwmW+ZmA/pUqSasKUWmPRWUYBCj09ahZGZ9ynGPXvUisXblhhTzU4TcAcbc1SjdEbGaYHjDmSNG3j5SexrPfTWmkkcD5Tz7V0cm0MEK5FDxqxK7eelJRTeprCrKOhkWliqKoEnH8QHQ1oeUEjdkxx+FItv5YI6ComuNoK4Jq00lYTvN6gFSd2ZyoAHCkZIqkbcLO25uD0K9QexrXWJMBz0x6dagmKxh9yqwI69qNlqaUpOLsjHgt52nHm/KD0Nb2m2GzcVcsp7t/KkswrOudrKwyox0NXrVWVZVHySZ9Ooz2pxSjqaVazasyciMR8FWhcbSM96Jo1WIg7Sr/dBPPv1oCyOu7YDj8hWdczz7WDckc9OMetaXsc8IczLVxAqL5cMnyj5s5/T8aihhSXAk4cHvyVPtVZLmS3ABG+UDLMnOR2PvUsF3EVE1wfLd+SR1HtSfKdHJJbF2K0SGba+xo8ZYsOD749a0FRYQ/z4wM5znIPQiqNlMGCupZgOfnGBtrUN758EsKoiuoyFHPHtVpHLUc72YRyNGPLIG/O4Fuee/FQpKkTM27sTnOQh9QPxqS9UokE371HjHCjB6/8A6qo3ivKuYHAAGQF7Hvn0p6oiMVIlnRreZJEyzOhbaO4+nvWZduYSXjIG/kRg9Pxq088K2ym4lYSlTznO3mse7u1RA0pZyRkEclefSpk+hrCm29Se4ndnWYP5jDgsDy3/ANaq7IRKSz4DAHFZ0WoLHdyiRWCsuVY8Yq8igRpIc7WwSTWW46lOUBLyJgAyD5gBjb0IpjyrHgHlNpJOehqZ7oLujXc7H7uB0+tUpkxulnYMwHyjoo+n+NNpPVGN3syNBJcSqEZli68nDN/hT51XaQAV5yoUcCoxKolXcxJAxwelOLqykScqPes15ky0GRbjDu2urFsA570xpBDM8jk5/nSibcrnjaB8oJ6VWdWaRg5x3BIq+mhk3cWaVWf5gNncjv8AjUVwQWCrtVT6npSykAIFOB124zzVO6eSS4jMi9+cHgCqWxJWnTLNg/L0pjOQdoOQRgHpVy7MatgnIz26iql2mAuW2kdMHk09iXIzp3/ekZIIGM44FUEHmM8oLHd1yPuj/wCvT9Rk3P5Q3ZJy3+FMmZkDKSPn6mhWEQBkVJSGwMjg9c1zeoRMwVlf5n3KD7E4rpifKhuJMA7eFJ+nWsC3ieZoVdQDzL6YHQfjUSBaMtxL5TJEBgKAB6CtRW3JsXkY+YgdKz53D3SlPlOABnofrV+JlgtpcsMnqcdTVxMp6szHiVIsbBtfJPHXNVYbwaLdRS3C+YsbA7M/fAOR/hW9LFujUjGOMZFc7deVc+JNNguQPs6SiaYnn5Aw/nTtqS3c172w0+5ZrgeIEHnEzN9pik8xdx6cZBx04rn/ABXex3VxYQ2s89xHb2v2c3Eg2mYgk5we3OBnsK63V9XE1/cWHiBoJbSRi0UtuFJtQfulCvbGMqe3vXNeLIRDcaVB5sU4jsQC0Lblb94/IP0psSfc92W8WLT3KbEKYIXdgN71PDdqltG8sgUs+NnUj8a5iKQRRIpkJZju+Zc8Ut5f+YwBdgmc7V6HHtWF9Ls96NK7sj0SwvfJ3LazKR1YdjW9aarG0aZhERH8ZJbP1FeXWWtyxRQlY9qr98O3QHv9K3ku5pgJQwKH7rBeDitFWtsYVMPd2Z1N35t2fNtmiDL8xGMGshUk3SSTxxOrty2Mlf8ACiyv8qiu4D9h7+tW4pEMg/eKqjq3v9KTalqQouCsygwPmSbkVUj5+U9fwqgtoks+/eyE5xgH9a2b+NmxmXe55JXGCO1QTbVgYlWLdOeOKzcbv0LTfQxJDukcswODhKWQCRT82COc1fkFutqCEkMhPfoPpVaTkBNh+bqazfY13KcS/vgeiDp3P41aIZgyg8f0p8MXdegqbaApK/ePenGNkK9yCCPL8AkAgfWrTBck5PXFRoNhZtwyRSOdqlgCynse1UnYnluWVCqrZOWqNo380EYAOKSCQOOQAw4+tI+WfIJ47e/pVXVritbckmTzOD+YqA2qiQvxu9DVqNyyjGOfanhGXO/vUtc2qFdrYqMhK5QHI42ntWZeIwI46/Lgnqa2JgFYsG29setVbi0dm3dQOeO1NttHRSaTuxmnbnkDqMbcDAFbsYG5XIIkXqDVCzQ7QGUrKQMNmtRwWRQ2Q/Cgk9T9atLQms05aELK0aKMEK2SCe1Y84dGcqN2zkEdD65rXlQsSx3bQfu5yCRUXlGRiY85xn8Kbuyac+TUzFMqSxhQfKMYy2M5XkjHpWejECWRG3YYHd12kV0jWhlZTDtRH4ZHbH0rLi05TM0JKxxpk5H3iadjrhVix9lelh3YsArMB69zitKMqsgRNqScsMHp+PvUGnwPbyMsVuBCGDbu2fXNSSt87qYPvDIIHTH92tI6bmFWUXKyEmvmdjHHIZtgLFQcH6e/tUUuri6to1DqJo/vpjGR6Gsy6uBCQUYiYf6t9oAH+yfesy3+0XxkWcnDN874x9APep9o0zZUY2uzRsdVmu55IMRrEGJQuOGf29MVUaSRmZJpQwMhkdiMY9fzwKSeK6hKwxRY53kryPTmq9350cStOYhI/CJ/F+XtUXb3NLLoUp3WcTtI21VQlQOg9KTTNQmusRiTaij739BVK9D+aGcKseMJGg4X/Gk0+CVcblwqnIYcVlzdjSpCLheR0W7ZEUiK/Oc5z1qtOxf5F+bbycHNRyJhA24luuc96jF4y3gQx7VPtx+NU2ea4q90W1JbbuX7wyNtSZPlsrKN2ckYqYKu5887RkAd6hnLBwi7SM8kCm421RySlcZGwVzk5JHQ9KRyXfO1d2PpQAvRs7lPQd6YZF54POT+VEexmysqsSy7S2B8p6UO8Yt12DL/AMQx0P8AWlM42Hdk5J49DVV0Z4n5yuRnjvVi3Ew3l7nK5AJ5qjcziOLex47VYuBuQhG49B0NZdy3nuC3KocfU0C5St9nJBdwfMY5waZcW4dgWJAXGRVkyFkIGAM9etRCXIlZs8cAiq0JkmYmpMZZvsXIZ2DH0xirCRRiB5VGMPtx/sKAB+tVRIR9ou2XMrEbBn0Hyir9uoMe1SrBCFK/3j/UVMVdu5Erme4KzCQR/K2QB6CtAqjxxQg8Njcf1FNnA2yF1JLEcDtU4XMybFAUAtg/lTjuS9iW4cR2+QMDHc1ydufOee8YFhO2yLHXaOB+daniKZvISFCd0vy4PHbk/wAqrWM0Njf2Ejn9xbyIWUDOADk1V9SYq5X1HSUt5Ct3fW1rcv1h2u20+jFQQD+eO9ZyafLZ6lsmUBlAOQQQcjIIPcEd66i+ilk1bTJHu5IntwAqxwO5m+YnfGVBDb855Pcg1V18eTNbRKqLJArCQKchCXZggI/uhgD/APWpJXYN2R6XdRKsYUdDWTcxBbVcE5z1NFFc0j6Oi9UFiizx4kGcpz74re0W+mgKwoRsZscjOPpRRThoOtuacB2w+aPvO20+gHPStS1ds9T2/Ciik/iMpGhJIxZDxleBRfE+akR5TYWx6niiirnscy3I4GNxOTIByMYA4HHaqxjUXMygYxnGKKKTWhaGq222BAGSKhgJcjPrRRUPcI9SSQBU4Heqk8zrCHB53bcdqKKoZLBlY2cE7iSOauWnzqFI4znj6UUVC3E9hbg7H+WguwhDbjknFFFaRHFLlFKCV1381LCMM3scUUUupUSwI1K9+oFDkhnXcSAuRnsaKK0lsStyCCRvlJw28nOatSII5CFJ+7n69qKKI7CY2P8AeqVbjPHy8Gp4YY3tjOyAyxkAN7Yooq4ik7IllBguLdYSUWeEM6g8ZzUNwPLud6n7iswHaiitJbEJ+7cw7pjNtSTBUAdsdTUstvFBJFaov7rpz1+uaKKy6nQm7GRrEj6dd/6K5XfgEk5rE1SVt7ljudz8znr+dFFRNs66HxIqRRLKEaQknnvWvFGotxj6UUVENxYt7FiT/U9BnPpVSYALvwN2euKKKctjzmya3lZ2IPTb0qrcuyyKAf8AOaKKpbIytuJLIysoU4yc0REvGd3rRRQ/iMSrexqrZXg7cn3qFJGkQ7j3H4cUUVa3Aiu5DBZfu1UMWxuxzWG4yoBJ4755oopPcuGxVmmkR5lU8L0zVLVJXFpEoYgSyBWx6HrRRQyHuQXBJutucKpUAD8v6VvWaqREMAZTtRRV0tzCoVr4n5j3HNRxO32kZOcJnmiik/iJ6GXfEy6neF+TEqKntkZP61lTLhByeRuNFFDFDcZZ3d1byiCC7uIoCCTGkpCn8K0RCjWuDnG3OM96KKIdQnuj/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This patient with erythema multiforme presented with non-targetoid erythematous papules on the face.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25155=[""].join("\n");
var outline_f24_36_25155=null;
var title_f24_36_25156="Cervical cancer screening tests: Visual inspection methods";
var content_f24_36_25156=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical cancer screening tests: Visual inspection methods",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25156/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25156/contributors\">",
"     Lynette Denny, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25156/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25156/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25156/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25156/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/36/25156/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual inspection of the cervix after application of Lugol's iodine, the first method used for cervical cancer screening, was introduced in the 1930s by Schiller [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25156/abstract/1\">",
"     1",
"    </a>",
"    ]. However, Schiller's test has poor specificity and was almost entirely replaced with the advent of cervical cytology.",
"   </p>",
"   <p>",
"    Current cervical cancer screening protocols typically include a combination of cervical cytology and human papillomavirus (HPV) testing. Visual inspection of the cervix has reemerged as a screening tool for low resource settings, despite its limited specificity, since it is economical and provides immediate results. Visual inspection can be performed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    (VIA) or Lugol's iodine (VILI). These procedures are also referred to as Visual Inspection with Acetic Acid (VIA) or Visual Inspection with Lugol&rsquo;s Iodine (VILI).",
"   </p>",
"   <p>",
"    Techniques for performing visual inspection of the cervix will be reviewed here. The utility of visual inspection methods, strategies for cervical cancer screening, and techniques for other tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19160?source=see_link\">",
"     \"Screening for cervical cancer in resource-limited settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual inspection is indicated for women for whom cervical cancer screening is recommended and for whom these methods are the best screening option (ie, women who do not have access to cervical cytology and HPV testing). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H20#H20\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Screening parameters'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19160?source=see_link&amp;anchor=H4#H4\">",
"     \"Screening for cervical cancer in resource-limited settings\", section on 'Approach to cervical cancer screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are NO absolute contraindications to visual inspection of the cervix. VIA, rather than VILI, should be performed in women with an allergy to iodine. Visual inspection can be performed during pregnancy, but cervical biopsies are relatively contraindicated in pregnant women unless invasive cancer is suspected.",
"   </p>",
"   <p>",
"    Active cervicitis is treated before visual inspection because inflammation and infection impede accurate assessment of epithelial abnormalities. Although vaginal infections do not interfere with evaluation, treatment before visual inspection may allow the patient to be more comfortable during the examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/64?source=see_link\">",
"     \"Acute cervicitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=see_link\">",
"     \"Approach to women with symptoms of vaginitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;VIA and VILI have similar efficacy for the detection of cervical intraepithelial neoplasia or cancer. In our experience, VIA allows a more nuanced and detailed examination of the cervix and is preferable to VILI. The efficacy of visual inspection methods for cervical cancer screening and comparisons with other methods are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19160?source=see_link&amp;anchor=H8#H8\">",
"     \"Screening for cervical cancer in resource-limited settings\", section on 'Visual inspection methods'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are used for the performance of visual inspection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examination table with stirrups or leg rests; if this is not available, the examination can be performed with the patient supine with knees bent and abducted (ie, frog legs position)",
"     </li>",
"     <li>",
"      Vaginal speculum",
"     </li>",
"     <li>",
"      Light source that can illuminate the cervix",
"     </li>",
"     <li>",
"      3 to 5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      or 4 to 5 percent Lugol's iodine",
"     </li>",
"     <li>",
"      Large cotton swabs",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Lugol's iodine is a solution of 5 g of iodine and 10 g of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/27/30134?source=see_link\">",
"     potassium iodide",
"    </a>",
"    in 100 mL distilled water [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25156/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visual inspection is performed using the naked eye, as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25156/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Position the patient in the dorsal lithotomy or frog leg position",
"     </li>",
"     <li>",
"      Insert a speculum into the vagina and visualize the cervix",
"     </li>",
"     <li>",
"      Inspect the cervix and note any lesions",
"     </li>",
"     <li>",
"      Apply either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      or Lugol's iodine using a cotton swab, wait for one minute",
"     </li>",
"     <li>",
"      Inspect the cervix again and note any lesions or color changes",
"     </li>",
"     <li>",
"      Document the findings",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    , a positive test is characterized by opaque, dense, well-defined acetowhite areas that touch the squamocolumnar junction or are close to the external os or by the presence of a cervical lesion that turns acetowhite (",
"    <a class=\"graphic graphic_picture graphicRef62988 \" href=\"UTD.htm?5/47/5872\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef51434 \" href=\"UTD.htm?17/39/18032\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25156/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. The absence of color change is a negative test.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     Acetic acid",
"    </a>",
"    dehydrates cells so that squamous cells with relatively large or dense nuclei (eg, metaplastic cells, dysplastic cells, cells infected with human papilloma virus) reflect light and therefore appear white. Blood vessels and columnar cells are not affected by acetic acid, but become easier to visualize against the white background. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link\">",
"     \"Colposcopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When using Lugol's iodine, a positive test consists of pale yellow areas against a darker background; uniform uptake of stain is a negative test. Glycogen containing cells will take up iodine and become dark brown. Nonglycogenated cells, such as normal columnar or glandular cells, high-grade lesions, and many low-grade lesions, will not take up iodine and remain light yellow (",
"    <a class=\"graphic graphic_picture graphicRef56093 \" href=\"UTD.htm?34/63/35829\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no known complications of visual inspection of the cervix. Patients may report a transient sensation of vaginal burning with application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    . If biopsy is performed, infection or excessive bleeding occurs rarely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link&amp;anchor=H13#H13\">",
"     \"Colposcopy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MODIFICATIONS OR ALTERNATIVE TECHNIQUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Magnification",
"    </span>",
"    &nbsp;&mdash;&nbsp;VIA can be combined with examination of the cervix with a 2 to 4x magnifying lens, in contrast to the 7.5 to 30x magnification used for colposcopy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25156/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, magnification does not appear to improve the performance of VIA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19160?source=see_link&amp;anchor=H10#H10\">",
"     \"Screening for cervical cancer in resource-limited settings\", section on 'VIA with magnification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Speculoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Speculoscopy is similar to VIA, with the addition of a blue-white chemiluminescent light source attached to the upper speculum blade. The examiner can assess the cervix for acetowhite lesions directly or with the use of limited magnification (4 to 6x).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cervicography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervicography refers to standardized photography of the cervix after the application of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"     acetic acid",
"    </a>",
"    . The 35 mm magnified images can then be interpreted by qualified evaluators anywhere in the world, and the patient triaged accordingly. In some clinical settings, cervicography is considered to be an adjunct to cervical cytology rather than a primary screening method.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FOLLOW-UP OF ABNORMAL FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Areas with abnormalities and gross cervical lesions should be biopsied, if possible. In protocols in which treatment immediately follows screening (\"see and treat\"), biopsy is important to identify women with invasive cancer. Features suggestive of cervical cancer include a lesion that involves three or four quadrants of the transformation zone or extends into the cervical canal or vaginal walls.",
"   </p>",
"   <p>",
"    Detection of cervical intraepithelial neoplasia is enhanced by obtaining multiple biopsies from the most abnormal appearing area",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    from more than one abnormal appearing area. Biopsies should be taken from inferior to superior to avoid bleeding over the target sites.",
"   </p>",
"   <p>",
"    Each specimen is individually labeled according to its location on the cervix (as if taken from the face of a clock) and placed in a separate, labeled container containing a permanent fixative.",
"   </p>",
"   <p>",
"    Biopsy of a large cervical mass presumed to be a cervical cancer may lead to significant bleeding. In such patients, it may be preferable to defer biopsy until a full examination under anesthesia can be performed for staging and where there are facilities to manage excessive bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Local anesthesia is not routinely used for biopsies of the cervix and upper vagina, since injection of the anesthetic is probably as painful as the biopsy. Distraction techniques (eg, asking the patient to cough at the time of biopsy) are as effective as local anesthetic injection and require less time. Topical and oral analgesics are ineffective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link&amp;anchor=H10#H10\">",
"     \"Colposcopy\", section on 'Biopsies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of an increased risk of bleeding, biopsies are relatively contraindicated in patients on anticoagulants, who have a known bleeding disorder, or who are pregnant. If a biopsy is necessary in such patients, appropriate steps should be taken to minimize bleeding and to treat heavy bleeding if it occurs.",
"   </p>",
"   <p>",
"    In settings where biopsy and treatment of lesions are not possible, women with abnormal findings should be referred to an appropriate clinician for further evaluation and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Visual inspection of the cervix after application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      (VIA) or Lugol's iodine (VILI) is used for cervical cancer screening in women who do not have access to cervical cytology or human papillomavirus testing. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no absolute contraindications to visual inspection of the cervix. VIA, rather than VILI, should be performed in women with an allergy to iodine. This examination can be performed during pregnancy; cervical biopsies are relatively contraindicated. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing cervical cancer screening with visual inspection of the cervix, we suggest VIA rather than VILI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Effectiveness'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19160?source=see_link&amp;anchor=H8#H8\">",
"       \"Screening for cervical cancer in resource-limited settings\", section on 'Visual inspection methods'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Visual inspection of the cervix is performed using the naked eye after application of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19011?source=see_link\">",
"       acetic acid",
"      </a>",
"      or Lugol's iodine. With acetic acid, a positive test is characterized by opaque, dense, well-defined acetowhite areas touching the squamocolumnar junction or close to the external os or presence of a cervical lesion that turns acetowhite (",
"      <a class=\"graphic graphic_picture graphicRef62988 \" href=\"UTD.htm?5/47/5872\">",
"       picture 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef51434 \" href=\"UTD.htm?17/39/18032\">",
"       picture 2",
"      </a>",
"      ). Using Lugol's iodine, a positive test consists of pale yellow areas against a darker background. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Areas with abnormalities and gross cervical lesions should be biopsied. In protocols in which treatment immediately follows screening (\"screen and treat\"), biopsy is important to identify women with invasive cancer who require further treatment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Follow-up of abnormal findings'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25156/abstract/1\">",
"      Schiller W. Leucoplakia, leucokeratosis, and carcinoma of the cervix. Am J Obstet Gynecol 1938; 35:17.",
"     </a>",
"    </li>",
"    <li>",
"     file://screening.iarc.fr/viavilichap3.php?lang=1 (Accessed on April 11, 2012).",
"    </li>",
"    <li>",
"     World Cancer Report 2008, Boyle P, Levin B (Eds), International Agency for Research on Cancer, Lyon Cedex, France 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25156/abstract/4\">",
"      Arbyn M, Sankaranarayanan R, Muwonge R, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008; 123:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25156/abstract/5\">",
"      Sankaranarayanan R, Shastri SS, Basu P, et al. The role of low-level magnification in visual inspection with acetic acid for the early detection of cervical neoplasia. Cancer Detect Prev 2004; 28:345.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3231 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-E64BEA0BEF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25156=[""].join("\n");
var outline_f24_36_25156=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Inspection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MODIFICATIONS OR ALTERNATIVE TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Magnification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Speculoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cervicography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FOLLOW-UP OF ABNORMAL FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3231\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3231|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/47/5872\" title=\"picture 1\">",
"      Low grade CIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/39/18032\" title=\"picture 2\">",
"      High grade CIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/63/35829\" title=\"picture 3\">",
"      Visual inspect lugols",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/64?source=related_link\">",
"      Acute cervicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36633?source=related_link\">",
"      Approach to women with symptoms of vaginitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=related_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19160?source=related_link\">",
"      Screening for cervical cancer in resource-limited settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_36_25157="Pleural plaques asbestos PA";
var content_f24_36_25157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Asbestos-related pleural plaques",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 329px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph shows multiple pleural plaques in a shipyard worker exposed to asbestos. These lesions can be mistaken for multiple pulmonary nodules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25157=[""].join("\n");
var outline_f24_36_25157=null;
var title_f24_36_25158="Overview of puncture wounds";
var content_f24_36_25158=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of puncture wounds",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25158/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25158/contributors\">",
"     Larry M Baddour, MD, FIDSA",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25158/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25158/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25158/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25158/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/36/25158/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 22, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Puncture wounds, particularly to the plantar surface of the foot, are common and occur in all age groups. For example, over 7 percent of patients with lower extremity trauma who presented to an emergency department in one survey had plantar puncture wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/1\">",
"     1",
"    </a>",
"    ]. Patients seek medical attention for these wounds for a variety of reasons including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Questions about the need for tetanus immunization",
"     </li>",
"     <li>",
"      Pain relief",
"     </li>",
"     <li>",
"      Treatment of established infection involving soft tissues or musculoskeletal structures",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical aspects and treatment approach to puncture wounds are reviewed here. Puncture wounds that occur in specialized settings such as water exposure are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=see_link\">",
"     \"Soft tissue infections following water exposure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Puncture wounds can occur in a broad array of circumstances. The majority of plantar puncture wounds are due to nails; less commonly, glass, wood, or other metal objects besides nails are the source of the puncture. In one series of children, these wounds occurred more often in the months of May through October [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/2\">",
"     2",
"    </a>",
"    ]. Superficial wounds generally heal without complications, but deeper penetration from the puncture is a risk factor for more serious infection. Puncture wounds of the metatarsal-phalangeal joints or surrounding tissue often penetrate deeper because this is a weight-bearing area [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serial analysis of a patient population over a seven-year period has identified risk factors for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The risk of infection was increased in patients who had either puncture wounds to the forefoot or wore shoes at the time of injury. A case control study evaluated 146 patients hospitalized with puncture wounds, 77 of whom had diabetes mellitus, some with neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/5\">",
"     5",
"    </a>",
"    ]. The diabetic patients presented to physicians later following puncture injury than patients without diabetes (8.7 versus 5.3 days) and more often developed osteomyelitis (35 versus 13 percent). They were also five times as likely to require multiple operations and 46 times as likely to have a lower extremity amputation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections complicating puncture wounds can be caused by a variety of microorganisms. Staphylococcus aureus and beta-hemolytic streptococci are common causes of skin and soft tissue infections and can produce wound infections after puncture. Streptococcus iniae can also cause infections complicating puncture wounds that occur during preparation of fresh seafood for ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/7\">",
"     7",
"    </a>",
"    ]. Gram-negative bacteria also have been recovered from infected sites. P. aeruginosa has been commonly isolated in patients who suffered plantar puncture while wearing tennis shoes, perhaps due to the moist inner sole of the shoe which would provide a suitable environment for growth of this organism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The place where the injury occurred also influences the infecting microorganisms. As an example, puncture in a barnyard should prompt consideration of bowel flora of farm animals as prospective pathogens, while injury in the vicinity of a pond should raise the possibility of Aeromonas species.",
"   </p>",
"   <p>",
"    When osteomyelitis arises following a puncture injury, S. aureus is the most common pathogen in diabetic patients and P. aeruginosa in nondiabetics [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/5\">",
"     5",
"    </a>",
"    ]. Polymicrobial osteomyelitis occurs more frequently in diabetics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful history is required to manage the patient and to identify risk factors for complications of the puncture injury. The following information is important in evaluating patients following puncture injury:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Description of the penetrating object",
"     </li>",
"     <li>",
"      Scene of the injury",
"     </li>",
"     <li>",
"      Depth of penetration",
"     </li>",
"     <li>",
"      Footwear, if plantar wound, at the time of injury",
"     </li>",
"     <li>",
"      Determination if a retained foreign body is present",
"     </li>",
"     <li>",
"      Elapsed time since the injury",
"     </li>",
"     <li>",
"      Medical history of the patient (especially history of diabetes mellitus, neuropathy, or vascular disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical examination should include an extensive evaluation of the involved area and a determination of the site of injury. The area should be inspected for retained foreign material and signs of infection. The vascular and neurologic status of the involved area should be evaluated.",
"   </p>",
"   <p>",
"    When to order plain radiographs or other imaging of the area is an issue for clinical judgment. Indications for use of plain radiographs include, but are not limited to the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inability to completely visualize the interior of the wound",
"     </li>",
"     <li>",
"      Deep wounds caused by glass",
"     </li>",
"     <li>",
"      If the patient believes there is a retained object",
"     </li>",
"     <li>",
"      If the object is small, thin, breakable, or brittle",
"     </li>",
"     <li>",
"      If the object, such as a sewing needle, can easily be buried beneath the skin surface",
"     </li>",
"     <li>",
"      If there is inordinate wound pain, localized tenderness over the wound, or a painful mass or discoloration under the skin surface",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The density, configuration, size, and orientation of the foreign body will determine whether a plain film is sufficiently sensitive to permit detection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/9\">",
"     9",
"    </a>",
"    ]. Use of an underpenetrated, soft tissue technique may improve the sensitivity of the plain film to detect foreign bodies in a puncture wound [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other techniques that have been used to detect foreign bodies include ultrasonography, computed tomography, and magnetic resonance imaging. The last technique may not be available in a timely fashion and cannot be used to identify foreign bodies made of metal. Nevertheless, MRI can be helpful when other techniques have failed to detect the presence of a suspected foreign body.",
"   </p>",
"   <p>",
"    We recommend radiographic evaluation for the presence of a retained foreign body in patients who present with evidence of infection or with relapsing infection despite local wound care and antibiotic administration. MRI is an excellent tool to determine the presence of soft tissue abscess, septic arthritis, and osteomyelitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=see_link\">",
"     \"Overview of osteomyelitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .) Computed tomography should be employed instead of MRI in patients with possible retention of metal foreign bodies.",
"   </p>",
"   <p>",
"    Triple-phase technetium bone scan is not as useful for distinguishing bone from soft tissue involvement because of the lack of anatomic detail and specificity of this technique. Acute bone trauma caused by a foreign object without accompanying infection also can produce a positive bone scan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF UNINFECTED PUNCTURE WOUNDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the common occurrence of puncture wounds, prospective investigation has not been conducted to identify effective management. However, we recommend addressing the following issues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tetanus immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tetanus can complicate a puncture wound and the patient's tetanus immunization status should be reviewed. Tetanus immunization should be administered to those who have completed only the primary series of immunization or who received a booster immunization more than five years previously (",
"    <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Tetanus toxoid (0.5 mL intramuscularly) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"     tetanus immune globulin",
"    </a>",
"    (250 units intramuscularly) should be given to patients with puncture wounds who have received less than three doses of tetanus toxoid or whose immunization status is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Foreign body removal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foreign bodies should be removed to decrease the chance of wound infection and to reduce pain in cases of plantar involvement, which can result in gait disturbances or impairment of mechanical function of the foot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scrubbing the surface of a puncture wound with an iodophor or other antiseptic solution and trimming the jagged edges of the wound is routine. The appropriateness of other treatment options in care of the wound, including coring, probing, and irrigating the puncture wound are less well-established [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. Deep irrigation of a puncture wound is difficult; local anesthesia is required and there are theoretical risks for dissemination of contaminating microorganisms. Probing and coring the wound are also controversial practices that require local anesthesia; there is no proof that these practices result in benefit to the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/3,9\">",
"     3,9",
"    </a>",
"    ]. We do not recommend routine application of any of these procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no prospective, randomized trials that have examined the role of antibiotic administration in the prevention of infection following puncture wounds. The lack of data makes it difficult to offer recommendations on antibiotic therapy and duration. Thus, the decision to administer antibiotics in high-risk patients should be left to the discretion of the treating physician [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/10\">",
"     10",
"    </a>",
"    ]. As a minimum, all patients with puncture wounds should be followed with frequent evaluations for evidence of infection regardless of whether or not they receive prophylactic antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF INFECTED PUNCTURE WOUNDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop puncture wound infections should be thoroughly evaluated for the presence of foreign bodies. The patient's tetanus immunization should also be reviewed as noted above. Surgical debridement or abscess drainage is an important component of treatment of infected puncture wounds. All surgical specimens should be sent for anaerobic and aerobic bacterial cultures and in vitro susceptibility obtained for each culture isolate; other cultures (eg, mycobacteria, fungi) should be obtained if the patient reports an unusual exposure (fish tank) or if previous routine bacterial cultures have been unrevealing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics should be administered in the setting of infection following puncture injury. Initial empiric therapy should include coverage for S. aureus and beta-hemolytic streptococci. Epidemiologic factors should dictate empiric coverage for additional organisms, including methicillin resistant Staphylococcus aureus (MRSA) (",
"    <a class=\"graphic graphic_table graphicRef53504 \" href=\"UTD.htm?5/9/5275\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    First generation cephalosporin provides coverage for methicillin susceptible S. aureus and beta-hemolytic streptococci.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    could be used for patients with risk factors for community acquired-MRSA infection. Patients with potential polymicrobial infection (puncture wound contaminated with dirt or feces), should receive broader treatment (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"     amoxicillin-clavulanate",
"    </a>",
"    ) with activity against gram negative and anaerobic organisms.",
"   </p>",
"   <p>",
"    Subsequently antibiotic therapy should be tailored to susceptibility testing of wound culture isolates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Plantar wounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two clinical trials have established that a 7 to 14 day course of therapy is sufficient for treatment of plantar wound infections, when coupled with initial surgical intervention; this is in contrast to the usual course of four weeks or longer for established osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one of these studies,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (400 mg IV twice daily for the first 24 hours followed by 750 mg PO twice daily) was administered to 23 adults suffering infections of the plantar surface of the foot after nail puncture wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/11\">",
"     11",
"    </a>",
"    ]. The duration of therapy was either 7 days for cellulitis or 14 days for early bone involvement (defined as osteochondritis based on radiography or bone scan). Ciprofloxacin was universally successful when combined with initial surgical drainage, debridement, or exploration. Microbiologic analysis revealed that 18 patients had P. aeruginosa, two had S. aureus, and one had both bacteria. All isolates were susceptible to ciprofloxacin.",
"   </p>",
"   <p>",
"    The second study was a 10-year evaluation of 77 children with puncture wound infections caused by Pseudomonas species [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25158/abstract/12\">",
"     12",
"    </a>",
"    ]. Short-course antibiotic treatment was successful in those children who underwent early surgical intervention. The average duration of treatment was 7.5 days following surgery; therapy was administered intravenously for the duration of treatment in patients with bone or joint involvement. Only two patients relapsed and both had previously undetected septic arthritis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     Ciprofloxacin",
"    </a>",
"    , either alone or in combination with an antipseudomonal beta-lactam (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    ), has been useful in patients with plantar puncture wound infection due to P. aeruginosa in the past. Resistance to ciprofloxacin among P. aeruginosa isolates is now frequently seen. If resistance to ciprofloxacin is present, then no oral treatment options are available. The newer fluoroquinolones (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) have less activity than ciprofloxacin against P. aeruginosa and should not be used instead of ciprofloxacin in cases of infection due to fluoroquinolone-susceptible P. aeruginosa. The newer fluoroquinolones have enhanced gram-positive activity and should be considered instead of ciprofloxacin in adults who have mixed infections due to susceptible, aerobic gram-negative bacilli (other than P. aeruginosa) and S. aureus. Fluoroquinolones can be administered orally after surgery has been performed and the patient is eating; a 24 hour intravenous course is common in such patients. Unless there is evidence of established osteomyelitis upon presentation, therapy for 7 to 14 days is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?30/34/31266?source=see_link\">",
"       \"Patient information: Tetanus (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43185?source=see_link\">",
"       \"Patient information: Taking care of cuts and scrapes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H407975478\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients seek medical attention for puncture wounds to the foot for a variety of reasons, including questions about the need for tetanus immunization, pain relief, and treatment of established infection involving soft tissues or musculoskeletal structures. The majority of plantar puncture wounds are due to nails. Superficial wounds generally heal without complications, but deeper penetration from the puncture is a risk factor for more serious infection. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors associated with infection following a puncture wound include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Forefoot injury.",
"     </li>",
"     <li>",
"      Wearing shoes at the time of the injury.",
"     </li>",
"     <li>",
"      Diabetes mellitus; diabetics are more likely than non-diabetics to present for medical care later, to develop osteomyelitis, and to require multiple operations and lower extremity amputation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infections complicating puncture wounds can be caused by a variety of microorganisms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Staphylococcus aureus and beta-hemolytic streptococci are common causes of skin and soft tissue infections and can produce wound infections after puncture.",
"     </li>",
"     <li>",
"      Pseudomonas aeruginosa has been commonly isolated in patients who suffered plantar puncture while wearing tennis shoes.",
"     </li>",
"     <li>",
"      When osteomyelitis arises following a puncture injury, S. aureus is the most common pathogen in diabetic patients and P. aeruginosa in nondiabetics.",
"     </li>",
"     <li>",
"      Polymicrobial osteomyelitis occurs more frequently in diabetics.",
"     </li>",
"     <li>",
"      Certain organisms are associated with specific exposures (eg, Streptococcus iniae with preparation of fresh seafood, Aeromonas spp with exposure to a pond). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A careful history is required to manage the patient and to identify risk factors for complications of the puncture injury. Physical examination should include an extensive evaluation of the involved area and a determination of the site of injury. The area should be inspected for retained foreign material and signs of infection. The vascular and neurologic status of the involved area should be evaluated. A plain radiograph or another imaging study is indicated if it is not possible to completely visualize the interior of the wound, if there is concern for a foreign body, or if there is inordinate wound pain, localized tenderness over the wound, or a painful mass or discoloration under the skin surface. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tetanus can complicate a puncture wound and the patient's tetanus immunization status should be reviewed:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tetanus immunization should be administered to those who have completed only the primary series of immunization or who received a booster immunization more than five years previously (",
"      <a class=\"graphic graphic_table graphicRef61087 \" href=\"UTD.htm?7/52/8013\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Tetanus toxoid (0.5 mL intramuscularly) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/293?source=see_link\">",
"       tetanus immune globulin",
"      </a>",
"      (250 units intramuscularly) should be given to patients with puncture wounds who have received less than three doses of tetanus toxoid or whose immunization status is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"       \"Tetanus-diphtheria toxoid vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Foreign bodies should be removed to decrease the chance of wound infection and to reduce pain in cases of plantar involvement, which can result in gait disturbances or impairment of mechanical function of the foot. Scrubbing the surface of a puncture wound with an iodophor or other antiseptic solution and trimming the jagged edges of the wound is routine. &nbsp;(See",
"      <a class=\"local\" href=\"#H7\">",
"       'Foreign body removal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Wound care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical debridement or abscess drainage is an important component of treatment of infected puncture wounds.All surgical specimens should be sent for anaerobic and aerobic bacterial cultures and in vitro susceptibility obtained for each culture isolate; other cultures (eg, mycobacteria, fungi) should be obtained if the patient reports an unusual exposure (fish tank) or if previous routine bacterial cultures have been unrevealing. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of infected puncture wounds'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antibiotics should be administered in the setting of infection following puncture injury:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Initial empiric therapy should include coverage for S. aureus and beta-hemolytic streptococci. Epidemiologic factors should dictate empiric coverage for additional organisms, including methicillin resistant Staphylococcus aureus (MRSA) (",
"      <a class=\"graphic graphic_table graphicRef53504 \" href=\"UTD.htm?5/9/5275\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First generation cephalosporin provides coverage for methicillin susceptible S. aureus and beta-hemolytic streptococci.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      could be used for patients with risk factors for community acquired-MRSA infection. Patients with potential polymicrobial infection (puncture wound contaminated with dirt or feces), should receive broader treatment (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/56/43912?source=see_link\">",
"       amoxicillin-clavulanate",
"      </a>",
"      ) with activity against gram negative and anaerobic organisms. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      , either alone or in combination with an antipseudomonal beta-lactam (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/33/16919?source=see_link\">",
"       cefepime",
"      </a>",
"      ), has been useful in patients with plantar puncture wound infection due to P. aeruginosa in the past. Resistance to ciprofloxacin among P. aeruginosa isolates is now frequently seen. The newer fluoroquinolones (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"       levofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      ) have less activity than ciprofloxacin against P. aeruginosa and should not be used instead of ciprofloxacin in cases of infection due to fluoroquinolone-susceptible P. aeruginosa. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Plantar wounds'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The newer fluoroquinolones have enhanced gram-positive activity and should be considered instead of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      in adults who have mixed infections due to susceptible, aerobic gram-negative bacilli (other than P. aeruginosa) and S. aureus. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Plantar wounds'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25158/abstract/1\">",
"      Reinherz RP, Hong DT, Tisa LM, et al. Management of puncture wounds in the foot. J Foot Surg 1985; 24:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25158/abstract/2\">",
"      Fitzgerald RH Jr, Cowan JD. Puncture wounds of the foot. Orthop Clin North Am 1975; 6:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25158/abstract/3\">",
"      Chisholm CD, Schlesser JF. Plantar puncture wounds: controversies and treatment recommendations. Ann Emerg Med 1989; 18:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25158/abstract/4\">",
"      Lavery LA, Harkless LB, Ashry HR, Felder-Johnson K. Infected puncture wounds in adults with diabetes: risk factors for osteomyelitis. J Foot Ankle Surg 1994; 33:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25158/abstract/5\">",
"      Lavery LA, Walker SC, Harkless LB, Felder-Johnson K. Infected puncture wounds in diabetic and nondiabetic adults. Diabetes Care 1995; 18:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25158/abstract/6\">",
"      Armstrong DG, Lavery LA, Quebedeaux TL, Walker SC. Surgical morbidity and the risk of amputation due to infected puncture wounds in diabetic versus nondiabetic adults. South Med J 1997; 90:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25158/abstract/7\">",
"      Koh TH, Sng LH, Yuen SM, et al. Streptococcal cellulitis following preparation of fresh raw seafood. Zoonoses Public Health 2009; 56:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25158/abstract/8\">",
"      Fisher MC, Goldsmith JF, Gilligan PH. Sneakers as a source of Pseudomonas aeruginosa in children with osteomyelitis following puncture wounds. J Pediatr 1985; 106:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25158/abstract/9\">",
"      Lammers RL, Magill T. Detection and management of foreign bodies in soft tissue. Emerg Med Clin North Am 1992; 10:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25158/abstract/10\">",
"      Chudnofsky CR, Sebastian S. Special wounds. Nail bed, plantar puncture, and cartilage. Emerg Med Clin North Am 1992; 10:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25158/abstract/11\">",
"      Raz R, Miron D. Oral ciprofloxacin for treatment of infection following nail puncture wounds of the foot. Clin Infect Dis 1995; 21:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25158/abstract/12\">",
"      Jacobs RF, McCarthy RE, Elser JM. Pseudomonas osteochondritis complicating puncture wounds of the foot in children: a 10-year evaluation. J Infect Dis 1989; 160:657.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7661 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25158=[""].join("\n");
var outline_f24_36_25158=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H407975478\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MANAGEMENT OF UNINFECTED PUNCTURE WOUNDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tetanus immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Foreign body removal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Wound care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT OF INFECTED PUNCTURE WOUNDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Plantar wounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H407975478\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7661\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7661|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/52/8013\" title=\"table 1\">",
"      Tetanus prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/9/5275\" title=\"table 2\">",
"      Risk factors for MRSA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4649?source=related_link\">",
"      Overview of osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/11/43185?source=related_link\">",
"      Patient information: Taking care of cuts and scrapes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?30/34/31266?source=related_link\">",
"      Patient information: Tetanus (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31687?source=related_link\">",
"      Soft tissue infections following water exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_36_25159="Technique of pericardiocentesis";
var content_f24_36_25159=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Technique of pericardiocentesis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25159/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25159/contributors\">",
"     Sunil Mankad, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25159/contributors\">",
"     Lawrence J Sinak, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25159/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25159/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25159/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25159/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/36/25159/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although percutaneous pericardiocentesis dates back to the 18",
"    <sup>",
"     th",
"    </sup>",
"    century, significant refinement incorporating ultrasound guidance has evolved over the last 30 years, making it a safer and simpler procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The most common indication for pericardiocentesis, or drainage of fluid from the pericardiac sac surrounding the heart, is to relieve cardiac tamponade by removing pericardial fluid. In the absence of cardiac tamponade, examination of the pericardial fluid can be helpful for diagnostic purposes in a variety of situations (eg, suspected purulent pericarditis or suspected neoplastic pericardial effusion). The pericardial fluid in such cases may help establish the diagnosis as well as guide treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35303?source=see_link\">",
"     \"Purulent pericarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=see_link\">",
"     \"Pericardial disease associated with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the preparation for, techniques involved in, and potential complications associated with pericardiocentesis. Detailed discussions regarding the etiology, diagnostic approach, and management of pericardial diseases and pericardial effusions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link\">",
"     \"Etiology of pericardial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=see_link\">",
"     \"Diagnosis and treatment of pericardial effusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=see_link\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H238570\">",
"    <span class=\"h1\">",
"     OBJECTIVES OF PERICARDIAL FLUID REMOVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardiocentesis should achieve several objectives:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Relief of cardiac tamponade, when present",
"     </li>",
"     <li>",
"      Obtain fluid for appropriate analysis (which may include biochemical, cytologic, bacteriologic,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunologic testing)",
"     </li>",
"     <li>",
"      Assessment of hemodynamics after pericardial pressure has been lowered to exclude effusive constrictive pericarditis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link&amp;anchor=H23#H23\">",
"       \"Constrictive pericarditis\", section on 'Effusive constrictive pericarditis'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If there is a strong suspicion of constrictive pericarditis or effusive-constrictive pericarditis, and the patient is hemodynamically stable to allow for the extra time needed, a right heart catheterization should precede pericardiocentesis, and the right heart catheter should remain in place until the procedure has been completed. Right heart and pericardial pressures are recorded simultaneously; the catheter is then pulled back to the right atrium where pressure is monitored throughout the procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\"",
"    </a>",
"    .) At the conclusion of pericardiocentesis, pericardial, right atrial, and pulmonary capillary wedge pressures are measured again. The pericardial pressure should be lower than right atrial and wedge pressures, which should then be normal in magnitude and waveform. Further evaluation for constrictive pericarditis may be necessary if these hemodynamic end points are not achieved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOICE OF PERCUTANEOUS PERICARDIOCENTESIS OR SURGICAL DRAINAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision of surgical versus percutaneous pericardiocentesis should be based on the individual experience at a particular institution [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Pericardial fluid can be sampled or drained either by percutaneous pericardiocentesis or via surgical incision. The risk of serious damage to the heart or a coronary artery with needle-based percutaneous pericardiocentesis has fallen appreciably in the last three decades, although a small risk of complications remains. A number of surgical techniques are available, but they, too, may result in complications, although less frequently. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=see_link&amp;anchor=H22#H22\">",
"     \"Pericardial disease associated with malignancy\", section on 'Surgical decompression of the pericardium'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A non-randomized comparison between a minimally invasive echocardiographically-guided percutaneous pericardiocentesis procedure and an open surgical approach in patients with cardiac tamponade suggested that the echocardiographically-guided approach was preferred because of lower complication and mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/7\">",
"     7",
"    </a>",
"    ]. This approach is also preferred in hemodynamically unstable patients because of its ability to be performed more rapidly, whereas an open surgical approach might be preferred for traumatic cases, purulent pericarditis, or with recurrent malignant pericardial effusions.",
"   </p>",
"   <p>",
"    In addition, there are several specific settings in which there is a clear preference for one of these procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Small, organized, or loculated effusions &ndash; With small, organized or loculated effusions, needle aspiration should generally be avoided unless a highly skilled operator well versed in echocardiographically-guided percutaneous techniques is available. On the other hand, large, clear effusions can usually be percutaneously drained safely and effectively.",
"     </li>",
"     <li>",
"      Acute cardiac tamponade complicating percutaneous coronary intervention &ndash; An exception to this rule regarding the size of an effusion is acute cardiac tamponade complicating a cardiac procedure (eg, percutaneous coronary intervention, invasive electrophysiology study or ablation) for which anticoagulation has been given. In this setting, the effusion is often small, but pericardial pressure rises very quickly. Efforts to achieve hemostasis generally include prolonged intracoronary balloon inflation and reversal of anticoagulation, when feasible. Thereafter, most skilled interventional cardiologists or electrophysiologists can safely tap the effusion, especially with echocardiographic guidance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=see_link&amp;anchor=H11#H11\">",
"       \"Periprocedural complications of percutaneous coronary intervention\", section on 'Perforation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Aortic dissection or myocardial rupture &ndash; Pericardiocentesis should generally not be attempted in patients with pericardial effusion due to aortic dissection or myocardial rupture, as relief of cardiac tamponade may lead to more severe bleeding. Such patients require emergent surgical intervention. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=see_link\">",
"       \"Management of aortic dissection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Surgical drainage is preferred in traumatic hemopericardium and purulent pericarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=see_link\">",
"       \"Post-cardiac injury syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35303?source=see_link\">",
"       \"Purulent pericarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In situations where a pericardial biopsy is needed, an open surgical procedure has historically been required to perform the pericardial biopsy. However, transcutaneous pericardioscopy with the use of a fiberoptic endoscope permits biopsy of the pericardium and myocardium, even in the absence of a large pericardial effusion [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/9\">",
"       9",
"      </a>",
"      ]. Thoracoscopic biopsy of the pericardium is another alternative [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1718814\">",
"    <span class=\"h2\">",
"     Relative contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;While pericardiocentesis can be safely performed in most patients, there are situations in which the procedure may need to be postponed.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe pulmonary hypertension &mdash; Caution must be taken if pericardiocentesis is performed in patients with severe pulmonary hypertension. In the setting of severe pulmonary hypertension, the pericardial effusion may be preventing significant dilatation of the right ventricle, which may be crucial to supporting the right ventricle. Drainage of the pericardial fluid may lead to loss of this support of the right ventricle, causing worsening of right ventricular function and more severe tricuspid regurgitation.",
"     </li>",
"     <li>",
"      Bleeding",
"      <span class=\"nowrap\">",
"       diathesis/coagulopathy",
"      </span>",
"      &mdash; The relative risks and benefits of pericardiocentesis should also be closely considered if a bleeding diathesis or coagulopathy is present. Although the risk of complications is low, bleeding risk is higher in the setting of coagulopathy. In addition, the subcostal approach should be avoided in the setting of a coagulopathy as bleeding from liver injury can be life threatening.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ELECTIVE PERICARDIOCENTESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elective pericardiocentesis should always be carried out or supervised by an experienced operator. In the absence of such an individual, serious consideration should be given to surgical drainage as a safer alternative. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Choice of percutaneous pericardiocentesis or surgical drainage'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Elective pericardiocentesis should be carried out in a location that is equipped for good quality physiologic monitoring in which high quality fluoroscopy or echocardiography is available to guide the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/6,8\">",
"     6,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to elective pericardiocentesis, several preparatory steps should be performed in an effort to optimize procedural success and minimize the potential for complications. Patients should undergo echocardiography to best define the effusion, and patients should be evaluated for bleeding risk. A pericardiocentesis kit containing all of the required items for pericardiocentesis should be readily available at the site where the procedure is performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H238601\">",
"    <span class=\"h3\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An echocardiogram should be done to document the presence of effusion, confirm the location and size of the effusion, and determine if the effusion is loculated. The effusion should be evaluated for evidence of right heart compression and reciprocal respiratory variation of left and right ventricular diastolic dimension, supporting the diagnosis of cardiac tamponade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=see_link&amp;anchor=H22#H22\">",
"     \"Cardiac tamponade\", section on 'Echocardiography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Echocardiography also provides direct visualization of cardiac structures and adjacent organs, which allows for better determination of the optimal access site and approach. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Technique'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Clotting and bleeding disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unless the procedure is very urgent or emergent, a clotting profile should be obtained and the result should be available before beginning the procedure. Patients with a bleeding diathesis or those who have been treated with anticoagulants or thrombolytics, are at increased risk for a hemorrhagic complication following pericardiocentesis. In such patients, the subxiphoid approach should not be used due to the risk of potential hepatic laceration and life-threatening bleeding.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    poses less of a problem than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or thrombolytics because the procedure can be postponed until the partial prothrombin time is normal, or protamine can be given to relatively quickly reverse the heparin effect. For patients taking warfarin, however, the higher the INR, the greater the risk associated with pericardiocentesis. When the INR exceeds 1.4, the options are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Postpone the procedure until the INR is normal",
"     </li>",
"     <li>",
"      Administer vitamin K",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fresh frozen plasma (and platelets if thrombocytopenia is also present)",
"     </li>",
"     <li>",
"      Manage the patient without pericardiocentesis",
"     </li>",
"     <li>",
"      Open surgical drainage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of hemodynamic compromise consistent with cardiac tamponade, it is generally preferred to delay the procedure until the INR has normalized or to manage the patient without pericardiocentesis. If cardiac tamponade is present and felt to be life threatening, it may not be possible to wait for the INR to normalize, and pericardiocentesis may need to be done on an emergent basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=see_link\">",
"     \"Emergency pericardiocentesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H238709\">",
"    <span class=\"h3\">",
"     Procedure location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the route of approach, the procedure should be performed in the cardiac catheterization laboratory or a procedure room with catheterization laboratory capabilities, even if fluoroscopy is not used. This allows for invasive hemodynamics to be more readily and accurately monitored and recorded in this environment. Additionally, this setting is preferred should a life threatening complication arise. It is important to have a skilled nurse, a monitor technician, and a sonographer present to assist with the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Electrocardiographic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard electrocardiographic (ECG) monitoring is mandatory. In addition, an electrogram recorded via a lead attached to the puncture needle can be used to warn the operator that the needle is in contact with myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/11\">",
"     11",
"    </a>",
"    ]. Myocardial contact causes a large elevation of the ST segment (\"current of injury\") that is much more readily appreciated than the smaller elevation in the standard lead.",
"   </p>",
"   <p>",
"    Attaching an ECG electrode to the needle, however, makes the procedure more cumbersome and requires electrical grounding to avoid the risk of a ground loop that could allow a current flowing along the needle to fibrillate the heart. This danger is magnified when a needle in a sheath is used for the puncture, because the current density is then maximal at the tip of the needle.",
"   </p>",
"   <p>",
"    For these reasons, we and many other cardiologists have abandoned routine use of the direct ECG lead.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Puncture needle",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needles suitable for elective pericardiocentesis should have appropriate characteristics to lessen the risk of cardiac injury. Needles should have a short bevel to lessen the risk of lacerating the myocardium or a coronary vessel and should be the correct length; a length of 10 cm is adequate for the needle for most patients. An 18-gauge thin-walled needle is usually ideal. Purulent or organized effusions may necessitate a larger bore needle, but open drainage is preferred for such effusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the greatest experience has previously been with fluoroscopic guidance and a subcostal approach, echocardiographic guidance is becoming increasingly popular, and, in experienced hands, it is now the preferred method in many institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/2,6,12\">",
"     2,6,12",
"    </a>",
"    ]. This approach has been documented to be effective in draining loculated effusions after cardiac surgery and in relieving tamponade associated with iatrogenic cardiac perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Echocardiography offers several advantages over fluoroscopy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Echocardiography permits identification of the configuration of the effusion, particularly where it is closest to the skin.",
"     </li>",
"     <li>",
"      Monitoring the position of the needle during the initial puncture is easier and more convenient than with fluoroscopy.",
"     </li>",
"     <li>",
"      Patient and staff are not exposed to radiation.",
"     </li>",
"     <li>",
"      Agitated saline with microbubbles, rather than radiopaque contrast, is used to verify that the needle is in the pericardial effusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the presence of the ultrasound probe on the field during the procedure can complicate the procedure and compromise aseptic technique.",
"   </p>",
"   <p>",
"    A 2003 task force of the American College of Cardiology (ACC), the American Heart Association (AHA), and the American Society of Echocardiography (ASE) on the use of echocardiography concluded that the weight of",
"    <span class=\"nowrap\">",
"     evidence/opinion",
"    </span>",
"    was in favor of",
"    <span class=\"nowrap\">",
"     usefulness/efficacy",
"    </span>",
"    for echocardiographic guidance and monitoring of pericardiocentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/15\">",
"     15",
"    </a>",
"    ]. We generally agree with the task force and recommend using an echocardiographically-guided approach for pericardiocentesis whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H238730\">",
"    <span class=\"h3\">",
"     Echocardiographic guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiographic guidance allows the operator to select the shortest route to the effusion, generally near the cardiac apex or along an edge of the sternum, as well as the utilization of a puncture site with the largest collection of fluid and shortest distance from the skin. In the largest published series (1127 therapeutic echocardiographically-guided pericardiocentesis cases), the para-apical location was the most frequently utilized location (68 percent), while the subcostal or subxiphoid was utilized as the ideal location in only 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Head-up tilting is less important and may not be required when a route other than the subcostal is selected. As mentioned, the operator has a greater choice of puncture sites, and no radiopaque contrast is required. When the apical route is chosen, the needle is directed parallel with the long axis of the left ventricle towards the aortic valve. For parasternal insertion, the puncture is made 1 cm lateral to the sternal edge in an effort to avoid both inadvertent puncture of the internal mammary artery when too medial as well as pneumothorax when too lateral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Subcostal approach with fluoroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;When it has been decided to use a subcostal approach, the patient should be propped up, usually at a slight angle (20 to 45&deg;), allowing the fluid to gravitate inferiorly. However, positioning the patient so that",
"    <span class=\"nowrap\">",
"     he/she",
"    </span>",
"    is comfortable is paramount to avoid patient movement. After sterilizing the area, the skin and subcutaneous tissues a few millimeters below and to one side of the xiphoid process are infiltrated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    . The puncture needle, attached to a syringe of lidocaine, is advanced posteriorly until it is below the costal margin. The needle is then directed cephalad and with much less posterior orientation. To accomplish this, the syringe is pressed toward the patient's abdomen and cautiously advanced cephalad. It is also usually directed toward the left shoulder but can be directed to the right shoulder or straight up. Lidocaine should be given whenever the patient experiences discomfort.",
"   </p>",
"   <p>",
"    Sometimes, but not always, a \"give\" or \"pop\" is appreciated when the pericardium is penetrated. Because the operator is not always aware when the pericardium has been penetrated, frequent gentle aspiration should be attempted until pericardial fluid enters the syringe effortlessly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Blood or pericardial fluid?",
"    </span>",
"    &nbsp;&mdash;&nbsp;If sanguineous fluid is aspirated, it is essential to ascertain immediately whether it is blood from a cardiac chamber or the pericardial space. A quick and simple test is to aspirate a small quantity of fluid into an empty syringe and place a few drops onto a clean dry sponge. The stain created is much lighter than that caused by pure blood.",
"   </p>",
"   <p>",
"    If the answer is not clear when the procedure is being monitored fluoroscopically, a small amount of radiopaque contrast can be injected. If there is no myocardial stain, which would indicate intramyocardial injection, a more generous contrast injection is made. Intracardiac contrast will be seen to circulate, whereas intrapericardial contrast gravitates to the dependent portion of the pericardial space.",
"   </p>",
"   <p>",
"    When echocardiography is guiding the procedure, agitated sterile saline is injected to clarify location. An intrapericardial position of the catheter or needle is indicated by a cluster of bubbles in the pericardial space. This is the standard contrast used for echocardiographically-guided pericardiocentesis and should also be used in other cases when iodine-containing contrast agent is contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pericardial catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the needle tip is securely within the pericardial space, a guidewire with a floppy tip should be advanced through the needle into the pericardial space. The tip should lie at about the level of the atrial appendage, preferably posteriorly. Once the wire is positioned, the needle is removed, and both an introducer catheter followed by a thin-walled pigtail catheter are advanced over the wire until its tip is near the atrial appendage. We recommend the use of an introducer catheter first and then placement of the pigtail catheter through the introducer catheter as this allows for easier manipulation of the pigtail catheter and ensures an ideal location for optimal drainage. The wire is then withdrawn and the catheter attached for pressure measurement. Right atrial and pulmonary wedge pressures may also be measured using a pulmonary arterial catheter. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluid is then aspirated, and pressures are often remeasured every several minutes to ascertain the hemodynamic result. We agree with the 2004 European Society of Cardiology guidelines, which recommend drainage of fluid in &lt;1000 mL sequential steps to avoid acute right ventricular dilatation, although this is a rare complication [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]. The procedure is continued until pericardial pressure is &lt;5 to 10 mmHg, at least during inspiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H238803\">",
"    <span class=\"h2\">",
"     Subsequent management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the initial pericardiocentesis, the patient should be observed in a unit equipped to monitor the electrocardiogram, the patency of the pericardial catheter, and the rate of drainage into a sealed container under slight negative pressure. In most cases, pericardiocentesis does not completely evacuate the effusion, and active secretion of fluid or bleeding may result in reaccumulation of an effusion. For these reasons, we recommend that the pericardial catheter be left in place for 24 to 48 hours or until the volume of drainage is less than 25",
"    <span class=\"nowrap\">",
"     mL/day.",
"    </span>",
"   </p>",
"   <p>",
"    Extended pericardial catheter drainage of pericardial effusions requiring intervention is associated with lower recurrence rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In a study of 157 consecutive patients with pericardial effusion treated with pericardiocentesis, the rate of recurrent pericardial effusions was significantly lower in patients treated with extended (mean 38 hours) catheter drainage (12 versus 52 percent among those without extended catheter drainage) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H238810\">",
"    <span class=\"h2\">",
"     Catheter maintenance",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stopcock should be attached to the end of the catheter to allow for easier cleansing of the catheter to prevent clot formation. Suction with a syringe should be gentle. Two techniques can be used to maintain patency of the catheter:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The catheter can be left on continuous suction except during frequent syringe aspirations and flushing. If cleansing is not performed frequently (eg, hourly), it will become plugged with fibrin.",
"     </li>",
"     <li>",
"      The catheter can be left closed and filled with urokinase for most of the time that it remains in place. Every few hours, the urokinase is removed and the catheter is allowed to drain for one hour and is then refilled with urokinase and closed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first option requires especially careful monitoring of the drainage because once the catheter plugs, it usually cannot be unplugged. The second alternative requires careful hemodynamic monitoring because rapid reaccumulation of effusion could cause tamponade to recur. We usually employ continuous drainage but clean the catheter periodically with urokinase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericardiocentesis performed electively under controlled conditions is generally safe and effective. The incidence of major complications in experienced hands is 1.2 to 1.6 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/2,6,13,14\">",
"     2,6,13,14",
"    </a>",
"    ]. In the largest series, major complications occurred in only 1.2 percent of cases of echocardiographically-guided pericardiocentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/6\">",
"     6",
"    </a>",
"    ]. Among the major complications were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiac chamber laceration &mdash; 0.4 percent of cases",
"     </li>",
"     <li>",
"      Intercostal vessel injury requiring surgical intervention &mdash; 0.4 percent of cases",
"     </li>",
"     <li>",
"      Pneumothorax requiring chest tube &mdash; 0.4 percent of cases",
"     </li>",
"     <li>",
"      Ventricular tachycardia &mdash; 0.1 percent of cases",
"     </li>",
"     <li>",
"      Bacteremia &mdash; 0.1 percent of cases",
"     </li>",
"     <li>",
"      Death &mdash; 0.1 percent of cases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The greatest danger may be from laceration of a coronary vessel. Inadvertent puncture of the left ventricle seldom, if ever, causes significant bleeding. Puncture of the right ventricle is usually not a serious matter in most cases, but the right ventricle, being thinner-walled, is more likely to bleed. Puncture of the right or left atrium is much less likely to occur, but would cause a greater degree of bleeding.",
"   </p>",
"   <p>",
"    Bleeding during pericardiocentesis may be silent, induce typical pericardial pain, or be the cause of acute tamponade. When pressure measurement, fluid analysis, or contrast injection (using saline bubbles or radiopaque media) demonstrate that a cardiac chamber has been entered and this event is followed by pain or hemodynamic deterioration, the central venous pressure should be reassessed. A value higher than that measured before the puncture indicates cardiac tamponade until proven otherwise.",
"   </p>",
"   <p>",
"    Other important fluoroscopic signs of acute tamponade during pericardiocentesis are further enlargement of the pericardio-cardiac silhouette and, in cases in which visible cardiac pulsation was detected at the beginning of the procedure, disappearance or marked diminution of the pulsations. Cardiac pulsation should be monitored carefully until a satisfactory intrapericardial location of a needle or catheter has been established.",
"   </p>",
"   <p>",
"    Rarely, pericardiocentesis to relieve cardiac tamponade is complicated by acute left ventricular failure with pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The cause of this complication is unknown. It has been reported in association with concurrent left ventricular dysfunction, a setting in which the acute increase in venous return can promote pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/20\">",
"     20",
"    </a>",
"    ]. However, pulmonary edema can occur in patients without apparent myocardial disease, suggesting that other mechanisms must be important. Acute dilation of the right ventricle following pericardiocentesis is also rare [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25159/abstract/16\">",
"     16",
"    </a>",
"    ]. Ultimately, however, the risk to the patient of ongoing cardiac tamponade is generally greater than the risk of either of these potential complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H238749\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pericardiocentesis, or drainage of fluid from the pericardiac sac surrounding the heart, is most commonly performed to relieve cardiac tamponade. In the absence of cardiac tamponade, examination of the pericardial fluid can be helpful in a variety of situations (eg, suspected purulent pericarditis or suspected neoplastic pericardial effusion). The pericardial fluid in such cases may help establish the diagnosis as well as guide treatment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to elective pericardiocentesis, several preparatory steps should be performed in an effort to optimize procedural success and minimize the potential for complications:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An echocardiogram should be done to document the presence of effusion, confirm the location and size of the effusion, and determine if the effusion is loculated. (See",
"      <a class=\"local\" href=\"#H238601\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Unless the procedure is very urgent or emergent, a clotting profile should be obtained, and the result should be available before beginning the procedure, as patients with a bleeding diathesis or those who have been treated with anticoagulants or thrombolytics are at increased risk for a hemorrhagic complication following pericardiocentesis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clotting and bleeding disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regardless of the route of approach, the procedure should be performed in the cardiac catheterization laboratory or procedure room with catheterization laboratory capabilities, even if fluoroscopy is not used, as this allows for invasive hemodynamics to be more readily and accurately monitored and recorded. (See",
"      <a class=\"local\" href=\"#H238709\">",
"       'Procedure location'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Needles suitable for elective pericardiocentesis should have a short bevel to lessen the risk of lacerating the myocardium or a coronary vessel and should be the correct length; a length of 10 cm is adequate for the needle for most patients. An 18-gauge thin-walled needle is usually ideal. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Puncture needle'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although the greatest experience has previously been with fluoroscopic guidance and a subcostal approach, pericardiocentesis with echocardiographic guidance is now the preferred method in many institutions. Echocardiographic guidance allows the operator to select the shortest route to the effusion, generally near the cardiac apex or along an edge of the sternum, as well as utilizing a puncture site with the largest collection of fluid and shortest distance from the skin. We recommend using an echocardiographically-guided approach for pericardiocentesis whenever possible. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pericardiocentesis does not completely evacuate the effusion in most cases, and active secretion of fluid or bleeding may result in reaccumulation of an effusion. For these reasons, we recommend that the pericardial catheter be left in place for 24 to 48 hours or until the volume of drainage is less than 25",
"      <span class=\"nowrap\">",
"       mL/day.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H238803\">",
"       'Subsequent management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pericardiocentesis performed electively under controlled conditions is generally safe and effective, with the incidence of major complications in experienced hands being 1.2 to 1.6 percent. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/1\">",
"      Kilpatrick ZM, Chapman CB. On pericardiocentesis. Am J Cardiol 1965; 16:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/2\">",
"      Tsang TS, Freeman WK, Sinak LJ, Seward JB. Echocardiographically guided pericardiocentesis: evolution and state-of-the-art technique. Mayo Clin Proc 1998; 73:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/3\">",
"      Krikorian JG, Hancock EW. Pericardiocentesis. Am J Med 1978; 65:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/4\">",
"      Sagrista-Suleda J MA, Soler-Soler J. Diagnosis and management of pericardial effusion. World journal of cardiology 2011; 3:5.",
"     </a>",
"    </li>",
"    <li>",
"     Spodick D. The Pericardium: A Comprehensive Textbook, Marcel Dekker, New York 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/6\">",
"      Tsang TS, Enriquez-Sarano M, Freeman WK, et al. Consecutive 1127 therapeutic echocardiographically guided pericardiocenteses: clinical profile, practice patterns, and outcomes spanning 21 years. Mayo Clin Proc 2002; 77:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/7\">",
"      Gumrukcuoglu HA, Odabasi D, Akdag S, Ekim H. Management of Cardiac Tamponade: A Comperative Study between Echo-Guided Pericardiocentesis and Surgery-A Report of 100 Patients. Cardiol Res Pract 2011; 2011:197838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/8\">",
"      Maisch B, Seferovi�� PM, Risti�� AD, et al. Guidelines on the diagnosis and management of pericardial diseases executive summary; The Task force on the diagnosis and management of pericardial diseases of the European society of cardiology. Eur Heart J 2004; 25:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/9\">",
"      Maisch B, Bethge C, Drude L, et al. Pericardioscopy and epicardial biopsy--new diagnostic tools in pericardial and perimyocardial disease. Eur Heart J 1994; 15 Suppl C:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/10\">",
"      Nugue O, Millaire A, Porte H, et al. Pericardioscopy in the etiologic diagnosis of pericardial effusion in 141 consecutive patients. Circulation 1996; 94:1635.",
"     </a>",
"    </li>",
"    <li>",
"     Shabetai R. The Pericardium, Grune and Stratton, New York 1981. p.338.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/12\">",
"      Callahan JA, Seward JB, Tajik AJ. Cardiac tamponade: pericardiocentesis directed by two-dimensional echocardiography. Mayo Clin Proc 1985; 60:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/13\">",
"      Tsang TS, Freeman WK, Barnes ME, et al. Rescue echocardiographically guided pericardiocentesis for cardiac perforation complicating catheter-based procedures. The Mayo Clinic experience. J Am Coll Cardiol 1998; 32:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/14\">",
"      Tsang TS, Barnes ME, Hayes SN, et al. Clinical and echocardiographic characteristics of significant pericardial effusions following cardiothoracic surgery and outcomes of echo-guided pericardiocentesis for management: Mayo Clinic experience, 1979-1998. Chest 1999; 116:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/15\">",
"      Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/16\">",
"      Armstrong WF, Feigenbaum H, Dillon JC. Acute right ventricular dilation and echocardiographic volume overload following pericardiocentesis for relief of cardiac tamponade. Am Heart J 1984; 107:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/17\">",
"      Tsang TS, Barnes ME, Gersh BJ, et al. Outcomes of clinically significant idiopathic pericardial effusion requiring intervention. Am J Cardiol 2003; 91:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/18\">",
"      Rafique AM, Patel N, Biner S, et al. Frequency of recurrence of pericardial tamponade in patients with extended versus nonextended pericardial catheter drainage. Am J Cardiol 2011; 108:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/19\">",
"      Wolfe MW, Edelman ER. Transient systolic dysfunction after relief of cardiac tamponade. Ann Intern Med 1993; 119:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25159/abstract/20\">",
"      Uemura S, Kagoshima T, Hashimoto T, et al. Acute left ventricular failure with pulmonary edema following pericardiocentesis for cardiac tamponade--a case report. Jpn Circ J 1995; 59:55.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4949 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25159=[""].join("\n");
var outline_f24_36_25159=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H238749\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H238570\">",
"      OBJECTIVES OF PERICARDIAL FLUID REMOVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOICE OF PERCUTANEOUS PERICARDIOCENTESIS OR SURGICAL DRAINAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1718814\">",
"      Relative contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ELECTIVE PERICARDIOCENTESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H238601\">",
"      - Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Clotting and bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H238709\">",
"      - Procedure location",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Electrocardiographic monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Puncture needle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Technique",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H238730\">",
"      - Echocardiographic guidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Subcostal approach with fluoroscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Blood or pericardial fluid?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pericardial catheterization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H238803\">",
"      Subsequent management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H238810\">",
"      Catheter maintenance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H238749\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/52/19273?source=related_link\">",
"      Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/59/4025?source=related_link\">",
"      Diagnosis and treatment of pericardial effusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44119?source=related_link\">",
"      Emergency pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=related_link\">",
"      Etiology of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25449?source=related_link\">",
"      Management of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/1/1050?source=related_link\">",
"      Pericardial disease associated with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20968?source=related_link\">",
"      Post-cardiac injury syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=related_link\">",
"      Pulmonary artery catheterization: Interpretation of tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35303?source=related_link\">",
"      Purulent pericarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_36_25160="Chlamydophila (Chlamydia) pneumoniae infection as a potential etiologic factor in atherosclerosis";
var content_f24_36_25160=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chlamydophila (Chlamydia) pneumoniae infection as a potential etiologic factor in atherosclerosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25160/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25160/contributors\">",
"     Jeffrey L Anderson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25160/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25160/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25160/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25160/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/36/25160/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerosis is a highly prevalent disease, responsible for the greatest morbidity and mortality in Western civilization. Many risk factors for the development of atherosclerosis, manifest as coronary heart disease (CHD) and myocardial infarction (MI), have been identified. These include hyperlipidemia, hypertension, smoking, and diabetes mellitus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .) However, much of the attributable risk remains unexplained.",
"   </p>",
"   <p>",
"    Inflammation plays a central role in the pathogenesis of atherosclerosis, suggesting the possible involvement of infectious agents. Among the organisms that have been implicated are cytomegalovirus, Helicobacter pylori, and Chlamydophila pneumoniae, formerly called Chlamydia pneumoniae (",
"    <a class=\"graphic graphic_figure graphicRef61628 \" href=\"UTD.htm?20/23/20863\">",
"     figure 1",
"    </a>",
"    ). Strong associations have been noted between C. pneumoniae and atherosclerosis, which provided the rationale for antibiotic therapy directed against C. pneumoniae",
"   </p>",
"   <p>",
"    The data regarding C. pneumoniae infection will be reviewed here. As will be seen, the data fail to support a benefit from anti-C. pneumoniae therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. pneumoniae is a recently recognized and characterized human pathogen; isolates from respiratory infections were first reported in 1986 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent epidemiologic studies found it to be the cause of 5 to 10 percent of respiratory infections in adults and children, making it the third most common etiologic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=see_link\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults\"",
"    </a>",
"    .) Antibody prevalence studies suggest that over 50 percent of adults worldwide have been exposed to C. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSOCIATION WITH ATHEROSCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. pneumoniae is transported from the respiratory tract to the vascular wall by circulating monocytes, and may persist within the monocytes for at least 10 days without cellular lysis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/4\">",
"     4",
"    </a>",
"    ]. Case reports have documented the ability of C. pneumoniae to cause vasculitis and myocarditis (",
"    <a class=\"graphic graphic_figure graphicRef61628 \" href=\"UTD.htm?20/23/20863\">",
"     figure 1",
"    </a>",
"    ). It also has been noted to cause accelerated atherosclerosis in animal models, possibly by inducing procoagulant protein (plasminogen activator inhibitor-1 and tissue factor) and proinflammatory cytokine (interleukin-6) expression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/5\">",
"     5",
"    </a>",
"    ]. More direct evidence of an association with atherosclerotic disease has been derived from serologic and pathologic studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relation between C. pneumoniae and atherosclerosis has been studied in mice with induced low density lipoprotein (LDL) receptor deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/6\">",
"     6",
"    </a>",
"    ]. The mice were studied in both normocholesterolemic (low cholesterol diet) and hypercholesterolemic (high cholesterol diet) conditions. C. pneumoniae, but not Chlamydia trachomatis, exacerbated the development of atherosclerosis (in terms of both lesion area and severity) only in the presence of hypercholesterolemia. The permissive role of hypercholesterolemia may be related to the necessity for an initial lesion before C. pneumoniae can infect and reside in the aortic tissues successfully.",
"   </p>",
"   <p>",
"    In another model in which rabbits were fed a diet enriched with a small amount of cholesterol, C. pneumoniae infection accelerated the development of atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/7\">",
"     7",
"    </a>",
"    ]. This change was prevented by the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    , providing further evidence for an etiologic relationship (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Serologic and PCR studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been frequent reports of an association between circulating C. pneumoniae antibody titers and CAD, as well as several negative studies. Most of these studies have used the presence of IgG or IgA antibodies to C. pneumoniae as a proxy for chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/8\">",
"     8",
"    </a>",
"    ]. The presence of circulating C. pneumoniae DNA in blood is a specific indicator of current infection which may be detected by use of the polymerase chain reaction (PCR); it may better identify patients who would benefit from antibiotic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two meta-analyses, which included 15 prospective trials evaluating IgG titers and 10 prospective trials evaluating IgA titers, found",
"    <strong>",
"     no",
"    </strong>",
"    significant association between coronary heart disease and IgG titers (odds ratio 1.15, 95 percent confidence interval [CI] 0.97 to 1.36) and a significant, but weak, association with IgA titers (odds ratio 1.25, 95% CI 1.03-1.53) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Case-control studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have compared serologic findings for C. pneumoniae in patients with CHD with matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. In a study of 213 patients with acute MI or CHD death compared with 405 controls, high titer (&ge;1:1024) C. pneumoniae antibody was associated with a significantly increased risk of cardiac events (odds ratio 2.2) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C. pneumoniae infection also may be present in patients with unstable angina. In a report of 256 patients with unstable angina, increased antibody titers to C. pneumoniae were significantly more common than in controls (36 versus 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all studies have found antibody positivity to correlate with coronary events. In a nested case-control analysis from the Physicians' Health Study, 343 participants who had a first MI were compared to 343 age and smoking-matched control subjects who did not have any vascular disease during a 12-year follow-up. The prevalence of seropositivity for Chlamydia was the same in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Prospective studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several additional studies have examined the rate of subsequent cardiac events in various high-risk populations after obtaining serologic data [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. One report described the effect of C. pneumoniae seropositivity on the risk of subsequent adverse cardiovascular events (recurrent MI, unstable angina, or cardiovascular death) in 220 patients who had had an MI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients with high antibody titers (&ge;1:64) had a significantly higher incidence of adverse events than those with negative titers (28 versus 7 percent). A subset of patients with high titers who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    had an event rate similar to seronegative subjects (8 percent), suggesting that treatment directed at C. pneumoniae may reduce the risk associated with this pathogen (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Possible role of antichlamydial therapy'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In contrast, in a much larger study of 3168 high risk patients (previous CHD, stroke, peripheral vascular disease, or diabetes) followed for 4.5 years in the HOPE study, there was no association between either IgG or IgA titers and subsequent cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Asymptomatic atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positive antibody titers to C. pneumoniae have been linked with the presence of asymptomatic atherosclerosis in the coronary, carotid, renal, and femoral arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/20-24\">",
"     20-24",
"    </a>",
"    ]. One report, for example, evaluated 1373 nondiabetic subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/21\">",
"     21",
"    </a>",
"    ]. C. pneumoniae antibodies were significantly associated with femoral artery calcification; after adjustment for other risk factors for atherosclerosis, the hazard ratio was 1.68 (95% CI 1.01-1.87).",
"   </p>",
"   <p>",
"    Another study evaluated autopsy data from 60 Alaskan native men who had serum specimens drawn a mean of 8.8 years before death, which occurred at a mean age of 34 years, primarily from non cardiovascular causes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/23\">",
"     23",
"    </a>",
"    ]. Serologic evidence for chlamydial infection frequently preceded both the earlier and the more advanced coronary atheromas that contained this intracellular organism, usually within macrophage foam cells. The odds ratio for C. pneumoniae in coronary tissue associated with a level of IgG antibody &ge;1:256 was 9.4 after adjusting for other confounding variables, including smoking.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Ischemic stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of an association between C. pneumoniae and ischemic stroke was examined in one study of 89 patients with a first ischemic stroke and 89 control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/25\">",
"     25",
"    </a>",
"    ]. After adjusting for other stroke risk factors, Chlamydia IgA was significantly associated with stroke risk (adjusted odds ratio 4.51) in both men and women, younger and older patients, and in multiple ethnic groups (blacks, whites, and Hispanics). IgG titers were also elevated in patients with strokes but the association was less strong (odds ratio 2.59).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pathologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;C. pneumoniae has been directly linked with coronary and carotid atherosclerotic disease in pathologic studies and may play a role in saphenous vein graft occlusion.",
"   </p>",
"   <p>",
"    Evidence for the organism has been found in coronary atheromas obtained at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. One postmortem study of 60 subjects detected intracellular infection with C. pneumoniae by direct immunofluorescence in 86 percent of patients with severe atherosclerosis but in only six percent with mild disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/28\">",
"     28",
"    </a>",
"    ]. However, another postmortem investigation of the coronary arteries of 33 patients using PCR for C. pneumoniae DNA found that the distribution did not correlate with the severity or extent of coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atherectomy specimens have also been examined for evidence of C. pneumoniae infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In a report of 90 consecutive patients with symptomatic CHD undergoing coronary atherectomy, the plaque specimens were positive for Chlamydial antigen by direct immunofluorescence in 66 (73 percent), and borderline positive in 5 (6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/30\">",
"     30",
"    </a>",
"    ]. In contrast only 1 of 24 control specimens (4 percent) was positive.",
"   </p>",
"   <p>",
"    C. pneumoniae also has been linked to atherosclerosis in carotid arteries. In one study, tissue obtained at carotid endarterectomy was examined by immunocytochemistry (ICC) and PCR for the presence of C. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/32\">",
"     32",
"    </a>",
"    ]. All five of the fresh endarterectomy specimens were positive for C. pneumoniae by ICC (three of five by PCR). A total of 56 archival formalin-fixed, paraffin-embedded carotid endarterectomy tissues were then examined by ICC; 32 were positive, while 13 normal carotid artery tissue sections from 6 patients were all negative for C. pneumoniae. In contrast, another analysis of 75 endarterectomy specimens by PCR found none positive for C. pneumoniae DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    C. pneumoniae has also been linked to occlusion of a saphenous vein graft after coronary artery bypass surgery (CABG). One study that examined 38 occluded saphenous vein grafts found that C. pneumoniae DNA was present in 25 percent and that viable organisms were recovered in 16 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/34\">",
"     34",
"    </a>",
"    ]. In comparison, only 1 of 20 native saphenous veins had evidence of C. pneumoniae infection.",
"   </p>",
"   <p>",
"    However, viable C. pneumoniae organisms are not specific for occluded bypass grafts. They have also been detected in as many as 50 percent of biopsy specimens at the site of vein graft insertion in the ascending aorta at the time of CABG [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POSSIBLE ROLE OF ANTICHLAMYDIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;These observations establish an association between C. pneumoniae and atherosclerosis, but do not prove causality. The organism may be an innocent bystander or a commensal to atherosclerotic tissue, rather than an inciter of chronic inflammation.",
"   </p>",
"   <p>",
"    A number of antibiotic trials, mostly using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and roxithromycin, have been performed in patients with stable coronary disease, acute MI, an acute coronary syndrome, coronary restenosis, and peripheral artery disease. A meta-analysis of these trials found no significant benefit of such therapy in preventing recurrent cardiac events or mortality over three months to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One concern with these antibiotic trials is that C. pneumoniae cannot be eliminated with standard antibiotics from circulating monocytes, which serve as the host and disseminate the pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/4\">",
"     4",
"    </a>",
"    ]. Another concern is that it cannot be determined whether any observed benefits are due to the antimicrobial or possible antiinflammatory effects of the drugs. Further concerns are whether the appropriate patient group (with active or latent infection) and the appropriate disease and stage (for example, early as compared with late; peripheral as compared with coronary atherosclerosis) have been targeted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stable coronary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three randomized trials &mdash; ACES, CLARICOR, and the much smaller ACADEMIC trial &mdash; evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    in patients with stable coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. None showed evidence of benefit.",
"   </p>",
"   <p>",
"    In the ACES trial, 4012 patients with stable coronary disease were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or placebo for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/37\">",
"     37",
"    </a>",
"    ]. At a mean follow-up of 3.9 years, azithromycin therapy failed to reduce the primary end point of death, nonfatal MI, revascularization, or hospitalization for unstable angina (risk reduction 1 percent, 95% CI -13 to +13 percent) or any of the individual components or stroke.",
"   </p>",
"   <p>",
"    In addition to absence of overall benefit, the CLARICOR trial of 4373 patients, in which the patients assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    were treated for only two weeks, showed a significant increase in overall mortality at three years follow-up, which was due to a significant increase in the tertiary end point of cardiovascular mortality (5.1 versus 3.5 percent, hazard ratio 1.45, 95% 1.09-1.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/38\">",
"     38",
"    </a>",
"    ]. This effect was not significant at one year, which led the authors to do a pooled analysis of the three trials with more than two years follow-up (CLARICOR, ACES, and PROVE-IT described below). Overall mortality was significantly increased (hazard ratio 1.20, 95% CI 1.04-1.39).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Post MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of antichlamydial therapy in the post MI patient was directly assessed in the WIZARD trial, which included 7747 patients who had had an MI more than six weeks prior to entry and had antichlamydia antibody titers &gt;1:16 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/41\">",
"     41",
"    </a>",
"    ]. The patients were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    (600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three days and then 600",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    or placebo for 12 weeks. After a median follow-up of 14 months, there was no significant difference in the combined end point of all-cause mortality, recurrent MI, revascularization procedures, or hospitalization for angina (14 versus 15 percent); there was also no significant difference in any of the components of the end point or in any subgroup.",
"   </p>",
"   <p>",
"    In a post-hoc treatment-by-time analysis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    significantly reduced the incidence of death or MI at six months (hazard ratio 0.67), while there was an insignificant trend for the composite end point. Thereafter, the benefit of azithromycin compared to placebo was gradually lost, suggesting a cytostatic rather than cytocidal effect of azithromycin when administered for only three months. However, the lack of benefit with one year of therapy in the ACES trial cited above raises serious doubt about the efficacy of longer term therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute coronary syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of antibiotic therapy in patients with an acute coronary syndrome has been evaluated in several controlled trials, with variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/42-47\">",
"     42-47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies, such as the ROXIS, STAMINA and AZACS trials, have evaluated relatively short courses of treatment. The largest of these, the AZACS trial, randomly assigned 1439 patients with an acute MI or unstable angina to a five day course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/44\">",
"     44",
"    </a>",
"    ]. After a six-month follow-up, there was no difference in the primary end point (all-cause mortality, nonfatal MI, or recurrent ischemia requiring revascularization) or secondary end point (new or worsening heart failure or ischemia requiring hospitalization).",
"   </p>",
"   <p>",
"    The possibility that a longer course of therapy might be required has been evaluated in three trials. The small CLARIFY and ANTIBIO trials, did not convincingly show benefit with longer treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The much larger and longer PROVE-IT trial also failed to show benefit when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/46/4836?source=see_link\">",
"     gatifloxacin",
"    </a>",
"    , which has been removed from the market in the United States, was chosen as the antibiotic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/48\">",
"     48",
"    </a>",
"    ]. In addition there was a nonsignificant 23 percent increase in overall mortality with gatifloxacin (3.1 versus 2.4 percent), which was entirely due to a nonsignificant increase in coronary mortality. This observation is consistent with the significant increase in mortality in the CLARICOR trial of patients with stable coronary disease, one of two other trials with a follow-up of more than two years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Stable coronary disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prevention of restenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential benefits of roxithromycin therapy in coronary restenosis were evaluated in the ISAR-3 trial of 1,010 patients undergoing angioplasty and stenting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/49\">",
"     49",
"    </a>",
"    ]. Patients received roxithromycin or placebo for 28 days. There were no differences noted in the primary end points of angiographic restenosis or target vessel revascularization comparing the roxithromycin group to placebo recipients at one year of follow-up; the rates of mortality (3.2 versus 2.6 percent) and nonfatal MI (4 versus 3.5 percent) were also similar. Patients with C. pneumoniae titers of 1:128 or 1:512 demonstrated less restenosis and target vessel revascularization if treated with roxithromycin. However, these patients made up only 25 and 5 percent of treated patients, respectively, and C. pneumoniae titer did not influence their rates of death or subsequent MI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Peripheral artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of roxithromycin (300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 30 days) to prevent progression of peripheral artery disease (PAD) was evaluated in a randomized, placebo-controlled trial of 40 men who were seropositive for C. pneumoniae and had established PAD and at least one carotid plaque detectable by ultrasonography [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/50\">",
"     50",
"    </a>",
"    ]. During 2.7 year follow-up, patients treated with roxithromycin had the following significant benefits compared to placebo:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fewer invasive revascularizations (5 versus 29 interventions)",
"     </li>",
"     <li>",
"      Less frequent limitation to 200 m walking distance (20 versus 65 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations need to be confirmed in a larger trial of patients with PAD, particularly in view of inconsistent benefit of antichlamydial therapy noted above in patients with coronary disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Carotid artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Roxithromycin has been evaluated for potential benefit in carotid artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/51\">",
"     51",
"    </a>",
"    ]. Of 272 patients with a history of minor stroke or transient ischemic attack, 125 were seropositive for C. pneumoniae. All subjects were randomly assigned to treatment with roxithromycin for 30 days or placebo. Carotid artery intimal-medial thickness (IMT) was measured by duplex ultrasonography at baseline and in follow-up.",
"   </p>",
"   <p>",
"    At two years, the C. pneumoniae positive subjects who were given roxithromycin had significantly less IMT progression than those given placebo (0.07",
"    <span class=\"nowrap\">",
"     mm/year",
"    </span>",
"    versus 0.11",
"    <span class=\"nowrap\">",
"     mm/year).",
"    </span>",
"    However, at three years and four years, the rate of IMT progression increased in the roxithromycin group and was no longer different from the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/52\">",
"     52",
"    </a>",
"    ]. There was no significant difference in IMT progression between the treatment and placebo groups for C. pneumoniae negative subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Summary of therapeutic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the pathogenetic data suggesting a link between C. pneumoniae and atherosclerotic disease are intriguing, the three largest trials &mdash; ACES in stable coronary disease, WIZARD in post-MI patients, and PROVE-IT after an acute coronary syndrome &mdash; with the longest duration of anti-C. pneumoniae therapy and the longest follow-up failed to show any significant reduction in coronary events (eg, death, nonfatal MI, revascularization, hospitalization for unstable angina) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/37,41,48\">",
"     37,41,48",
"    </a>",
"    ]. In the three trials combined of almost 16,000 patients, the rate of coronary events was 19 percent with antibiotic therapy compared to 20 percent with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, the CLARICOR trial of patients with stable coronary disease found significant increases at two years (but not one year) in overall and coronary mortality with only two weeks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/38\">",
"     38",
"    </a>",
"    ]. A pooled analysis with the other two trials with more than two years follow-up (ACES and PROVE-IT) also showed a significant increase in overall mortality (hazard ratio 1.20, 95% CI 1.04-1.39) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these findings, we conclude that standard antibiotics with anti-C. pneumoniae activity are",
"    <strong>",
"     not",
"    </strong>",
"    effective for secondary prevention of cardiovascular disease and should",
"    <strong>",
"     not",
"    </strong>",
"    be given for this purpose. These trials weaken, but do not eliminate, a possible link between C. pneumoniae infection and atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25160/abstract/54\">",
"     54",
"    </a>",
"    ]. The antibiotics used might not be effective against C. pneumoniae within plaque-resident macrophages or therapy may have been given too late in the course of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33320807\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observations raise the possibility of a causal role for Chlamydophila pneumoniae (C. pneumoniae) in the pathogenesis of atherosclerotic cardiovascular disease. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Epidemiology'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Association with atherosclerosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following is a summary of these observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C. pneumoniae is human respiratory pathogen with antibody prevalence studies suggesting that over 50 percent of adults worldwide have been exposed.",
"     </li>",
"     <li>",
"      C. pneumoniae may be transported from the respiratory tract to the vascular wall by circulating monocytes.",
"     </li>",
"     <li>",
"      C. pneumoniae facilitates atherosclerosis in certain animal models.",
"     </li>",
"     <li>",
"      C. pneumoniae has been found in atherosclerotic plaques in autopsy and atherectomy specimens.",
"     </li>",
"     <li>",
"      An association between IgG and IgA antibody titers to C. pneumoniae and atherosclerotic disease has been reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of antibiotic trials, mostly using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    and roxithromycin, have been performed in patients with coronary artery disease. However, there is no consistent and convincing evidence of benefit from antibiotic therapy in these patients. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Possible role of antichlamydial therapy'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/1\">",
"      Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986; 315:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/2\">",
"      Grayston JT. Infections caused by Chlamydia pneumoniae strain TWAR. Clin Infect Dis 1992; 15:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/3\">",
"      Aldous MB, Grayston JT, Wang SP, Foy HM. Seroepidemiology of Chlamydia pneumoniae TWAR infection in Seattle families, 1966-1979. J Infect Dis 1992; 166:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/4\">",
"      Gieffers J, F&uuml;llgraf H, Jahn J, et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation 2001; 103:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/5\">",
"      Dechend R, Maass M, Gieffers J, et al. Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-kappaB and induces tissue factor and PAI-1 expression: a potential link to accelerated arteriosclerosis. Circulation 1999; 100:1369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/6\">",
"      Hu H, Pierce GN, Zhong G. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. J Clin Invest 1999; 103:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/7\">",
"      Muhlestein JB, Anderson JL, Hammond EH, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/8\">",
"      Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/9\">",
"      Wong YK, Dawkins KD, Ward ME. Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol 1999; 34:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/10\">",
"      Danesh J, Whincup P, Walker M, et al. Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis. BMJ 2000; 321:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/11\">",
"      Danesh J, Whincup P, Lewington S, et al. Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study and meta-analysis. Eur Heart J 2002; 23:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/12\">",
"      Siscovick DS, Schwartz SM, Corey L, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults : the Cardiovascular Health Study. Circulation 2000; 102:2335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/13\">",
"      Gabriel AS, Gnarpe H, Gnarpe J, et al. The prevalence of chronic Chlamydia pneumoniae infection as detected by polymerase chain reaction in pharyngeal samples from patients with ischaemic heart disease. Eur Heart J 1998; 19:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/14\">",
"      Toss H, Gnarpe J, Gnarpe H, et al. Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J 1998; 19:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/15\">",
"      Ridker PM, Kundsin RB, Stampfer MJ, et al. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/16\">",
"      Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/17\">",
"      Smieja M, Gnarpe J, Lonn E, et al. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/18\">",
"      Chandra HR, Choudhary N, O'Neill C, et al. Chlamydia pneumoniae exposure and inflammatory markers in acute coronary syndrome (CIMACS). Am J Cardiol 2001; 88:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/19\">",
"      Anderson JL, Carlquist JF, Muhlestein JB, et al. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J Am Coll Cardiol 1998; 32:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/20\">",
"      Melnick SL, Shahar E, Folsom AR, et al. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Am J Med 1993; 95:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/21\">",
"      Lehto S, Niskanen L, Suhonen M, et al. Association between Chlamydia pneumoniae antibodies and intimal calcification in femoral arteries of nondiabetic patients. Arch Intern Med 2002; 162:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/22\">",
"      van der Ven AJ, Hommels MJ, Kroon AA, et al. Chlamydia pneumoniae seropositivity and systemic and renovascular atherosclerotic disease. Arch Intern Med 2002; 162:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/23\">",
"      Davidson M, Kuo CC, Middaugh JP, et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998; 98:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/24\">",
"      Sander D, Winbeck K, Klingelh&ouml;fer J, et al. Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity. Circulation 2001; 103:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/25\">",
"      Elkind MS, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumoniae and the risk of first ischemic stroke : The Northern Manhattan Stroke Study. Stroke 2000; 31:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/26\">",
"      Kuo CC, Shor A, Campbell LA, et al. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993; 167:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/27\">",
"      Vink A, Poppen M, Schoneveld AH, et al. Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual. Circulation 2001; 103:1613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/28\">",
"      Ericson K, Saldeen TG, Lindquist O, et al. Relationship of Chlamydia pneumoniae infection to severity of human coronary atherosclerosis. Circulation 2000; 101:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/29\">",
"      Thomas M, Wong Y, Thomas D, et al. Relation between direct detection of Chlamydia pneumoniae DNA in human coronary arteries at postmortem examination and histological severity (Stary grading) of associated atherosclerotic plaque. Circulation 1999; 99:2733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/30\">",
"      Muhlestein JB, Hammond EH, Carlquist JF, et al. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996; 27:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/31\">",
"      Maass M, Bartels C, Engel PM, et al. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998; 31:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/32\">",
"      Grayston JT, Kuo CC, Coulson AS, et al. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995; 92:3397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/33\">",
"      Apfalter P, Barousch W, Nehr M, et al. No evidence of involvement of Chlamydia pneumoniae in severe cerebrovascular atherosclerosis by means of quantitative real-time polymerase chain reaction. Stroke 2004; 35:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/34\">",
"      Bartels C, Maass M, Bein G, et al. Detection of Chlamydia pneumoniae but not cytomegalovirus in occluded saphenous vein coronary artery bypass grafts. Circulation 1999; 99:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/35\">",
"      Nystr&ouml;m-Rosander C, Edvinsson M, Thelin S, et al. Chlamydophila pneumonia: Specific mRNA in aorta ascendens in patients undergoing coronary artery by-pass grafting. Scand J Infect Dis 2006; 38:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/36\">",
"      Wells BJ, Mainous AG 3rd, Dickerson LM. Antibiotics for the secondary prevention of ischemic heart disease: a meta-analysis of randomized controlled trials. Arch Intern Med 2004; 164:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/37\">",
"      Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005; 352:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/38\">",
"      Jespersen CM, Als-Nielsen B, Damgaard M, et al. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ 2006; 332:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/39\">",
"      Anderson JL, Muhlestein JB, Carlquist J, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999; 99:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/40\">",
"      Muhlestein JB, Anderson JL, Carlquist JF, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000; 102:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/41\">",
"      O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA 2003; 290:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/42\">",
"      Gurfinkel E, Bozovich G, Daroca A, et al. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 350:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/43\">",
"      Gurfinkel E, Bozovich G, Beck E, et al. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999; 20:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/44\">",
"      Cercek B, Shah PK, Noc M, et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet 2003; 361:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/45\">",
"      Stone AF, Mendall MA, Kaski JC, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002; 106:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/46\">",
"      Sinisalo J, Mattila K, Valtonen V, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 2002; 105:1555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/47\">",
"      Zahn R, Schneider S, Frilling B, et al. Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation 2003; 107:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/48\">",
"      Cannon CP, Braunwald E, McCabe CH, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005; 352:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/49\">",
"      Neumann F, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 2001; 357:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/50\">",
"      Wiesli P, Czerwenka W, Meniconi A, et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: a randomized, double-blind, placebo-controlled trial. Circulation 2002; 105:2646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/51\">",
"      Sander D, Winbeck K, Klingelh&ouml;fer J, et al. Reduced progression of early carotid atherosclerosis after antibiotic treatment and Chlamydia pneumoniae seropositivity. Circulation 2002; 106:2428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/52\">",
"      Sander D, Winbeck K, Klingelh&ouml;fer J, et al. Progression of early carotid atherosclerosis is only temporarily reduced after antibiotic treatment of Chlamydia pneumoniae seropositivity. Circulation 2004; 109:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/53\">",
"      Danesh J. Antibiotics in the prevention of heart attacks. Lancet 2005; 365:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25160/abstract/54\">",
"      Anderson JL. Infection, antibiotics, and atherothrombosis--end of the road or new beginnings? N Engl J Med 2005; 352:1706.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1495 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-C08C8C0CB4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25160=[""].join("\n");
var outline_f24_36_25160=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33320807\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSOCIATION WITH ATHEROSCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Animal models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Serologic and PCR studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Case-control studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Prospective studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Asymptomatic atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pathologic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POSSIBLE ROLE OF ANTICHLAMYDIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stable coronary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Post MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prevention of restenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Carotid artery disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Summary of therapeutic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33320807\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1495\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1495|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/23/20863\" title=\"figure 1\">",
"      Chlamydia and atherosclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_36_25161="Indinavir: Drug information";
var content_f24_36_25161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Indinavir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/28/3525?source=see_link\">",
"    see \"Indinavir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/39/28281?source=see_link\">",
"    see \"Indinavir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Crixivan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Crixivan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F182574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Protease Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F182541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Unboosted regimen:",
"     </i>",
"     800 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Ritonavir-boosted regimen:",
"     </i>",
"     Ritonavir 100-200 mg twice daily plus indinavir 800 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustments for indinavir when administered in combination therapy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delavirdine, itraconazole, or ketoconazole: Reduce indinavir dose to 600 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Efavirenz: Increase indinavir dose to 1000 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lopinavir and ritonavir (Kaletra&trade;): Indinavir 600 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nelfinavir: Increase indinavir dose to 1200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nevirapine: Increase indinavir dose to 1000 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rifabutin: Reduce rifabutin to",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     the standard dose plus increase indinavir to 1000 mg every 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F182558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/39/28281?source=see_link\">",
"      see \"Indinavir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     HIV: Children 4-15 years (investigational): 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 8 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F182542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F182543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Mild-moderate impairment due to cirrhosis, monotherapy: 600 mg every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F182511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Crixivan&reg;: 200 mg, 400 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F182497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F182514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink at least 48 oz of water daily. Administer with water, 1 hour before or 2 hours after a meal. May also be administered with other liquids (eg, skim milk, juice, coffee, tea) or a light meal (eg, toast, corn flakes). Administer around-the-clock to avoid significant fluctuation in serum levels. May be taken with food when administered in combination with ritonavir.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F182512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection; should always be used as part of a multidrug regimen (at least three antiretroviral agents)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F182580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Indinavir may be confused with Denavir&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F182572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (17%), nausea (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Hyperbilirubinemia (14%; dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Renal: Nephrolithiasis/urolithiasis, including flank pain with/without hematuria (29%, pediatric patients; 12% adult patients; dose dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (5%), dizziness (3%), somnolence (2%), fever (2%), malaise (2%), fatigue (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (4%), rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (8%), diarrhea (3%), taste perversion (3%), acid reflux (3%), anorexia (3%), appetite increased (2%), dyspepsia (2%), serum amylase increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (2%), anemia (1%), thrombocytopenia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased (4% to 5%), jaundice (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (8%), weakness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Dysuria (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal distention, acute renal failure, alopecia, anaphylactoid reactions, angina, arthralgia, bleeding (spontaneous in patients with hemophilia A or B), cerebrovascular disorder, cholesterol increased, crystalluria, depression, dry skin, erythema multiforme, fat redistribution, hemolytic anemia, hepatic failure, hepatitis, hydronephrosis, hyperpigmentation, immune reconstitution syndrome, interstitial nephritis (with medullary calcification and cortical atrophy), leukocyturia (severe and asymptomatic), MI, new-onset diabetes, pancreatitis, paresthesia (oral), paronychia, pharyngitis, pyelonephritis, QT prolongation, renal insufficiency, renal failure, Stevens-Johnson syndrome, torsade de pointes, triglycerides increased, upper respiratory infection, urticaria, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F182517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to indinavir or any component of the formulation; concurrent use of alfuzosin, alprazolam, amiodarone, cisapride, ergot alkaloids, lovastatin, midazolam (oral), pimozide, simvastatin, St John&rsquo;s wort, or triazolam; sildenafil  (when used for pulmonary artery hypertension [eg, Revatio&reg;])",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F182501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolytic anemia: Has been associated with hemolytic anemia; discontinue if diagnosed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperbilirubinemia: Has been observed frequently. Do not use concurrently with atazanavir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrolithiasis/urolithiasis: May cause nephrolithiasis/urolithiasis; discontinue if signs and symptoms occur. Adequate hydration is recommended. Risk is substantially higher in pediatric patients versus adults. Symptoms may require temporary interruption of therapy (1-3 days) or discontinuation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tubulointerstitial nephritis: May cause tubulointerstitial nephritis (rare); severe asymptomatic leukocyturia may warrant evaluation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Changes in glucose tolerance, hyperglycemia, exacerbation of diabetes, DKA, and new-onset diabetes mellitus have been reported in patients receiving protease inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemophilia A or B: Use with caution in patients with hemophilia A or B; increased bleeding during protease inhibitor therapy has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: May cause hepatitis and/or exacerbate pre-existing hepatic dysfunction; use with caution in patients with underlying hepatic disease, such as hepatitis B or C or cirrhosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Concomitant use of indinavir with some drugs may require cautious use, may not be recommended, may require dosage adjustments, or may be contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F182568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (strong)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F182505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Indinavir may increase the serum concentration of ALPRAZolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May enhance the adverse/toxic effect of Indinavir. Indinavir may enhance the adverse/toxic effect of Atazanavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atovaquone: May decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Indinavir. Indinavir may increase the serum concentration of Bosentan. Management: Initiate bosentan at, or adjust bosentan to, 62.5 mg once daily or every other day (based on tolerability) in indinavir-treated patients (see ritonavir for dosing if that agent is used). Additionally, monitor for possible reduced response to indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the serum concentration of Indinavir. Management: Indinavir should be administered on an empty stomach at least 1 hour apart from administration of buffer-containing formulations of didanosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Indinavir. Management: The appropriate dose adjustments for indinavir when used together with efavirenz are unknown. The use of higher unboosted indinavir doses is not likely an adequate approach.  Use of a ritonavir-boosted indinavir regimen could be considered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir, saquinavir, and lopinavir (with low-dose ritonavir). Management: Low-dose ritonavir boosting must be used when any protease inhibitor is used with etravirine.  Avoid use of etravirine in combination with atazanavir, fosamprenavir, full-dose ritonavir (600 mg twice daily), or tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Indinavir may increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Indinavir.  Management: Reduce the normal indinavir adult dose to 600 mg every 8 hours when given with itraconazole.  Monitor for increased systemic effects (including adverse/toxic effects) of itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Indinavir may increase the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Indinavir.  Management: Reduce the normal indinavir adult dose to 600 mg every 8 hours when given with ketoconazole.  Monitor for increased systemic effects (including adverse/toxic effects) of ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Indinavir. Management: Increased indinavir doses may be needed when used with nevirapine; however, specific dosing guidelines have not been established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Indinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Indinavir may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Indinavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Venlafaxine: May decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F182532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Indinavir bioavailability may be decreased if taken with food. Meals high in calories, fat, and protein result in a significant decrease in drug levels. Indinavir serum concentrations may be decreased by grapefruit juice. Management: Administer with water 1 hour before or 2 hours after a meal. May also be administered with other liquids (eg, skim milk, juice, coffee, tea) or a light meal (eg, toast, corn flakes). Administer around-the-clock to avoid significant fluctuation in serum levels. Drink at least 48 oz of water daily. May be taken with food when administered in combination with ritonavir.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Garlic may decrease the levels/effects of protease inhibitors. St John's wort appears to induce CYP3A enzymes and has lead to 57% reductions in indinavir AUCs and 81% reductions in trough serum concentrations, which may lead to treatment failures. Management: Avoid garlic and St John's wort while taking indinavir.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F182507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F182520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Placental passage in humans is minimal. No increased risk of overall birth defects has been observed according to data collected by the antiretroviral pregnancy registry. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and protease inhibitors (PIs) should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk. Hyperbilirubinemia may occur in neonates following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to indinavir. Until optimal dosing during pregnancy has been established, the manufacturer does not recommend indinavir use in pregnant patients. The DHHS Perinatal HIV Guidelines consider indinavir an agent to be used in special circumstances when preferred and alternative agents cannot be used; however, if needed, indinavir must be used in combination with low-dose ritonavir during pregnancy (with ritonavir boosting, 82% of pregnant women reached target trough concentrations).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F182547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F182521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F182522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken without food but with water 1 hour before or 2 hours after a meal. Administration with lighter meals (eg, dry toast, skim milk, corn flakes) resulted in little/no change in indinavir concentration. If taking with ritonavir, may take with food. Patient should drink at least 48 oz of water daily.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F182519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Crixivan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (360): $548.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (42): $127.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F182509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor viral load, CD4 count, triglycerides, cholesterol, glucose, liver function tests, CBC, urinalysis (severe leukocyturia should be monitored frequently).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F182523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aviran (MX);",
"     </li>",
"     <li>",
"      Crixivan (AT, AU, BB, BE, BG, BM, BO, BR, BS, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, IE, IL, IT, JM, KP, LU, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, RU, SE, SG, SK, SV, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Elvenavir (AR);",
"     </li>",
"     <li>",
"      Inavir (TH);",
"     </li>",
"     <li>",
"      Indilan (MX);",
"     </li>",
"     <li>",
"      Indivan (PY);",
"     </li>",
"     <li>",
"      Indivir (IN);",
"     </li>",
"     <li>",
"      Virxit (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F182500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Binds to the site of HIV-1 protease activity and inhibits cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F182516\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Administration with a high fat, high calorie diet resulted in a reduction in AUC and in maximum serum concentration (77% and 84% respectively); lighter meal resulted in little or no change in these parameters.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4; seven metabolites of indinavir identified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Good",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.8 &plusmn; 0.4 hour; hepatic insufficiency: 2.8 &plusmn; 0.5 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 0.8 &plusmn; 0.3 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (83%; 19% as unchanged drug); urine (19%; 9% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      CDC and the National Foundation for Infectious Disease, &ldquo;Update: Provisional Public Health Service Recommendations for Chemoprophylaxis After Occupational Exposure to HIV,&rdquo;",
"      <i>",
"       MMWR",
"      </i>",
"      , 1996, 45(22):468-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/36/25161/abstract-text/8622618/pubmed\" id=\"8622618\" target=\"_blank\">",
"        8622618",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Deeks SG, Smith M, Holodniy M, et al, &ldquo;HIV-1 Protease Inhibitors. A Review for Clinicians,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 277(2):145-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/36/25161/abstract-text/8990341/pubmed\" id=\"8990341\" target=\"_blank\">",
"        8990341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hilts AE and Fish DN, &ldquo;Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55:2528-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/36/25161/abstract-text/9853641/pubmed\" id=\"9853641\" target=\"_blank\">",
"        9853641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kakuda TN, Struble KA, and Piscitelli SC, &ldquo;Protease Inhibitors for the Treatment of Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55(3):233-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/36/25161/abstract-text/9492254/pubmed\" id=\"9492254\" target=\"_blank\">",
"        9492254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufman MB and Simionatto C, &ldquo;A Review of Protease Inhibitor-Induced Hyperglycemia,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(1):114-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/36/25161/abstract-text/9917085/pubmed\" id=\"9917085\" target=\"_blank\">",
"        9917085",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaul DR, Cinti SK, Carver PL, et al, &ldquo;HIV Protease Inhibitors: Advances in Therapy and Adverse Reactions, Including Metabolic Complications,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(3):281-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/36/25161/abstract-text/10221367/pubmed\" id=\"10221367\" target=\"_blank\">",
"        10221367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDonald CK and Kuritzkes DR, &ldquo;Human Immunodeficiency Virus Type 1 Protease Inhibitors,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1997, 157(9):951-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/36/25161/abstract-text/9140265/pubmed\" id=\"9140265\" target=\"_blank\">",
"        9140265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mueller BU, Smith S, Sleasman J, et al, &ldquo;A Phase I/II Study of the Protease Inhibitor Indinavir (MK-0639) in Children With HIV Infection,&rdquo;",
"      <i>",
"       Int Conf AIDS",
"      </i>",
"      , 1996, 11:37.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rana KZ and Dudley MN, &ldquo;Human Immunodeficiency Virus Protease Inhibitors,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(1):35-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/36/25161/abstract-text/9917077/pubmed\" id=\"9917077\" target=\"_blank\">",
"        9917077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stein DS, Fish DG, Bilello JA, et al, &ldquo;A 24-Week Open-Label Phase I/II Evaluation of the HIV Protease Inhibitor MK-639 (Indinavir),&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 1996, 10(5):485-92.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8558 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-655B890CD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25161=[""].join("\n");
var outline_f24_36_25161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182536\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182537\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182574\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182541\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182558\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182542\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897848\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182543\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182511\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182497\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182514\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182512\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182580\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182572\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182517\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182501\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182568\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182505\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182532\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182507\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182520\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182547\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182521\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182522\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182519\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182509\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182523\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182500\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182516\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8558\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8558|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/28/3525?source=related_link\">",
"      Indinavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/39/28281?source=related_link\">",
"      Indinavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_36_25162="Pathogenesis of Sjögren's syndrome";
var content_f24_36_25162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of Sj&ouml;gren's syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25162/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25162/contributors\">",
"     Robert Fox, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25162/contributors\">",
"     Paul Creamer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25162/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25162/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/36/25162/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/36/25162/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/36/25162/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is much to suggest that Sj&ouml;gren's syndrome (SS) is, like many connective tissue diseases, an autoimmune disorder. Support for this hypothesis includes a female preponderance, distinctive HLA associations, familial clustering with other autoimmune processes, the presence of autoantibodies, and the existence of shared clinical features (arthritis, Raynaud phenomenon, serositis) with other autoimmune connective tissue diseases.",
"   </p>",
"   <p>",
"    The close relationship of primary SS and systemic lupus erythematosus (SLE) has led to the suggestion that primary SS likely shares common pathogenetic features with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/1\">",
"     1",
"    </a>",
"    ]. If it is considered that SLE consists of several subgroups that are each characterized by particular autoantibodies and HLA-DR alleles, then SS has close similarities to one of these SLE subsets (ie, HLA-DR3, anti-SSA antibody positive). In this regard, SS might be loosely considered a subset of SLE, characterized by particular homing receptors that allow lymphocytic infiltrates into particular extranodal sites, such as salivary and lacrimal glands. Thus, the features of SS include ocular and oral dryness, as well as increased frequency of lymphoproliferative disorders including an elevated risk of lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the relative ease and safety of biopsying the target organ of inflammation (eg, the salivary or lacrimal gland, or conjunctiva), SS provides a prototype for understanding the interaction of immune and neuro-endocrine systems. With availability of techniques of molecular biology to analyze the plethora of proteins (proteomics) of small tissue samples and fluids, it should be possible to correlate the changes in tissue with those in blood and draining fluids (ie, tears and saliva) in order to assess prognosis and to provide biomarkers for response to therapy.",
"   </p>",
"   <p>",
"    Studies have suggested an important role for B-cells and type I interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/2-6\">",
"     2-6",
"    </a>",
"    ], in contrast to the pivotal role of TNF in RA patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. These observations will drive the next stage of therapeutic trials in SS.",
"   </p>",
"   <p>",
"    Although features of dry eyes, dry mouth and systemic manifestations such as vasculitis remain well understood, the vague symptoms of muscle pain, mild cognitive defects and fatigue (fibromyalgia-like) remain poorly characterized at a molecular level, and treatment for these common symptoms will depend on further understanding of pathogenesis.",
"   </p>",
"   <p>",
"    Our current understanding of the pathogenesis of SS is reviewed here. The clinical manifestations, diagnosis, and treatment and prognosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26826?source=see_link\">",
"     \"Treatment of dry eyes in Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=see_link\">",
"     \"Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2282?source=see_link\">",
"     \"Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An overview of pathogenesis is given prior to discussion of specific steps and has been reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/10\">",
"     10",
"    </a>",
"    ]. An overlap of a subset of systemic lupus erythematosus (SLE) and SS is evident in their clinical manifestations, their laboratory abnormalities (ie, ANA and anti-SS-A antibody), their genetics (HLA-DR3) and their treatment. Further, the gene signatures in both SLE and SS include a predominant type I interferon expression of mRNA expression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/11-14\">",
"     11-14",
"    </a>",
"    ]. Thus, it might be humorously expressed that SS is really SLE with homing receptors to particular sites such as salivary and lacrimal glands, as well as to other sites that characterize extraglandular involvement in SS. The pathogenesis of SLE is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=see_link\">",
"     \"Epidemiology and pathogenesis of systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The overlap of SS and SLE includes many features, but the most distinct features of SS are lymphocytic infiltrative and those of SLE appear antibody-mediated (immune complex leading to complement activation). Thus, we see a somewhat distinct pattern of pathogenesis in SS in comparison to SLE. The lung disease in SS tends to be interstitial pneumonitis rather than pleurisy and the renal disease is interstitial nephritis rather than glomerulonephritis. Thus, the damage seen in SLE tends to be antibody mediated, while that in SS tends towards lymphocytic infiltrative. In this regard, SS is a \"lymphocyte\" aggressive disorder that starts with lymphocytic infiltration into lacrimal and salivary glands where lymphocytes are not normally found. Thus, it should not be surprising that SS patients have a highly increased frequency of lymphoma, the ultimate outcome in a \"lymphocyte\" infiltrative disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\", section on 'Lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possibility that estrogen increases the risk of development of sicca symptoms is suggested by the predominance of women with primary SS (96 percent in one population based study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/15\">",
"     15",
"    </a>",
"    ]) and by the increased prevalence of ocular dryness in postmenopausal women receiving hormone replacement therapy (HRT), particularly estrogen alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/16\">",
"     16",
"    </a>",
"    ]. In a report from the Women's Health Study, each three year increase in HRT use was associated with a significant 15 percent increase in risk of the diagnosis of dry eye syndrome or severe symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/16\">",
"     16",
"    </a>",
"    ]. This may reflect an effect of estrogen on the tear film.",
"   </p>",
"   <p>",
"    The pathogenesis of SS includes multiple different steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial steps in pathogenesis probably involve glandular, vascular endothelial cells, the glandular epithelial cells or their underlying",
"      <span class=\"nowrap\">",
"       stromal/dendritic",
"      </span>",
"      cells [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/17\">",
"       17",
"      </a>",
"      ]. In an animal model of SS (eg, the nonobese diabetic - severe combined immunodeficient [NOD-SCID] mouse), changes of epithelial cells and local endothelial venules occur in the absence of functional lymphocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/18\">",
"       18",
"      </a>",
"      ], as well as elaboration of metalloproteinases. These changes are present in both male and female NOD mice [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/19\">",
"       19",
"      </a>",
"      ]. However, dryness in the NOD-SCID mouse does not occur until T-lymphocytes occur in the gland. Important steps will include the upregulation of adhesion proteins and the elaboration of chemokines that promote trafficking of lymphocytes [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. In addition to vascular and glandular cells, abnormalities of dendritic cells have been suggested as an important feature of organ specific lymphocytic localization [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/22\">",
"       22",
"      </a>",
"      ] where dendritic cells are proposed to cause abnormal of retention of lymphocytes in the tissues.",
"     </li>",
"     <li>",
"      Environmental triggers may include a viral infection of the glands or any intercurrent infection that stimulates dendritic or glandular cells to activate the HLA-independent \"innate immune system.\" The innate immune system utilizes Toll and Toll-like receptors that recognize conserved molecular patterns (pathogen-associated molecular patterns), which are shared by large groups of microorganisms and apoptotic products [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/23\">",
"       23",
"      </a>",
"      ]. Also, it has been suggested that x-chromosome linked factors may influence apoptosis in SS patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/24\">",
"       24",
"      </a>",
"      ]. These changes will lead to liberation of chemokines and upregulation of adhesive molecules that direct lymphoid migration into the gland. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"       \"Toll-like receptors: Roles in disease and therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Migration of the lymphocytes to the gland in response to chemokines, adhesion to specific vascular adhesion molecules and entry into the glandular cells where they interact with dendritic cells and epithelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/25\">",
"       25",
"      </a>",
"      ]. The acquisition of lymphoid features by inflammatory foci in SS is critically associated with the enlargement of the inflammatory foci and with the expression of certain chemokines (eg, CXCL and CCL21) by T-cells within the infiltrate, but is not associated with their expression by epithelial cells [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/24,26\">",
"       24,26",
"      </a>",
"      ]. Overexpression of CXC chemokine receptor 4 (CXCR4) by circulating blood B cells does not translate into enhanced migratory response to the cognate ligand, CXC ligand 12 (CXCL12). Retention of CXCR4+, CXCR5+, CD27+ memory B cells in the inflamed glands seems to contribute to diminished peripheral CD27+ memory B cells in primary SS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The innate and acquired immune systems can be mutually co-stimulatory [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/28\">",
"       28",
"      </a>",
"      ]. Studies on cytokine production in the salivary gland biopsies using gene profiling suggest an important role for type I and type II interferons in this perpetuation of the immune response [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/25,29\">",
"       25,29",
"      </a>",
"      ]. The process of continued stimulation of T- and B-cells may lead to gene mutations in B-cells that eventuate in pseudolymphoma and frank lymphoma. B-cell activation is associated with increased BAFF activation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/30\">",
"       30",
"      </a>",
"      ]. Of particular interest, a rationale for the association of anti-SS-A antibody and SS has been proposed [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. It is known that SS-A binds to hYRNA (a double stranded RNA) and that SS-A may migrate to the surface of apoptotic glandular cells. The complex of",
"      <span class=\"nowrap\">",
"       SS-A/hYRNA",
"      </span>",
"      and antibody would form an immune complex that could bind to the Toll receptor and Fc receptor of dendritic cells. The resulting activation of dendritic cells would provide the type I interferon gene signature reported in SS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/31\">",
"       31",
"      </a>",
"      ]. Further, the association of antibody SS-A production with HLA-DR3 would provide a further bridge between genetics, antibody formation and the gene expression profile.",
"     </li>",
"     <li>",
"      Glandular destruction may occur by",
"      <span class=\"nowrap\">",
"       perforin/granzyme",
"      </span>",
"      A methods as well as",
"      <span class=\"nowrap\">",
"       Fas/Fas",
"      </span>",
"      Ligand mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/32\">",
"       32",
"      </a>",
"      ]. However, only partial destruction of the gland is noted in most patients and it is likely that local production of cytokines, autoantibodies and metalloproteinases leads to dysfunction of the residual glandular tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. This may be manifested in the abnormal location of aquaporin in glandular cells in both the SS salivary glands and in the NOD mouse model, due to the influence of outside-inside signaling provided by the extracellular matrix on glandular differentiation and function [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/35\">",
"       35",
"      </a>",
"      ]. These factors may influence the transport of aquaporin in lacrimal and salivary glands [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Within the glands (and in other lymphoid tissues), activation of T-lymphocytes and B-lymphocytes occurs as a result of HLA-DR restricted antigen presenting cells in the presence of co-stimulatory molecules. This is called the \"acquired immune system\" that perpetuates immune response with memory lymphocytes and autoantibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/38\">",
"       38",
"      </a>",
"      ]. Extraglandular manifestations occur as a result of lymphocytic infiltration into other tissues or generation of pathogenetic autoantibodies.",
"     </li>",
"     <li>",
"      The potential role of antibodies against the muscarinic (M) receptor for acetylcholine has been reviewed [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/39\">",
"       39",
"      </a>",
"      ]. Although initially, it was difficult to demonstrate that these antibodies reacted with the extracellular domain of the human M3 receptor, subsequent reports suggested methods to detect such binding [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/40\">",
"       40",
"      </a>",
"      ] and perhaps include SS in the spectrum of autoimmune disorders such as Grave's disease or myasthenia gravis where anti-receptor antibodies are pathogenetic. It remains to be seen whether such antibodies in SS are primary or secondary phenomena.",
"     </li>",
"     <li>",
"      The sensation of \"dryness\" depends on a functional circuit that starts at the mucosal surface (ie, unmyelinated nerves of corneal membrane or oral mucosa) that sends afferent nerves to specific areas of the mid-brain [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. The midbrain (salivatory and lacrimatory nuclei) then sends efferent adrenergic and cholinergic nerves back to the glands to regulate secretion. This may help explain the high prevalence of sicca symptoms in non-SS patients including Alzheimer disease and fibromyalgia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical-pathology correlation of a patient's sensation of dry eyes consists of several components [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. The patient's description of increased work of blinking refers to the increased viscosity of the lid traversing the globe. As a consequence of lymphoid infiltration into the lacrimal glands, there is a decrease in aqueous tear production due to partial destruction of the glands and due to the decreased secretory ability of the residual glands as a result of local cytokine production. Only about 50 percent of the",
"    <span class=\"nowrap\">",
"     acini/ducts",
"    </span>",
"    are destroyed on biopsy in patients with significantly dry eyes or mouth, so the residual glands are functionally impaired.",
"   </p>",
"   <p>",
"    The patients also describe pain in the eye [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/46\">",
"     46",
"    </a>",
"    ]. Dryness of the cornea may cause exfoliation of the superficial corneal epithelium leaving corneal erosions, resulting in considerable ocular discomfort, which is chronic in nature, because of the characteristics of SS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/47\">",
"     47",
"    </a>",
"    ]. The cornea is the tissue most densely innervated in the body and receives sensory and autonomic nerves fibers that are located primarily in the epithelial layer and are supplied by the long ciliary nerves, derived from the trigeminal nerve (cranial nerve V). There are two types of nerve fibers in the corneal epithelium: the myelinated A-delta fibers that run parallel to the corneal surface within the basal cell layer, and the unmyelinated C fibers that turn upward from the epithelial plexus toward the surface [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/47\">",
"     47",
"    </a>",
"    ]. A-delta fibers are large-diameter, straight nerves that respond primarily to mechanical stimuli, whereas C fibers are small-diameter, beaded nerves that respond to thermal and chemical stimuli.",
"   </p>",
"   <p>",
"    The stimulus, triggering the activation of these cells, activates neural mechanisms responsible for perception of acute pain, with consequent behavioral adaptation aimed to give protection from the irritating stimulus. The persistent C fiber input can easily lead to the summation (wind-up) of stimuli, resulting in augmented responses of the spinal trigeminal nuclei neurons and final central sensitization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. It will also activate the parasympathetic innervation of the lacrimal glands and conjunctival goblet cells resulting in their increased secretion. However, in chronic inflammatory conditions such as SS, summation of peripheral input may occur since C fiber activity starts to dominate the A-delta fiber activity, resulting in an active inhibition of the parasympathetic system at the central level of the peri-aqueductal grey area of the limbic system [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. This results in further peripheral sympathetic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parasympathetic dysfunction in SS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY OF THE SALIVARY GLAND INFILTRATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal pathological lesion of SS is a lymphocytic infiltration, which is common to all affected organs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/52\">",
"     52",
"    </a>",
"    ]. The salivary and lacrimal glands are the most frequently affected and also the most easily biopsied. The infiltrates consist of focal aggregates (50 or more cells) of lymphocytes, beginning around the ducts and spreading to involve the whole lobule (",
"    <a class=\"graphic graphic_picture graphicRef79996 \" href=\"UTD.htm?17/10/17577\">",
"     picture 1",
"    </a>",
"    ). Although some lobules are completely destroyed by this process, the overall architecture is preserved, with other lobules remaining intact and apparently normal. There is associated hyperplasia of salivary ductal epithelium that, together with the lymphocytic infiltrate, results in clinical enlargement of the gland.",
"   </p>",
"   <p>",
"    Immunohistology shows that 75 percent of the infiltrating cells are T lymphocytes, mainly of the",
"    <span class=\"nowrap\">",
"     helper/inducer",
"    </span>",
"    (CD4) subset [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/53\">",
"     53",
"    </a>",
"    ] and the \"memory\" phenotype expressing the adhesion molecule LFA-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/54\">",
"     54",
"    </a>",
"    ]. The majority express the alpha-beta T-cell receptor with only 1 to 5 percent expressing the \"fetal\" gamma-delta receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/55\">",
"     55",
"    </a>",
"    ]. Studies of T cell receptor gene usage have been conflicting but overall, as in RA, there is little evidence to support restricted T-cell repertoire usage in SS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/56\">",
"     56",
"    </a>",
"    ]. The salivary epithelial cells express high levels of HLA-DR and B7 co-stimulatory molecules, particularly in areas of intense lymphocytic infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. One interpretation of these findings is that there is local presentation of an unknown antigen by HLA class II expressing epithelial cells to CD4+ T-cells.",
"   </p>",
"   <p>",
"    Approximately 10 percent of infiltrating lymphocytes are B-cells that are almost always found within clusters of T-cells. There are also numerous plasma cells secreting large amounts of immunoglobulin, much of it oligoclonal. Natural killer cells are absent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CO-FACTORS IN PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors may contribute to the pathogenesis of SS including genetic factors, viruses, cytokines, and autoantibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A familial tendency to SS has been well documented, including the occurrence of a variety of autoimmune disorders in relatives of patients with this disorder. Using California criteria, \"definite\" or \"probable\" SS occurred in 4.4 percent in first-degree relatives in one series, all of whom were female and older than the probands [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/59\">",
"     59",
"    </a>",
"    ]. Family members are also more likely to have autoantibodies. In one report, for example, the following observations were noted in families of",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    positive patients with primary SS or SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Twenty-one percent of first-degree relatives and 11 percent of second-degree relatives had detectable levels of",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      antibodies. The frequency increased to 41 percent in relatives considered to have clinical or serologic evidence of autoimmune disease. The comparable value in relatives from healthy families was 6 percent.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Anti-La/SSB",
"      </span>",
"      antibodies were infrequent in the relatives.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The best genetic marker for SS appears to lie within the MHC complex. In Caucasians, primary SS is associated with an increased frequency of HLA DR3 (DRB1*03) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], in particular with the extended haplotype HLA-DR3, B8, DQ-2, and the C4A null gene. This haplotype is found in approximately 50 percent of cases but also in 20 to 25 percent of the healthy Caucasian population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic factors are more closely associated with autoantibody production than with the disease itself. Thus, if patients producing anti-Ro or anti-La antibodies are considered, the frequency of HLA-DR3 in Caucasians rises to 60 to 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is, however, considerable heterogeneity in the HLA-DR association across different ethnic groups. Greek and Israeli patients show a link to DR5 as opposed to DR3 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/64\">",
"     64",
"    </a>",
"    ], while different haplotypes are also seen in Japanese (DRB1*0405-DRB4*0101-DQA1*0301-DQB1*0401), Chinese (DRB1*0803-DQA1*0103-DQB1*0601), and Spanish (DRB1*15) patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These differences could be explained if the true association lies with HLA-DQA1 that is itself in linkage disequilibrium with both DR3 and DR5. Structural analysis has lent some support to this hypothesis. One series, for example, found that all 106 subjects with Sj&ouml;gren's syndrome or systemic lupus erythematosus who produced anti-Ro antibodies had glutamine at position 34 of DQA1",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    leucine at position 26 of DQB1 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/67\">",
"     67",
"    </a>",
"    ]. Although the incidence of having one \"risk\" allele out of four is high due to chance alone, there seems to be a gene dose effect with an increasing risk of producing anti-Ro antibodies in association with a greater number of such DQA and DQB alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genes other than those of the HLA loci may also be associated with an increased risk of disease. Suggested candidate genes and polymorphisms include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IL-10 promoter polymorphisms &mdash; Effects upon IL-10 production could affect the balance of subsets of helper T-cells to favor cell-mediated damage to affected exocrine glands [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/70\">",
"       70",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=see_link\">",
"       \"Role of cytokines in the immune system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CTLA-4 &mdash; Two common haplotypes of the cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) gene may be associated with an increased risk of developing primary SS and with serologic and extraglandular features [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IRF5 gene &mdash; An association between a common interferon regulatory factor-5 (IRF5) gene polymorphism and primary SS was noted in a single study of 212 patients and 162 healthy blood donors in France [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Viral infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A role for viruses in the pathogenesis of SS is suggested by a number of observations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Certain viruses, particularly the ubiquitous herpes viruses such as Epstein-Barr virus (EBV), frequently infect the major site of pathology in SS, the salivary glands. A characteristic of such infections is the ability of primary infections to progress to lifelong latent infection characterized by cycles of reactivation.",
"     </li>",
"     <li>",
"      EBV has the ability to induce strong immune responses by T-cells.",
"     </li>",
"     <li>",
"      The La antigen, a target of autoantibody production in SS, is involved in processing viral RNA. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link\">",
"       \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      At least three viruses, human T-lymphotropic virus (HTLV) type I, HIV, and hepatitis C, are known to be associated with clinical syndromes which share many features of SS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Epstein-Barr virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial interest focused on three viruses: EBV, cytomegalovirus; and human herpesvirus-6 (HHV-6) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/74\">",
"     74",
"    </a>",
"    ]. Studies are complicated by the high level of infection within the general population, and data from serologic studies has been conflicting. Some reports have found raised antibody titers to all three viruses in SS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/75,76\">",
"     75,76",
"    </a>",
"    ], while other workers have noted no increase compared to the normal population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Similarly, although genetic material from EBV can be detected in SS salivary tissue by DNA hybridization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/79\">",
"     79",
"    </a>",
"    ] similar findings can also be seen in normal individuals. Furthermore, even when EBV is detected in salivary tissue, less than 1 percent of cells are infected, and there may be a delay of many years between primary infection and the development of SS.",
"   </p>",
"   <p>",
"    Because a causative link between these ubiquitous viruses and disease is difficult to prove, attention has become focused on the detection of unusual virus genomes or atypical immune responses to virus by the host. As an example, a study of Chinese patients with SS found that genetic material from EBV was detectable but differed from that of normal EBV in that the DNA contained an unusual genomic deletion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/80\">",
"     80",
"    </a>",
"    ]. It is therefore possible that the EBV in patients with SS differs structurally or antigenically from that in controls or that some subjects have an HLA restricted inability to clear EBV infected cells, thereby predisposing these individuals to persistent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Retroviruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retroviruses are capable of disrupting the immune system by infecting immune cells, possibly leading to suppression, destruction, or stimulation of T-cells, increased production of antibodies, and development of malignancies such as lymphomas. At least two retroviruses, HIV and HTLV-I, are known to cause SS-like syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two groups have independently confirmed the presence of HTLV-I genome in salivary gland tissue from patients with SS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. In both cases, only the tax gene was detectable with pol, gag, and env being apparently absent. It is possible that these results represent infection with a defective virus in which all genes other than tax have been deleted. This is an attractive theory, since it would explain the lack of easy vertical transmission that would be expected in complete virus infection. There are other diseases in which defective HTLV-I proviruses are thought to play a role, such as mycosis fungoides and HTLV-I-associated T cell leukemia. However, it is also possible that failure to detect other parts of the genome is due to technical factors associated with PCR or that the finding of tax itself is due to contamination artifact [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/56\">",
"     56",
"    </a>",
"    ]. The fact that two independent groups found similar results makes the last two explanations less likely.",
"   </p>",
"   <p>",
"    In both studies, no patient had serum antibodies to HTLV-I. This is in marked contrast to earlier reports from Japan and the United States, suggesting an increase in antibodies to HTLV-I in patients with SS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. It is unclear whether some subgroups of SS patients are able to produce antibodies to HTLV-I while others are not.",
"   </p>",
"   <p>",
"    Further support for a role for HTLV-I comes from a transgenic mouse model in which the tax gene has been inserted [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/87\">",
"     87",
"    </a>",
"    ]. These animals develop a spontaneous sialadenitis characterized by focal proliferation of ductal epithelial cells within the major and minor salivary glands followed by lymphocytic infiltration.",
"   </p>",
"   <p>",
"    A subgroup of patients with HIV infection, for example, develop diffuse infiltrative lymphocytosis (DILS), which is almost indistinguishable from SS with xerostomia, keratoconjunctivitis sicca (KCS), and bilateral parotid swelling. This disorder differs from SS in that the infiltrate in the salivary glands is predominantly CD8+ T cells, antibodies are seen less frequently, there is an excess of males (3:1), and there are different HLA associations (HLA-DR5 and DR6) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Hepatitis C virus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis C virus (HCV) is increasingly recognized as a cause of a SS-like syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. A mild sialadenitis is common and a lymphocytic infiltrate can be detected in the glands [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/91\">",
"     91",
"    </a>",
"    ]. Such patients may also have type II mixed cryoglobulinemia and produce rheumatoid factor [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/92\">",
"     92",
"    </a>",
"    ]; in comparison, antibodies to Ro and La are typically absent. Thus, rather than representing an etiologic factor for primary SS, HCV infection should be part of the differential diagnosis of sicca symptoms, especially in patients who lack anti-Ro or -La antibodies. It is important to recognize the presence of autoimmune disease in chronic HCV infection, since patients with concurrent autoimmune hepatitis may flare after therapy with interferon alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/93\">",
"     93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36505?source=see_link&amp;anchor=H6#H6\">",
"     \"Principles of interferon therapy in liver disease and the induction of autoimmunity\", section on 'Liver disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Coxsackievirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coxsackievirus infection may play a role in primary SS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/94\">",
"     94",
"    </a>",
"    ]. This was suggested by a study of minor salivary gland biopsies; coxsackievirus RNA was identified in extracts of tissue in seven of eight with primary SS, but from none of those with secondary SS or from control tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/95\">",
"     95",
"    </a>",
"    ]. Immunohistochemical staining with a monoclonal antibody to a viral protein revealed reactivity in 11 of 12 samples from patients with primary SS, one of eight with secondary SS, and none of the controls. A report from another center failed to confirm the report of coxsackie virus in SS tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, no single virus is clearly implicated in the pathogenesis of SS. Although virus can be detected in many patients, no virus has been present at high levels in target tissues. It is possible that low levels of virus-infected cells may be sufficient to break tolerance to autoantigens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sensation of dry and painful eyes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic correlate of the patient's symptom of dry eyes is the increased friction as the upper lid moves over the ocular globe.",
"   </p>",
"   <p>",
"    As a result of lacrimal gland dysfunction, the tear film becomes unstable and the corneal surface is subject to desiccation. As a result, there is decrease in goblet cell function and further decrease in mucin production. The resulting cycle leads to influx of inflammatory cells and activation of metalloproteinases. The inflammation leads to activation of afferent sensory nerves that go to the midbrain where they lead to cholinergic signals that trigger the salivary gland. However, the lymphocytic infiltrates and their cytokines within the lacrimal gland prevent adequate product of aqueous tears and the cycle of desiccation and pain continues as the clinical syndrome of keratoconjunctivitis sicca. The new term, dysfunctional tear syndrome, reflects the spectrum of changes in the ocular surface and tear film in addition to the decrease in aqueous tear production.",
"   </p>",
"   <p>",
"    A similar cycle of events is proposed to occur in the mouth where the viscosity of the buccal mucosa during events such as talking and swallowing is maintained by a saliva that also contains a gel of mucins and proteins. A major difference between the mouth and the eye is that the mouth is a \"dirty\" (ie, bacterial exposed) environment while the eye has little or no residual bacteria. As a result, additional complications such as altered oral microflora and biofilm develop in SS patients, and there are alterations in the normal low molecular weight proteins (called defensins) found in normal saliva.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytokines are polypeptide mediators of inflammation, produced by T-cells, macrophages and other immune cells, which act to regulate other cells of the immune system (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=see_link\">",
"     \"Role of cytokines in the immune system\"",
"    </a>",
"    ). Salivary epithelial cells are able to produce a large amount and wide variety of cytokines including interleukin 2 (IL-2), interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor alpha (TNF-alpha), interferon gamma (IFNg) and transforming growth factor beta 1 (TGF-beta 1) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/97\">",
"     97",
"    </a>",
"    ]. The presence of an infiltrating lymphoid focus within the gland appears to modulate cytokine gene expression by the salivary epithelial cells.",
"   </p>",
"   <p>",
"    IFNg may have a particularly important role:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunohistological staining identifies many IFNg producing cells in salivary gland tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/14\">",
"       14",
"      </a>",
"      ]. Staining for IFNg is maximal in duct epithelium, and there is a strong correlation between IFNg staining and HLA-DR expression [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment of salivary gland cultures with IFNg increases HLA-DR and cytoplasmic La expression; on the other hand, expression is reduced by the addition of anti-IFNg antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these results suggest a pivotal role for IFNg, secreted by infiltrating lymphocytes, resulting in increased HLA-DR expression, antigen presentation by epithelial cells, and a specific T-cell response within the salivary gland.",
"   </p>",
"   <p>",
"    Transforming growth factor-beta and IL-3 have also been reported in the absence of IL-4 and IL-5. This profile has the characteristics of a T-helper type 1 (Th1) response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=see_link&amp;anchor=H13#H13\">",
"     \"Role of cytokines in the immune system\", section on 'T cell subsets'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;SS is characterized by the presence of certain autoantibodies that by some criteria, are required for the diagnosis to be made, especially",
"    <span class=\"nowrap\">",
"     Anti-Ro/SSA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-La/SSB.",
"    </span>",
"    Antibodies to acetylcholine receptors of salivary glands have been found and could account for decreased secretion from histologically normal glands. Antisalivary gland antibodies can be detected in some patients but they are infrequent and present at low titer, suggesting a secondary response to tissue already damaged by another process. Antinuclear antibodies, as detected by immunofluorescence using Hep-2 cells, are present in 90 percent of patients and high titer rheumatoid factor is also frequently found. Some patients may have autoantibody production within exocrine glands. Ectopic lymphoid germinal centers in such patients contain antigen presenting dendritic cells, T-cells, and B lymphocytes and provide a conducive microenvironment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/100\">",
"     100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Ro/SSA and La/SSB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most interest in patients with SS has focused on the antibodies directed against nuclear proteins",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     La/SSB.",
"    </span>",
"    These antibodies can be detected in serum and may be produced locally in salivary glands [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/101\">",
"     101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=see_link\">",
"     \"The anti-Ro/SSA and anti-La/SSB antigen-antibody systems\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Perhaps the most carefully studied of these autoantigens is SSA Ro52, which belongs to the tripartite motif (TRIM) or RING-B-box-coiled-coil (RBCC) protein family, thus comprising an N-terminal RING, followed by a B-box and a coiled-coil region 34. Several different proteomic functions have been suggested for Ro52, including DNA binding, protein interactions and Zn(2+)-binding. Two structured parts of Ro52 have identified, corresponding to the RING-B-box and the coiled-coil regions, respectively. Secondary structure analysis by circular dichroism (CD) spectroscopy indicated that the two subregions are independently structured. The entire RING-B-box region displayed Zn(2+)-dependent stabilization against proteolysis in the presence of Zn(2+), indicating functional Zn(2+)-binding sites in both the RING and the B-box. However, no stabilization with DNA was detected, irrespective of Zn(2+), thus suggesting that the RING-B-box region does not bind DNA. Immunologic analysis of the stable protein regions with sera from patients with Sj&ouml;gren's syndrome shows that immunodominant epitopes to a large extent are localized in the structurally stable parts of Ro52. The results form a basis for further Ro52 functional studies on the proteome level.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       Anti-Ro/SSA",
"      </span>",
"      antibodies are found in over 70 to 90 percent patients with SS and about 35 to 50 percent of patients with lupus [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/102\">",
"       102",
"      </a>",
"      ]. These antibodies are predominantly of the IgG1 subclass and recognize at least two proteins complexed with RNA: a 52 kD, 475 amino acid protein and a 60 kD 525 amino acid protein. Anti-52 kD antibodies are found more frequently in SS than RA or SLE, whereas anti-60 kD antibodies are more prevalent in SS associated with SLE [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/103\">",
"       103",
"      </a>",
"      ]. Both antigens are located primarily in the nucleus, but expression in cytoplasm and on the cell surface also occurs.",
"      <br/>",
"      <br/>",
"      A sicca syndrome and",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      antibodies can also occur in primary biliary cirrhosis. The",
"      <span class=\"nowrap\">",
"       anti-Ro/SSA",
"      </span>",
"      antibodies in this setting are directed against a smaller epitope on the 52 kD protein than in primary SS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Anti-La/SSB",
"      </span>",
"      antibodies are found in 50 percent of patients with SS. These antibodies recognize a 47 kD phosphoprotein associated with newly synthesized RNA polymerase III transcripts. The gene encoding SSB is unusual in that it has two promoter sites, encoding for two different size mRNAs, and raising the possibility of gene switching under disease conditions [",
"      <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/105\">",
"       105",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In vitro, antibodies to Ro are capable of mediating cytotoxicity against targets coated with Ro antigen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/106\">",
"     106",
"    </a>",
"    ]. There is, however, no direct evidence that antibodies to Ro or La are pathogenic in vivo. Although predominantly nuclear in location, cell surface expression with antibody binding has been demonstrated in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/107\">",
"     107",
"    </a>",
"    ]; expression is increased by exposure to ultraviolet light which may be relevant considering the photosensitive nature of skin lesions in SLE. There is also some evidence that the epithelial cells of salivary glands in SS express the La antigen as judged by binding of anti-La antibody to epithelial cells on histological sections from salivary gland biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/108\">",
"     108",
"    </a>",
"    ]. These antigens could be exposed to circulating autoantibodies.",
"   </p>",
"   <p>",
"    The most compelling evidence for a pathogenic role for autoantibodies in SS comes from patients with neonatal lupus, the most serious manifestation of which is complete heart block. Both anti-Ro and anti-La antibodies are found in 80 to 90 percent of mothers (some of whom have Sj&ouml;gren's syndrome) of children with neonatal lupus, and almost all with complete heart block. Ro and La antigens are abundant in fetal heart tissue between 18 and 24 weeks. Maternal IgG anti-Ro and -La antibodies can cross the placenta and bind to fetal cardiac conducting tissue, resulting in autoimmune damage to the atrioventricular node and surrounding tissues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Anti-alpha-fodrin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no pathogenic role has yet been found for antibodies directed against alpha-fodrin (an actin-binding protein), their presence may be more sensitive and specific for Sj&ouml;gren's syndrome than anti-Ro",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-La antibodies. As an example, anti-alpha-fodrin antibodies were found in 41 of 43 patients with primary Sj&ouml;gren's syndrome and 5 of 8 with secondary Sj&ouml;gren's syndrome, but none of 21 patients with SLE, 14 with RA, or 15 healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/109\">",
"     109",
"    </a>",
"    ]. Similar sensitivity, but slightly less specificity, has been noted in children with primary Sj&ouml;gren's syndrome or SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/110\">",
"     110",
"    </a>",
"    ]. However, lower sensitivity and specificity have been reported by others with anti-alpha fodrin antibodies present in 16 of 56 (29 percent) patients with primary Sj&ouml;gren's syndrome and in 25 of 53 (47 percent) of those with SLE without sicca symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/111\">",
"     111",
"    </a>",
"    ]. Anti-alpha-fodrin antibodies of the IgA class appear to be less sensitive for primary and secondary disease (approximately 60 to 65 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/112\">",
"     112",
"    </a>",
"    ]. Additional study of the clinical use of testing for anti-alpha-fodrin antibodies is needed to assess their role in diagnosis of Sj&ouml;gren's syndrome. However, the most recent studies have suggested that IgG anti-fodrin antibodies are present in low titers and in a lower proportion of SS patients than initially reported in single center studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/113-115\">",
"     113-115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Anti-acetylcholine receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients with SS, autoantibodies directed against acetylcholine receptors may block neuroglandular transmission, thereby resulting in sicca symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. These antibodies may be found in both primary and secondary SS. In one study of 15 patients with SS, antibodies were found in 5 of 9 subjects with primary and 6 of 6 with secondary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/118\">",
"     118",
"    </a>",
"    ]. In animal models, these anti-M3 acetylcholine receptor antibodies decrease glandular secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/116\">",
"     116",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Islet cell autoantigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Islet cell autoantigen 69 (ICA69) is a protein that is present in salivary and lacrimal glands as well as pancreatic beta cells and tissue of the nervous system. In one study, elevated levels of autoantibodies to this protein were frequently found in the serum of patients with primary SS (8 of 9 patients), but not in patients with SLE (0 of 6) or in healthy controls (0 of 12) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/119\">",
"     119",
"    </a>",
"    ]. In a murine model of SS (the nonobese diabetic or NOD mouse), in which spontaneous lymphocytic infiltration of the lacrimal and salivary glands occurs, animals that did not express the ICA69 protein had a markedly slower progression of glandular lymphocytic infiltration than wild-type or heterozygous ICA69 knockouts. Testing for anti-ICA69 antibodies is not recommended at this time. However, if larger studies confirm the differential presence in SS versus SLE, or other rheumatic disorders, testing for these antibodies may find a role in clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hormonal influences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility that estrogen increases the risk of development of sicca symptoms is suggested by the predominance of women with primary SS (96 percent in one population based study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/15\">",
"     15",
"    </a>",
"    ]) and by the increased prevalence of ocular dryness in postmenopausal women receiving hormone replacement therapy (HRT).",
"   </p>",
"   <p>",
"    The influence of HRT was illustrated in an observational study of 25,665 postmenopausal women; the risk of dry eye syndrome was increased in those on unopposed estrogen or combined estrogen-progestin therapy compared to nonusers (RR 1.69 and 1.29; 95% CI 1.49-1.91 and 1.13-1.48, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/16\">",
"     16",
"    </a>",
"    ]. This may reflect an effect of estrogen on the tear film. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Microchimerism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microchimerism, the persistence of some cells derived from another individual, has been suggested to be important in the pathogenesis of some systemic disorders that share features with chronic graft versus host disease. This phenomenon has been the subject of much investigation in systemic sclerosis (scleroderma). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\", section on 'Graft versus host disease or microchimerism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A possible role for microchimerism in patients with primary SS was suggested by the finding of DNA sequences derived from the Y chromosome in biopsy material from labial salivary glands of 36 percent of patients with SS but in none of 10 patients with other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/120\">",
"     120",
"    </a>",
"    ]. Male DNA sequences were not detected in cells obtained from peripheral blood but were present in fluid obtained by bronchoalveolar lavage in 22 percent of SS patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Effector mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major pathways for killing by cytotoxic T lymphocytes (CTL) have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/121\">",
"     121",
"    </a>",
"    ]. Both have been suggested to be important in SS.",
"   </p>",
"   <p>",
"    The first mechanism is the Fas-FasL cytotoxic pathway. Fas (CD95, APO-1) is a member of the tumor necrosis factor (TNF) receptor family of cell surface proteins which with its ligand, FasL, is thought to have an important role in regulating immune responses and maintaining self tolerance. Ligation of Fas and FasL is capable of delivering either an apoptotic death signal to a cell or a costimulatory signal. FasL expression in induced by MHC class II and antigen interaction on activated T-cells (predominantly of the Th1 subset) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/122\">",
"     122",
"    </a>",
"    ] and on CD8+ cytotoxic T-cells.",
"   </p>",
"   <p>",
"    Fas expression has been demonstrated on ductal epithelial cells from patients with SS, particularly in areas of heavy inflammatory cell infiltrate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/123,124\">",
"     123,124",
"    </a>",
"    ]. Although this is a potential mechanism for cell death in SS, apoptosis is the result of a fine balance between pro-apoptotic proteins such as Fas and anti-apoptotic proteins such as bcl-2 and bcl-x-1. The relative contribution of each in SS remains to be evaluated.",
"   </p>",
"   <p>",
"    A second mechanism of cytotoxicity involves the translation and secretion of cytolytic granules containing perforin, granzymes, and other cytotoxins. Granzyme A mRNA is present in salivary gland lymphocytes in SS and levels of mRNA have been found to correlate with the size of the infiltrate and clinical activity of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/125\">",
"     125",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     NEW DIRECTIONS IN STUDY OF PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein components of the tears of patients may help distinguish those with SS from others with complaints related to ocular dryness. One promising approach to identifying disease biomarkers in tear fluid uses a proteomic technique. A description of proteomics is beyond the scope of this discussion. The technology utilized is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=see_link\">",
"     \"Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential of a proteomic approach using surface enhanced laser",
"    <span class=\"nowrap\">",
"     desorption/ionization",
"    </span>",
"    time-of-flight mass spectrometry (SELDI-TOF-MS) is illustrative [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/126\">",
"     126",
"    </a>",
"    ]. Thirty-one SS patients and 57 control subjects were enrolled to this study. There were 23 patients with primary SS, eight with secondary SS, 14 with dry eyes, 22 with miscellaneous ocular diseases, and 21 of healthy volunteers. Multiple protein changes were reproducibly detected in the primary SS group, including 10 potential novel biomarkers. Seven of the biomarkers, referred to by their",
"    <span class=\"nowrap\">",
"     mass/charge",
"    </span>",
"    <span class=\"nowrap\">",
"     (m/z)",
"    </span>",
"    ratio were down-regulated (2094, 2743, 14191, 14702, 16429, 17453, 17792",
"    <span class=\"nowrap\">",
"     m/z)",
"    </span>",
"    and three biomarkers (3483, 4972, 10860",
"    <span class=\"nowrap\">",
"     m/z)",
"    </span>",
"    were up-regulated in primary SS group when compared to the protein profiles of control subjects. When cutoff value of SS down-score was set less than 0.5, this result yielded 87 percent sensitivity and 100 percent specificity. There was a significant inverse correlation between SS down-scores and epithelial damages of the ocular surface in primary SS patients. These findings support the potential of proteomic pattern technology in tear fluids as the noninvasive diagnostic test for primary SS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/36/25162/abstract/126\">",
"     126",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=see_link\">",
"       \"Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      SS is a systemic autoimmune disease characterized by infiltration of glandular tissue by predominantly CD4 T lymphocytes. The glandular epithelial cells express high levels of HLA-DR: it is possible that these cells are presenting antigen (viral or autoantigen) to the invading T-cells. Cytokine production follows, with IFNg and IL-2 being especially important. There is also evidence of B-cell activation with autoantibody production and an increase in B-cell malignancy.",
"     </li>",
"     <li>",
"      It remains unclear, however, how these changes result in the clinical manifestations of SS. The traditional view that chronic inflammation results in tissue destruction of the exocrine glands is almost certainly not the whole story. There is, for example, a poor correlation between the amount of damage upon biopsy and the measured decrease in fluid production, as the reduction in saliva is often greater than expected from the histologic appearance. Furthermore, some patients with low basal levels of salivary secretion are capable of producing normal amounts after stimulation by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/36/33344?source=see_link\">",
"       pilocarpine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/1\">",
"      Fox RI, Liu AY. Sj&ouml;gren's syndrome in dermatology. Clin Dermatol 2006; 24:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/2\">",
"      D&ouml;rner T. Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl 2006; 77:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/3\">",
"      Isenberg DA. B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 2006; 77:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/4\">",
"      Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sj&ouml;gren's syndrome: an open-label phase II study. Arthritis Rheum 2005; 52:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/5\">",
"      Pijpe J, van Imhoff GW, Vissink A, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. Ann Rheum Dis 2005; 64:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/6\">",
"      Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005; 64:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/7\">",
"      Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sj&ouml;gren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sj&ouml;gren's Syndrome (TRIPSS). Arthritis Rheum 2004; 50:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/8\">",
"      Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sj&ouml;gren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004; 50:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/9\">",
"      Zandbelt MM, de Wilde P, van Damme P, et al. Etanercept in the treatment of patients with primary Sj&ouml;gren's syndrome: a pilot study. J Rheumatol 2004; 31:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/10\">",
"      Fox RI. Sj&ouml;gren's syndrome. Lancet 2005; 366:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/11\">",
"      Hjelmervik TO, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sj&ouml;gren's syndrome patients from healthy control subjects. Arthritis Rheum 2005; 52:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/12\">",
"      B&aring;ve U, Alm GV, R&ouml;nnblom L. The combination of apoptotic U937 cells and lupus IgG is a potent IFN-alpha inducer. J Immunol 2000; 165:3519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/13\">",
"      B&aring;ve U, Magnusson M, Eloranta ML, et al. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol 2003; 171:3296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/14\">",
"      B&aring;ve U, Nordmark G, L&ouml;vgren T, et al. Activation of the type I interferon system in primary Sj&ouml;gren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005; 52:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/15\">",
"      Pillemer SR, Matteson EL, Jacobsson LT, et al. Incidence of physician-diagnosed primary Sj&ouml;gren syndrome in residents of Olmsted County, Minnesota. Mayo Clin Proc 2001; 76:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/16\">",
"      Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA 2001; 286:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/17\">",
"      Tapinos NI, Polihronis M, Tzioufas AG, Moutsopoulos HM. Sj&ouml;gren's syndrome. Autoimmune epithelitis. Adv Exp Med Biol 1999; 455:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/18\">",
"      Robinson CP, Yamamoto H, Peck AB, Humphreys-Beher MG. Genetically programmed development of salivary gland abnormalities in the NOD (nonobese diabetic)-scid mouse in the absence of detectable lymphocytic infiltration: a potential trigger for sialoadenitis of NOD mice. Clin Immunol Immunopathol 1996; 79:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/19\">",
"      da Costa SR, Wu K, Veigh MM, et al. Male NOD mouse external lacrimal glands exhibit profound changes in the exocytotic pathway early in postnatal development. Exp Eye Res 2006; 82:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/20\">",
"      Salomonsson S, Larsson P, Tengn&eacute;r P, et al. Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic inflammatory disease Sj&ouml;gren's syndrome. Scand J Immunol 2002; 55:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/21\">",
"      Xanthou G, Polihronis M, Tzioufas AG, et al. \"Lymphoid\" chemokine messenger RNA expression by epithelial cells in the chronic inflammatory lesion of the salivary glands of Sj&ouml;gren's syndrome patients: possible participation in lymphoid structure formation. Arthritis Rheum 2001; 44:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/22\">",
"      Ma-Krupa W, Jeon MS, Spoerl S, et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004; 199:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/23\">",
"      Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/24\">",
"      Nakamura H, Kawakami A, Yamasaki S, et al. Expression and function of X chromosome-linked inhibitor of apoptosis protein in Sj&ouml;gren's syndrome. Lab Invest 2000; 80:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/25\">",
"      Jonsson R, Gordon TP, Konttinen YT. Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sj&ouml;gren's syndrome. Curr Rheumatol Rep 2003; 5:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/26\">",
"      Barone F, Bombardieri M, Manzo A, et al. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sj&ouml;gren's syndrome. Arthritis Rheum 2005; 52:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/27\">",
"      Hansen A, Reiter K, Ziprian T, et al. Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sj&ouml;gren's syndrome. Arthritis Rheum 2005; 52:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/28\">",
"      Santiago-Raber ML, Baccala R, Haraldsson KM, et al. Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice. J Exp Med 2003; 197:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/29\">",
"      Ogawa N, Ping L, Zhenjun L, et al. Involvement of the interferon-gamma-induced T cell-attracting chemokines, interferon-gamma-inducible 10-kd protein (CXCL10) and monokine induced by interferon-gamma (CXCL9), in the salivary gland lesions of patients with Sj&ouml;gren's syndrome. Arthritis Rheum 2002; 46:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/30\">",
"      Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005; 1050:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/31\">",
"      B&aring;ve U, Vallin H, Alm GV, R&ouml;nnblom L. Activation of natural interferon-alpha producing cells by apoptotic U937 cells combined with lupus IgG and its regulation by cytokines. J Autoimmun 2001; 17:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/32\">",
"      Bolstad AI, Eiken HG, Rosenlund B, et al. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sj&ouml;gren's syndrome. Arthritis Rheum 2003; 48:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/33\">",
"      Konttinen YT, Hukkanen M, Kemppinen P, et al. Peptide-containing nerves in labial salivary glands in Sj&ouml;gren's syndrome. Arthritis Rheum 1992; 35:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/34\">",
"      Konttinen YT, K&auml;sn&auml;-Ronkainen L. Sj&ouml;gren's syndrome: viewpoint on pathogenesis. One of the reasons I was never asked to write a textbook chapter on it. Scand J Rheumatol Suppl 2002; 116:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/35\">",
"      Konttinen YT, Tensing EK, Laine M, et al. Abnormal distribution of aquaporin-5 in salivary glands in the NOD mouse model for Sj&ouml;gren's syndrome. J Rheumatol 2005; 32:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/36\">",
"      Tsubota K, Hirai S, King LS, et al. Defective cellular trafficking of lacrimal gland aquaporin-5 in Sj&ouml;gren's syndrome. Lancet 2001; 357:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/37\">",
"      Steinfeld S, Cogan E, King LS, et al. Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sj&ouml;gren's syndrome patients. Lab Invest 2001; 81:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/38\">",
"      Sawalha AH, Potts R, Schmid WR, et al. The genetics of primary Sj&ouml;gren's syndrome. Curr Rheumatol Rep 2003; 5:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/39\">",
"      Dawson L, Tobin A, Smith P, Gordon T. Antimuscarinic antibodies in Sj&ouml;gren's syndrome: where are we, and where are we going? Arthritis Rheum 2005; 52:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/40\">",
"      Kov&aacute;cs L, Marczinovits I, Gy&ouml;rgy A, et al. Clinical associations of autoantibodies to human muscarinic acetylcholine receptor 3(213-228) in primary Sjogren's syndrome. Rheumatology (Oxford) 2005; 44:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/41\">",
"      Stern ME, Beuerman RW, Fox RI, et al. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol 1998; 438:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/42\">",
"      Fox RI, Stern M. Sj&ouml;gren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol Suppl 2002; 116:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/43\">",
"      Begley CG, Himebaugh N, Renner D, et al. Tear breakup dynamics: a technique for quantifying tear film instability. Optom Vis Sci 2006; 83:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/44\">",
"      de Paiva CS, Pflugfelder SC. Tear clearance implications for ocular surface health. Exp Eye Res 2004; 78:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/45\">",
"      Tiffany JM. The viscosity of human tears. Int Ophthalmol 1991; 15:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/46\">",
"      Chen X, Gallar J, Belmonte C. Reduction by antiinflammatory drugs of the response of corneal sensory nerve fibers to chemical irritation. Invest Ophthalmol Vis Sci 1997; 38:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/47\">",
"      Auran JD, Koester CJ, Kleiman NJ, et al. Scanning slit confocal microscopic observation of cell morphology and movement within the normal human anterior cornea. Ophthalmology 1995; 102:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/48\">",
"      van Bijsterveld OP, Kruize AA, Bleys RL. Central nervous system mechanisms in Sj&ouml;gren's syndrome. Br J Ophthalmol 2003; 87:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/49\">",
"      Kov&aacute;cs L, T&ouml;r&ouml;k T, Bari F, et al. Impaired microvascular response to cholinergic stimuli in primary Sj&ouml;gren's syndrome. Ann Rheum Dis 2000; 59:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/50\">",
"      Barendregt PJ, van der Heijde GL, Breedveld FC, Markusse HM. Parasympathetic dysfunction in rheumatoid arthritis patients with ocular dryness. Ann Rheum Dis 1996; 55:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/51\">",
"      Mandl T, Bornmyr SV, Castenfors J, et al. Sympathetic dysfunction in patients with primary Sj&ouml;gren's syndrome. J Rheumatol 2001; 28:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/52\">",
"      Daniels TE. Labial salivary gland biopsy in Sj&ouml;gren's syndrome. Assessment as a diagnostic criterion in 362 suspected cases. Arthritis Rheum 1984; 27:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/53\">",
"      Adamson TC 3rd, Fox RI, Frisman DM, Howell FV. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren's syndrome using monoclonal antibodies. J Immunol 1983; 130:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/54\">",
"      Skopouli FN, Fox PC, Galanopoulou V, et al. T cell subpopulations in the labial minor salivary gland histopathologic lesion of Sj&ouml;gren's syndrome. J Rheumatol 1991; 18:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/55\">",
"      Zumla A, Mathur M, Stewart J, et al. T cell receptor expression in Sj&ouml;gren's syndrome. Ann Rheum Dis 1991; 50:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/56\">",
"      Price EJ, Venables PJ. The etiopathogenesis of Sj&ouml;gren's syndrome. Semin Arthritis Rheum 1995; 25:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/57\">",
"      Fox RI, Bumol T, Fantozzi R, et al. Expression of histocompatibility antigen HLA-DR by salivary gland epithelial cells in Sj&ouml;gren's syndrome. Arthritis Rheum 1986; 29:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/58\">",
"      Manoussakis MN, Dimitriou ID, Kapsogeorgou EK, et al. Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sj&ouml;gren's syndrome. Arthritis Rheum 1999; 42:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/59\">",
"      Foster H, Walker D, Charles P, et al. Association of DR3 with susceptibility to and severity of primary Sj&ouml;gren's syndrome in a family study. Br J Rheumatol 1992; 31:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/60\">",
"      Arnett FC, Hamilton RG, Reveille JD, et al. Genetic studies of Ro (SS-A) and La (SS-B) autoantibodies in families with systemic lupus erythematosus and primary Sj&ouml;gren's syndrome. Arthritis Rheum 1989; 32:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/61\">",
"      Foster H, Stephenson A, Walker D, et al. Linkage studies of HLA and primary Sj&ouml;gren's syndrome in multicase families. Arthritis Rheum 1993; 36:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/62\">",
"      Gottenberg JE, Busson M, Loiseau P, et al. In primary Sj&ouml;gren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum 2003; 48:2240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/63\">",
"      Wilson RW, Provost TT, Bias WB, et al. Sj&ouml;gren's syndrome. Influence of multiple HLA-D region alloantigens on clinical and serologic expression. Arthritis Rheum 1984; 27:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/64\">",
"      Papasteriades CA, Skopouli FN, Drosos AA, et al. HLA-alloantigen associations in Greek patients with Sj&ouml;gren's syndrome. J Autoimmun 1988; 1:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/65\">",
"      Kang HI, Fei HM, Saito I, et al. Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients with primary Sj&ouml;gren's syndrome. J Immunol 1993; 150:3615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/66\">",
"      Mattey DL, Gonz&aacute;lez-Gay MA, Hajeer AH, et al. Association between HLA-DRB1*15 and secondary Sj&ouml;gren's syndrome in patients with rheumatoid arthritis. J Rheumatol 2000; 27:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/67\">",
"      Reveille JD, Macleod MJ, Whittington K, Arnett FC. Specific amino acid residues in the second hypervariable region of HLA-DQA1 and DQB1 chain genes promote the Ro (SS-A)/La (SS-B) autoantibody responses. J Immunol 1991; 146:3871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/68\">",
"      Scofield RH, Harley JB. Association of anti-Ro/SS-A autoantibodies with glutamine in position 34 of DQA1 and leucine in position 26 of DQB1. Arthritis Rheum 1994; 37:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/69\">",
"      Bolstad AI, Wassmuth R, Haga HJ, Jonsson R. HLA markers and clinical characteristics in Caucasians with primary Sj&ouml;gren's syndrome. J Rheumatol 2001; 28:1554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/70\">",
"      Hulkkonen J, Pertovaara M, Antonen J, et al. Genetic association between interleukin-10 promoter region polymorphisms and primary Sj&ouml;gren's syndrome. Arthritis Rheum 2001; 44:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/71\">",
"      Downie-Doyle S, Bayat N, Rischmueller M, Lester S. Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sj&ouml;gren's syndrome. Arthritis Rheum 2006; 54:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/72\">",
"      Miceli-Richard C, Comets E, Loiseau P, et al. Association of an IRF5 gene functional polymorphism with Sj&ouml;gren's syndrome. Arthritis Rheum 2007; 56:3989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/73\">",
"      Triantafyllopoulou A, Moutsopoulos H. Persistent viral infection in primary Sjogren's syndrome: review and perspectives. Clin Rev Allergy Immunol 2007; 32:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/74\">",
"      Miyasaka N, Yamaoka K, Tateishi M, et al. Possible involvement of Epstein-Barr virus (EBV) in polyclonal B-cell activation in Sj&ouml;gren's syndrome. J Autoimmun 1989; 2:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/75\">",
"      Shillitoe EJ, Daniels TE, Whitcher JP, et al. Antibody to cytomegalovirus in patients with Sj&ouml;gren's syndrome. As determined by an enzyme-linked immunosorbent assay. Arthritis Rheum 1982; 25:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/76\">",
"      Biberfeld P, Petr&eacute;n AL, Eklund A, et al. Human herpesvirus-6 (HHV-6, HBLV) in sarcoidosis and lymphoproliferative disorders. J Virol Methods 1988; 21:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/77\">",
"      Venables PJ, Ross MG, Charles PJ, et al. A seroepidemiological study of cytomegalovirus and Epstein-Barr virus in rheumatoid arthritis and sicca syndrome. Ann Rheum Dis 1985; 44:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/78\">",
"      Venables PJ, Baboonian C, Horsfall AC, et al. The response to Epstein-Barr virus infection in Sj&ouml;gren's syndrome. J Autoimmun 1989; 2:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/79\">",
"      Karameris A, Gorgoulis V, Iliopoulos A, et al. Detection of the Epstein Barr viral genome by an in situ hybridization method in salivary gland biopsies from patients with secondary Sj&ouml;gren's syndrome. Clin Exp Rheumatol 1992; 10:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/80\">",
"      Gan YJ, Shirley P, Zeng Y, Sixbey JW. Human oropharyngeal lesions with a defective Epstein-Barr virus that disrupts viral latency. J Infect Dis 1993; 168:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/81\">",
"      Fox RI. Epidemiology, pathogenesis, animal models, and treatment of Sj&ouml;gren's syndrome. Curr Opin Rheumatol 1994; 6:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/82\">",
"      Vernant JC, Buisson G, Magdeleine J, et al. T-lymphocyte alveolitis, tropical spastic paresis, and Sj&ouml;gren syndrome. Lancet 1988; 1:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/83\">",
"      Sumida T, Yonaha F, Maeda T, et al. Expression of sequences homologous to HTLV-I tax gene in the labial salivary glands of Japanese patients with Sj&ouml;gren's syndrome. Arthritis Rheum 1994; 37:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/84\">",
"      Mariette X, Agbalika F, Daniel MT, et al. Detection of human T lymphotropic virus type I tax gene in salivary gland epithelium from two patients with Sj&ouml;gren's syndrome. Arthritis Rheum 1993; 36:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/85\">",
"      Terada K, Katamine S, Eguchi K, et al. Prevalence of serum and salivary antibodies to HTLV-1 in Sj&ouml;gren's syndrome. Lancet 1994; 344:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/86\">",
"      Talal N, Dauphin&eacute;e MJ, Dang H, et al. Detection of serum antibodies to retroviral proteins in patients with primary Sj&ouml;gren's syndrome (autoimmune exocrinopathy). Arthritis Rheum 1990; 33:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/87\">",
"      Green JE, Hinrichs SH, Vogel J, Jay G. Exocrinopathy resembling Sj&ouml;gren's syndrome in HTLV-1 tax transgenic mice. Nature 1989; 341:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/88\">",
"      Kordossis T, Paikos S, Aroni K, et al. Prevalence of Sj&ouml;gren's-like syndrome in a cohort of HIV-1-positive patients: descriptive pathology and immunopathology. Br J Rheumatol 1998; 37:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/89\">",
"      Mariette X, Zerbib M, Jaccard A, et al. Hepatitis C virus and Sj&ouml;gren's syndrome. Arthritis Rheum 1993; 36:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/90\">",
"      Ramos-Casals M, Mu&ntilde;oz S, Zer&oacute;n PB. Hepatitis C virus and Sj&ouml;gren's syndrome: trigger or mimic? Rheum Dis Clin North Am 2008; 34:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/91\">",
"      Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of Sj&ouml;gren's syndrome associated with chronic hepatitis C virus liver disease. Lancet 1992; 339:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/92\">",
"      Ferri C, La Civita L, Longombardo G, et al. Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. Lupus 1998; 7:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/93\">",
"      Garc&iacute;a-Buey L, Garc&iacute;a-Monz&oacute;n C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/94\">",
"      Triantafyllopoulou A, Moutsopoulos HM. Autoimmunity and coxsackievirus infection in primary Sjogren's syndrome. Ann N Y Acad Sci 2005; 1050:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/95\">",
"      Triantafyllopoulou A, Tapinos N, Moutsopoulos HM. Evidence for coxsackievirus infection in primary Sj&ouml;gren's syndrome. Arthritis Rheum 2004; 50:2897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/96\">",
"      Mariette X, Agbalika F, Zucker-Franklin D, et al. Detection of the tax gene of HTLV-I in labial salivary glands from patients with Sj&ouml;gren's syndrome and other diseases of the oral cavity. Clin Exp Rheumatol 2000; 18:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/97\">",
"      Sun D, Emmert-Buck MR, Fox PC. Differential cytokine mRNA expression in human labial minor salivary glands in primary Sj&ouml;gren's syndrome. Autoimmunity 1998; 28:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/98\">",
"      Oxholm P, Daniels TE, Bendtzen K. Cytokine expression in labial salivary glands from patients with primary Sj&ouml;gren's syndrome. Autoimmunity 1992; 12:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/99\">",
"      Brookes SM, Price EJ, Venables PJ, Maini RN. Interferon-gamma and epithelial cell activation in Sj&ouml;gren's syndrome. Br J Rheumatol 1995; 34:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/100\">",
"      Salomonsson S, Jonsson MV, Skarstein K, et al. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sj&ouml;gren's syndrome. Arthritis Rheum 2003; 48:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/101\">",
"      Tengn&eacute;r P, Halse AK, Haga HJ, et al. Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sj&ouml;gren's syndrome. Arthritis Rheum 1998; 41:2238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/102\">",
"      Gordon TP, Bolstad AI, Rischmueller M, et al. Autoantibodies in primary Sj&ouml;gren's syndrome: new insights into mechanisms of autoantibody diversification and disease pathogenesis. Autoimmunity 2001; 34:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/103\">",
"      St Clair EW, Burch JA Jr, Saitta M. Specificity of autoantibodies for recombinant 60-kd and 52-kd Ro autoantigens. Arthritis Rheum 1994; 37:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/104\">",
"      D&ouml;rner T, Feist E, Held C, et al. Differential recognition of the 52-kd Ro(SS-A) antigen by sera from patients with primary biliary cirrhosis and primary Sj&ouml;gren's syndrome. Hepatology 1996; 24:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/105\">",
"      Tr&ouml;ster H, Metzger TE, Semsei I, et al. One gene, two transcripts: isolation of an alternative transcript encoding for the autoantigen La/SS-B from a cDNA library of a patient with primary Sj&ouml;grens' syndrome. J Exp Med 1994; 180:2059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/106\">",
"      Norris DA, Ryan SR, Fritz KA, et al. The role of RNP, Sm, and SS-A/Ro-specific antisera from patients with lupus erythematosus in inducing antibody-dependent cellular cytotoxicity (ADCC) of targets coated with nonhistone nuclear antigens. Clin Immunol Immunopathol 1984; 31:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/107\">",
"      Lee LA, Weston WL, Krueger GG, et al. An animal model of antibody binding in cutaneous lupus. Arthritis Rheum 1986; 29:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/108\">",
"      Vitali C, Gravili C, Scamardella M, et al. Do the epithelial cells of salivary glands in Sj&ouml;gren's syndrome express the La antigen? Preliminary results of an immunohistochemical study (abstract). Arthritis Rheum 1995; 38(suppl): S403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/109\">",
"      Haneji N, Nakamura T, Takio K, et al. Identification of alpha-fodrin as a candidate autoantigen in primary Sj&ouml;gren's syndrome. Science 1997; 276:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/110\">",
"      Maeno N, Takei S, Imanaka H, et al. Anti-alpha-fodrin antibodies in Sj&ouml;gren's syndrome in children. J Rheumatol 2001; 28:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/111\">",
"      Nordmark G, Rorsman F, R&ouml;nnblom L, et al. Autoantibodies to alpha-fodrin in primary Sj&ouml;gren's syndrome and SLE detected by an in vitro transcription and translation assay. Clin Exp Rheumatol 2003; 21:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/112\">",
"      Witte T, Matthias T, Arnett FC, et al. IgA and IgG autoantibodies against alpha-fodrin as markers for Sj&ouml;gren's syndrome. Systemic lupus erythematosus. J Rheumatol 2000; 27:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/113\">",
"      Ruiz-T&iacute;scar JL, L&oacute;pez-Longo FJ, S&aacute;nchez-Ram&oacute;n S, et al. Prevalence of IgG anti-{alpha}-fodrin antibodies in Sjogren's syndrome. Ann N Y Acad Sci 2005; 1050:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/114\">",
"      Sordet C, Gottenberg JE, Goetz J, et al. Anti-{alpha}-fodrin autoantibodies are not useful diagnostic markers of primary Sj&ouml;gren's syndrome. Ann Rheum Dis 2005; 64:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/115\">",
"      Locht H, Pelck R, Manthorpe R. Diagnostic and prognostic significance of measuring antibodies to alpha-fodrin compared to anti-Ro-52, anti-Ro-60, and anti-La in primary Sj&ouml;gren's syndrome. J Rheumatol 2008; 35:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/116\">",
"      Robinson CP, Brayer J, Yamachika S, et al. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sj&ouml;gren's syndrome. Proc Natl Acad Sci U S A 1998; 95:7538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/117\">",
"      Bacman S, Perez Leiros C, Sterin-Borda L, et al. Autoantibodies against lacrimal gland M3 muscarinic acetylcholine receptors in patients with primary Sj&ouml;gren's syndrome. Invest Ophthalmol Vis Sci 1998; 39:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/118\">",
"      Waterman SA, Gordon TP, Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sj&ouml;gren's syndrome. Arthritis Rheum 2000; 43:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/119\">",
"      Winer S, Astsaturov I, Cheung R, et al. Primary Sj&ouml;gren's syndrome and deficiency of ICA69. Lancet 2002; 360:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/120\">",
"      Kuroki M, Okayama A, Nakamura S, et al. Detection of maternal-fetal microchimerism in the inflammatory lesions of patients with Sj&ouml;gren's syndrome. Ann Rheum Dis 2002; 61:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/121\">",
"      K&auml;gi D, Vignaux F, Ledermann B, et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/122\">",
"      Ramsdell F, Seaman MS, Miller RE, et al. Differential ability of Th1 and Th2 T cells to express Fas ligand and to undergo activation-induced cell death. Int Immunol 1994; 6:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/123\">",
"      Tsubota K, Fujita H, Tadano K, et al. Abnormal expression and function of Fas ligand of lacrimal glands and peripheral blood in Sj&ouml;gren's syndrome patients with enlarged exocrine glands. Clin Exp Immunol 2002; 129:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/124\">",
"      Humphreys-Beher MG, Peck AB, Dang H, Talal N. The role of apoptosis in the initiation of the autoimmune response in Sj&ouml;gren's syndrome. Clin Exp Immunol 1999; 116:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/125\">",
"      Alpert S, Kang HI, Weissman I, Fox RI. Expression of granzyme A in salivary gland biopsies from patients with primary Sj&ouml;gren's syndrome. Arthritis Rheum 1994; 37:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/36/25162/abstract/126\">",
"      Tomosugi N, Kitagawa K, Takahashi N, et al. Diagnostic potential of tear proteomic patterns in Sj&ouml;gren's syndrome. J Proteome Res 2005; 4:820.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5620 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25162=[""].join("\n");
var outline_f24_36_25162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW OF PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY OF THE SALIVARY GLAND INFILTRATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CO-FACTORS IN PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Viral infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Epstein-Barr virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Retroviruses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Coxsackievirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sensation of dry and painful eyes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Ro/SSA and La/SSB",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Anti-alpha-fodrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Anti-acetylcholine receptors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Islet cell autoantigen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hormonal influences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Microchimerism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Effector mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      NEW DIRECTIONS IN STUDY OF PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5620\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5620|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/10/17577\" title=\"picture 1\">",
"      Lip gland biopsy in Sjogrens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37562?source=related_link\">",
"      Epidemiology and pathogenesis of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39674?source=related_link\">",
"      Overview of gene expression profiling, proteomics, and microRNA profiling in clinical oncology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/63/19450?source=related_link\">",
"      Pathogenesis of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=related_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36505?source=related_link\">",
"      Principles of interferon therapy in liver disease and the induction of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4231?source=related_link\">",
"      Role of cytokines in the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/23/8568?source=related_link\">",
"      The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/12/26826?source=related_link\">",
"      Treatment of dry eyes in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36762?source=related_link\">",
"      Treatment of dry mouth and other non-ocular sicca symptoms in Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2282?source=related_link\">",
"      Treatment of systemic and extraglandular manifestations of Sj&ouml;gren&rsquo;s syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_36_25163="MDS outcome by FAB subgroup";
var content_f24_36_25163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50664&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Myelodysplastic syndrome: survival and leukemic evolution related to French-American-British (FAB) subgroups",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        RA",
"       </td>",
"       <td class=\"subtitle1\">",
"        RARS",
"       </td>",
"       <td class=\"subtitle1\">",
"        RAEB",
"       </td>",
"       <td class=\"subtitle1\">",
"        RAEB-T",
"       </td>",
"       <td class=\"subtitle1\">",
"        CMML",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proportion of all patients with MDS, percent",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Median survival, months",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transformation to AML, percent",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from a data meta-analysis and Greenberg PL. Myelodysplastic Syndrome. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ, Shattil SJ (Eds), Churchill Livingstone, New York 2000. p.1106.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25163=[""].join("\n");
var outline_f24_36_25163=null;
var title_f24_36_25164="Tumors reported to cause NICTH";
var content_f24_36_25164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69283&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tumors reported to cause nonislet cell tumor hypoglycemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Carcinomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Adrenal cortex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Bile duct",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Breast",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cervix",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Colon",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Esophagus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Larynx",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lung",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ovary",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prostate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Stomach",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Other tumors",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carcinoid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fibrosarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fibrous tumor of the pleura",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemangiopericytoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hepatoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hypernephroma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leiomyosarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Liposarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Meningioma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mesothelioma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Multiple myeloma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neurilmoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neurofibroma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neurofibrosarcoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pheochromocytoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Wilm's tumor",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25164=[""].join("\n");
var outline_f24_36_25164=null;
var title_f24_36_25165="LVH and cardiovascular risk";
var content_f24_36_25165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F52329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F52329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Cardiovascular risk with LVH by echocardiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 215px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Four-year, age-adjusted incidence of cardiovascular events in men and women in the Framingham Study according to left ventricular mass determined by echocardiography. Subjects with increased left ventricular mass (far right panel) had a marked increase in cardiovascular risk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Levy, D, Garrison, RJ, Savage, DD, et al, N Engl J Med 1990; 322:1561.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25165=[""].join("\n");
var outline_f24_36_25165=null;
var title_f24_36_25166="Dietary sources of iron PI";
var content_f24_36_25166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary sources of iron",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food",
"       </td>",
"       <td class=\"subtitle1\">",
"        Approximate measure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Iron (mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        High iron sources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cream of Wheat (quick or instant)*",
"       </td>",
"       <td>",
"        1/2 cup",
"       </td>",
"       <td>",
"        7.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kidney, beef",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        5.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver, beef",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        5.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver, calf",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        9.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver, chicken",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liverwurst",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        3.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prune juice",
"       </td>",
"       <td>",
"        1/2 cup",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spinach",
"       </td>",
"       <td>",
"        1/2 cup",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Moderate iron sources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        All-Bran cereal",
"       </td>",
"       <td>",
"        1/2 cup",
"       </td>",
"       <td>",
"        2.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Almonds, dried unblanched",
"       </td>",
"       <td>",
"        1/2 cup",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Dried beans and peas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Baked beans, no pork",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Blackeye peas, cooked",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        0.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chick peas, dry",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Great northern beans, cooked",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Green peas, cooked",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lentils, dry",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lima beans, cooked",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Navy beans, cooked",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Red beans, dry",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Soybeans, cooked",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        1.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        White beans, dry",
"       </td>",
"       <td class=\"sublist_other\">",
"        1/4 cup",
"       </td>",
"       <td class=\"sublist_other\">",
"        3.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beef, cooked",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        2-3",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ham, cooked",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lamb, cooked",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peaches, dried",
"       </td>",
"       <td>",
"        1/4 cup",
"       </td>",
"       <td>",
"        2.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Peanuts, roasted without skins",
"       </td>",
"       <td>",
"        3 1/2 oz (100 g)",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pork, cooked",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        2-3",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prunes, dried",
"       </td>",
"       <td>",
"        2 large",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Scallops",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        1.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Turkey, cooked",
"       </td>",
"       <td>",
"        2 oz (60 g)",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Approximate iron content of children's favorite foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        Hamburger, small",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        1",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Large",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        5.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Big Mac",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        4.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Quarter Pounder",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        5.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spaghetti with meatballs",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frankfurter and beans",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td>",
"        4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pork and beans",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raisins",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        5/8 cup",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cereals, fortified",
"       </td>",
"       <td>",
"        1 serving",
"       </td>",
"       <td>",
"        4.5-17.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nuts",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td>",
"        5.0-7.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Seeds, sunflower",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        3 1/2 oz (100 g)",
"       </td>",
"       <td>",
"        7.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chile con carne",
"       </td>",
"       <td>",
"        1 cup",
"       </td>",
"       <td>",
"        3.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beef burrito or tostado",
"       </td>",
"       <td>",
"        1 medium",
"       </td>",
"       <td>",
"        3.4-4.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cheese pizza",
"       </td>",
"       <td>",
"        2 slices",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cheese pizza with beef",
"       </td>",
"       <td>",
"        2 slices",
"       </td>",
"       <td>",
"        4.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White bread",
"       </td>",
"       <td>",
"        1 piece",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Or other fortified cereals which contain 10 mg of iron per ounce or 100 percent RDA per serving.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     As organ meats are generally high in cholesterol, these iron-rich foods should be eaten in moderation.",
"     <br/>",
"     &Delta; Depending on cut, the greatest amounts of iron are generally found in the chuck, flank, and bottom round cuts of beef.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Depending on cut, the greatest amounts of iron are generally found in the loin, sirloin, tenderloin, and picnic shoulder cuts of pork.",
"     <br/>",
"     &sect; Raisins, nuts, and seeds are not generally recommended for children under age three because of risk of choking.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Walker WA, Watkins JB (Eds), Nutrition in Pediatrics, 2nd ed, BC Decker, Inc, London 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25166=[""].join("\n");
var outline_f24_36_25166=null;
var title_f24_36_25167="Fetal skin edema";
var content_f24_36_25167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fetal skin edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Location over the fetal ear helps to distinguish this edema from a cystic hygroma or nuchal thickening.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Svena Julien, MD and Charles Lockwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_36_25167=[""].join("\n");
var outline_f24_36_25167=null;
